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Future antimicrobial drug design and resistance minimisation, requires an
understanding of current antimicrobial action and resistance. This study investigated
bactericidal action and resistance within two antimicrobial groups; the
fluoroquinolones and the aminoglycosides.
The importance of target protein mutation to fluoroquinolome resistance was
characterised in an outbreak of fluoroquinolone resistant Escherichia coli (n=17),
and allowed a direct comparison with previous data deduced solely from in vitro
laboratory selected mutants. Resistance to ciprofloxacin ranged from (MICs)
0.25—>256mg/L, with 7/17 isolates highly resistant (MICs=>32mg/L). A genotypic
analysis by Random Amplified Polymorphic DNA (RAPD) typing, demonstrated that
clonal spread of two strains was responsible for the highly resistant isolates.
Enterobacterial intergenic concensus (ERIC) PCR typing supported RAPD results
whereas PFGE and AFLP analysis were unsuccessful in typing isolates. A sequential
increase in resistance was observed in both strains providing a unique opportunity to
study resistance acquisition in the clinic. Five isolates (TYPE-I) showed the
following increase in resistance: - MICs of ciprofloxacin 8-» 32—> 128—>256 mg/L.
Gene amplification and sequencing showed that all isolates contained mutations
Ser83->Leu and Asp87—>Asn/Tyr in DNA Gyrase GyrA, and mutation Ser80->Ile in
Topoisomerase IV ParC. Isolates with ciprofloxacin MICs of 128 and 256 mg/L, had
the additional mutation Glu84—>Lys in ParC. Four isolates (RAPD type II) showed
an increase in resistance from a clinically sensitive (MIC=lmg/L) to a highly resistant
(MIC=:32mg/L) phenotype. The sensitive isolates (n=3) contained mutations
Ser83—>Leu in GyrA and Ser80—>Ile in ParC. With progression to clinical resistance
this strain additionally acquired mutations Asp87—>Asn in GyrA, and Glu84—>Val in
ParC. This indicates that selection of high-level resistance is dependent upon second
step mutations in both DNA gyrase and topoisomerase IV enzymes, as loss of Ser83
in GyrA and Ser80 in ParC do not, in themselves, confer the highly resistant
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phenotype. These results also confirm that DNA Gyrase is the primary quinolone
target in E. coli.
DNA gyrase mutations Ser83-ALeu and Asp87->Asn were created by site-directed
mutagenesis to allow the contribution of single amino-acid changes to resistance to
be assessed. Expression of the Ser83—>Leu mutant was unsuccessful due to multiple
primer insertions during PCR stage. The contribution of Asp87—»Asn to
fluoroquinolone resistance was assessed by expression in a temperature sensitive (Ts)
gyrA mutant. Resistance to quinolones nalidixic acid, ciprofloxacin, gemifloxacin,
moxifloxacin and sparfloxacin increased 3 to 8 fold when compared to the wild-type.
Resistance levels were however not clinically significant, confirming that secondary
mutations are required to confer the clinically resistant phenotype. Resistance
conferred by this mutation demonstrates the importance of this amino acid in drug-
target binding.
The role of Ribosomal S12 mutations in aminoglycoside action and resistance was
characterised in a step-wise mutation study. The S12 mutation Lys87-»Arg confers
streptomycin resistance of >1500mg/L in a single step selection; however the role of
this S12 mutation in resistance to other aminoglycosides has not been previously
characterised. Mutants of E. coli NCTC10418 were selected in four steps (I-IV) on
aminoglycoside containing plates. Lack of cross-resistance between streptomycin
mutants and other aminoglycosides (gentamicin, neomycin, kanamycin, tobramycin),
suggested that the streptomycin target may not be shared by other aminoglycosides.
Cross-resistance between neomycin, tobramycin and kanamycin mutants, implied that
these drugs may share similar targets and binding pockets. PCR amplification and
sequencing of the rpsL gene encoding the S12 protein demonstrated a Lys87—>Glu
mutation in streptomycin resistant mutants. Ribosomal S12 mutations were absent in
gentamicin, neomycin, kanamycin and tobramycin resistant mutants. Replacement of
Lys87 with a glutamic acid residue resulted in a streptomycin MIC of 25mg/L.
Mutation in S12 Lys87 to a basic arginine (MIC=1500mg/L) residue rather than an
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acidic glutamic acid (MIC=25mg/L) residue results in elevated resistance and hence
probably reduced binding. Lack of additional mutations in 2nd, 3rd and 4th step mutants
implicated the role of alternative ribosomal proteins/targets in streptomycin action.
The requirement of protein synthesis in bactericidal aminoglycoside action was
analysed. Pre-incubation with chloramphenicol significantly reduced streptomycin
bactericidal activity, indicating a role of protein synthesis in cell death. Substituting
streptomycin (lmg/L) for chloramphenicol gave a similar significant reduction in
bactericidal activity, indicating that at sub-lethal concentrations streptomycin acts as a
protein synthesis inhibitor, which blocks its own cell death when challenged with a
higher concentration. Streptomycin induced cell death thereby requires additional
protein synthesis dependent death mechanisms. Stationary phase cells were resistant
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The development of antibiotics in the 1960s revolutionised medicine to such an extent
that the threat posed to man by bacterial infection was believed to be over. This
however was a premature prediction, with antibiotic resistance now disabling even the
most potent drugs in our antibiotic armoury. The dissemination of resistance
pathogens is a major threat to public heath, and now over 40 years since their first
development, antibiotic discovery is back on the agenda. The design of novel and
more effective antimicrobial agents to combat the multi-resistant pathogens we face,
demands a detailed understanding of interactions between the drug and its target site.
As our knowledge grows on how resistance mutations affect these interactions, it will
be possible to design drugs which have greater potency and less potential to select
resistance. Advances in understanding bacterial physiology and population dynamics
shed new light on the way in which antibiotics elicit cell death. The involvement of
secondary target pathways, stress response, protein synthesis subsequent to initial
target binding may be crucial to cell death. Deciphering which proteins are important




1.2 Bactericidal Antibiotic Action
After several decades of research into the bactericidal action of existing antibiotics,
the mechanisms by which they kill bacteria still remain a mystery. Most researchers
focus their attention on understanding the bactericidal mechanism of a single agent or
group of agents, due to the fact that mechanism of action studies are complicated and
groups are diverse. They may, however, lose insight into mechanisms of cell death
which are conserved among diverse groups of drugs such as a requirement for protein
synthesis, induction of stress response, and a role of signal transduction.
1.2.1 P-lactams
Penicillins and other 3-lactam derivatives bind to penicillin binding proteins (PBPs),
which are involved in synthesising and shaping the bacterial cell wall (Tipper &
Strominger, 1965). Tipper and Strominger (1965) originally proposed that binding to
PBPs, and consequent inhibition of peptidoglycan assembly resulted in a mechanically
weakened cell wall, where the internal osmotic pressure and mechanical forces were
believed to result in lysis. Subsequent work however has shown that penicillin induced
lysis is enzymatically mediated, and involves a set of cellular enzymes the murein
hydrolases (autolysins) which hydrolyse peptidoglycan (Rogers & Forsberg,1971).
The discovery that lysis is murein hydrolase dependent does not however explain
lethality. Penicillin exerts a potent bactericidal response in the absence of murein
hyrolase activity, suggesting that lysis and lethality may be two separate events
(Moreillon, 1990). Loss of culture viability occurs shortly after penicillin exposure,
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whereas lysis occurs after a lag phase, indicating that lysis is a secondary event. This
begs the question as to what is responsible for lethality.
The key to understanding P-lactam cell death could come from looking at the way
bacteria respond to antimicrobials at different growth phases. When non-growing or
slowly growing bacteria are challenged with p-lactams, they survive (Tuomanen,
1986). The stringent (stress) response encoded by the relA gene is also known to have
a protective effect from antibiotic action (Cashel et al., 1996). For example, starved
bacteria will bind antibiotic but they do not die (Cashel et al., 1996). The
accumulation of 3\5 bispyrophosphate (ppGpp) which is synthesised by ppGpp
sythetase I accumulates and shuts down the synthesis ofDNA, phospholipids and cell
wall peptidoglycan (Metzger et al., 1988, Sokawa et al., 1968). Antibiotic-induced
autolysis is blocked by an uncharacterised defect in autolysin activation. This
protection from death or phenotypic tolerance is a source of residual bacteria
surviving antimicrobial therapy, and can thereby lead to treatment failure, and
promotion of resistance acquisition. It is known that Escherichia coli can grow up to
two hours in the presence of penicillin, with cells taking the form of filaments
increasing in length at an exponential rate (Rolinson, 1980; Gardner, 1940). Removal
of antibiotic allows the filaments to divide again, suggesting that the lethality does not
occur until lysis (Starka & Moravora, 1967).
It is clear that the binding of penicillins to their target does not directly cause cell
death. A second bacterial process to trigger endogenous suicidal enzymes that
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dissolve the cell during autolysis is the most likely cause, although the signal and
trigger pathway remain unknown (Novak et al., 2000). The identification of a two
component regulatory system (VNcRS) which affects bacterial susceptibility to a wide
range of antibiotics may shed light on the way bacteria regulate their suicidal autolytic
pathways. Novak et al. (1999) have demonstrated that a secreted peptide Pep27 can be
sensed by the VNcRS system which initiates a set of uncharacterised events leading to
cell death. After secretion and accumulation of the peptide during late log and
stationary phase, it is likely to be sensed by histadine/phosphatase VncS receptors
triggering pathways leading to cell death. The stringent response is known to
downregulate autolysis in bacteria, and it has been shown that this peptide along with
P-lactam agents can relax this response, and thereby may regulate this pathway. The
way in which (3-lactams feed into this pathway remains to be established. The finding
that the heat shock response can inhibit cell lysis but not cell death adds further
evidence to the role of the stringent response pathway (Powell & Young, 1991).
Peptidoglycan biosyntheis involves a complex system of proteins with specialised
functions. It appears that cell lethality is due to regulation by a signal transduction
mechanism, the stimuli for which remain to be identified. The whole picture of the
bactericidal mechanism of 3-lactams is only just being comprehended, and may




Trimethoprim is a selective inhibitor of the enzyme dihyrofolate reductase which
reduces dihyrdofolic acid (DHF) to tetrahydrofolic acid (THF) (Amyes & Smith,
1974). The consequent depletion of tetrahyrofolates which are required for amino-
acid (methionine and glycine) and purine synthesis leads to inhibition of DNA and
protein synthesis. Like other bactericidal drugs trimethoprim does not elicit a
bactericidal response in the absence of protein synthesis, as shown when bacteria are
challenged in minimal media or in the presence of chloramphenicol, a protein synthesis
inhibitor (Amyes & Smith, 1974).
Bacteria exposed to trimethoprim undergo filamentation suggesting that the SOS
response is induced, as the SOS gene sfiA codes for a protein that binds to sfiB gene
product, which is essential for septation. The SOS induction has been shown to
contribute to lethality, as SOS deficient strains have increased resistance to
trimethoprim (Lewin & Amyes, 1991). The involvement of the SOS response and the
requirement for protein synthesis suggest that a higher regulatory signal transduction
pathway may be operating in trimethoprim induced cell death.
1.2.3 Aminoglycosides
Aminoglycosides primarily affect the process of translation in prokaryotes, via binding
to the 30S ribosomal subunit and consequently inhibiting protein synthesis. The
molecular basis for protein synthesis inhibition is due to a number of effects, such as
binding to 16S RNA (Fourmy el al., 1996), unstable initiation complex formation and
5
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elongation inhibition (Hausner et al., 1988), along with misreading during translation
(Gorini,1974). These effects do not however explain why aminoglycosides are lethal
to bacterial cells.
Chloramphenicol and other protein synthesis inhibitors which interact with the
ribosome exert bacteriostatic action, and ethionine a strong inducer of misreading
does not produce a rapid killing effect (Pine, 1978). Binding of streptomycin to
ribosomes is reversible and ribosomes are not irreversibly inactivated (Chang & Flaks,
1972). Efflux of antibiotic from cells would therefore be expected after a suspension
has been diluted for plating, which would lead to a bacteriostatic rather than a
bactericidal effect. Protein synthesis may not therefore be the sole target of
aminoglycoside action. Paradoxically it is also suggested that bactericidal activity
cannot proceed without protein synthesis (Jawetz et al., 1952).
The finding that streptomycin uptake is irreversible (Muir et al., 1984) led Davis
(1987) to propose the most recent and widely accepted hypothesis for aminoglycoside
action. The following sequence of events was proposed to account for cell death : 1)
antibiotic penetrates through imperfections in the growing membrane, 2) antibiotic
binds to ribosomes inducing misreading, 3) misread protein is incorporated into the
membrane creating channels, thus permitting influx of antibiotic, initiating the
autocatalytic process of increasing influx, misreading and channel formation, 4)
antibiotic concentration reaches a level that blocks protein synthesis due to binding to
6
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initiating ribosomes, 5) lethality is due to irreversible uptake and persistent protein
synthesis inhibition.
The Davis hypothesis may be widely accepted, however, there are a number of
reasons why it is unconvincing. It is firstly unclear why streptomycin uptake is
irreversible (Nichols, 1989), and Davis does not propose an explanation. The reason
why bactericidal aminoglycosides like streptomycin and gentamicin are bactericidal,
whereas compounds which have closely related structures like the aminocyclitols are
only bacteriostatic can also not be explained. It also remains controversial whether
misreading is required for bactericidal action (Hausner et al., 1988). Some
aminoglycoside rpsL revertants that have increased sensitivity to streptomycin show
no effect on misreading (Dabbs, 1980), and error frequency can also be reduced to
normal when streptomycin is removed suggesting that misreading is reversible
(Edelmann & Gallant, 1977). A further argument against the Davis hypothesis is that
treatment with streptomycin increases the passive permeability of the E. coli
membrane to several small ions (Busse et al, 1992), however the changes are small
and the membrane potential remains high meaning that transmembrane channels are
highly unlikely.
The fact that aminoglycoside treated cells have enhanced protease activity (Hipkiss &
Kogut, 1973) led Busse et al.(1992) to propose an explanation as to why
aminoglycosides remain in cells. They proposed that rapid proteolysis ofmistranslated
proteins in the cell membrane cages the antibiotics within cells, leading to prolonged
7
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protein synthesis inhibition. However, sensitive cells treated with streptomycin lose
colony forming ability before many of the changes in metabolism implying that binding
to a critical target and consequent protein synthesis inhibition do not necessarily
constitute the lethal event (Hancock 1981).
Aminoglycosides may have a second target site responsible for the lethal event.
Hancock (1981) originally proposed that the oriC DNA membrane attachment site
was affected in aminoglycoside treated cells. Subsequently Matsunaga et al. (1986)
demonstrated the ability of hebakacin and related aminoglycosides to inhibit re¬
initiation of DNA replication and oriC membrane attachment. Attachment of oriC
DNA to the membrane is required for initiation of chromosome replication. The
sequential events of membrane damage and inhibition of DNA initiation and protein
synthesis may progress synergistically resulting in cell death.
The involvement of stress proteins has also been implicated in aminoglycoside action.
Bakker (1992) demonstrated that hygromycin B, a bactericidal aminocyclitol, which
does not induce misreading may induce lethality as a side effect. After hygromycin B
challenge, E. coli produced certain proteins such as EFtu and OmpA with high speed
and fidelity. They also showed that streptomycin, gentamicin and neomycin treated
cells produced stress proteins postulated to be DnaK and GroEL as well as Lon and
other proteases. The role of these proteins in cell death has not been assessed. It is
clear that despite a large body of research on aminoglycoside induced cell death, the




Fluoroquinolones are broad-spectrum potent antimicrobial compounds that target two
essential enzymes in the bacterial cell, DNA gyrase and topoisomerase IV (Levine el
al. 1998). DNA gyrase is constituted of two sub-units encoded by the genes gyrA and
gyrB (Swanberg & Wang, 1987), with topoisomerase IV constituting of parC and
parE (grlA and grlB in Staphylococcus aureus) gene products (Kato et al., 1990).
DNA Gyrase introduces negative supercoils into DNA, and thereby relieves the
torsional stress which would be expected ahead of transcription and replication
complexes (Reece & Maxwell, 1991). Topoisomerase IV (TopoIV) is a decatenating
enzyme, unlinking newly replicated DNA, thereby allowing proper chromosome and
plasmid segregation. As quinolones inhibit these essential enzymes bacterial growth
inhibition is expected, however these drugs are bactericidal, and their death
mechanism appears to be much more complex than simple enzyme inhibition.
Before an understanding of the basis of quinolone action can be deduced, it is
important to analyse the morphological and physiological effects on bacteria. These
include an inhibition of DNA and protein synthesis, (Piddock et al., 1990), induction
of the SOS response (Piddock & Wise, 1987) and cell filamentation (Diver & Wise,
1986). It is likely that DNA damage caused by quinolones activates RecA which turns
on the SOS response due to interaction with LexA, consequently resulting in cell
filamentation. Piddock and Walters (1992) used mutants of E. coli deficient in SOS
response to demonstrate that SOS had a role in repair ofDNA damage induced by the
quinolones. The heat shock response is also induced (Krueger and Walker, 1984),
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however its precise significance is unknown. It may have a role in degrading SOS
proteins and is likely to be a secondary effect in quinolone action (Walker, 1984).
The physiological effects of quinolones seem diverse, however they can be partly
explained by the molecular effects of the drugs on their targets proteins. Snyder and
Drlica (1979) demonstrated that inhibition of DNA synthesis correlated with the
formation of oxolinic acid/gyrase complexes, leading them to hypothesise that such
complexes may block replication folk movement. Complexes are also formed by drug
interaction with topoisomerase IV in a similar manner, with analysis of quinolone/
topoisomerase IV complexes indicating that quinolones stimulate DNA cleavage/
religation reactions (Anderson et al., 1998). It is worth noting that due to their
different roles in DNA replication, the interaction with gyrase causes a rapid inhibition
ofDNA synthesis, whereas TopoIV targeting does not lead to a rapid block in DNA
replication (Khodursky et al., 1995). These lesions on the DNA consequently block
the movement of polymerases. These complexes can be converted to lesions which




Figure 1.1: Intracellular action of fluoroquinolones
Gyrase orTopoisomerase IV + DNA





{DNA broken but restrained by
topoisomerase subunits; DNA
synthesis, cell growth blocked)
Release of broken DNA ends
(Cell death)
(From Drlica & Zhao, 1997)
It is important not to oversimplify the mechanism of quinolone action. Although we
have an understanding of quinolone target interactions, we do not know the precise
mechanism of cell death after complex formation. Trapping of the cleaved
DNA/topoisomerase complex is only the first in an intricate series of events (notably
SOS induction, and illegitimate recombination) leading to cell death. Smith (1986)
showed the response of an E. coli population when challenged with the quinolone
antibiotics (Figure 1.2). This survival curve demonstrates that fluoroquinolones have
an optimal bactericidal concentration, above which killing activity decreases. It was
hypothesised that RNA and protein synthesis inhibition may account for the second
11
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phase of quinolone activity in which increasing drug concentrations lead to less
killing, thereby demonstrating a requirement ofprotein synthesis in cell death.
Figure 1.2: Optimum bactericidal concentration (Smith, 1986)
Survival of E. coli KL16 cells challenged with: — nalidixic acid ■, norfloxacin □
ofloxacin •; ciprofloxacin O; after 3 h growth.
Smith (1986) proposed three mechanisms of quinolone killing:- Mechanism A
(common to all quinolones) requires RNA and protein synthesis and is only effective
against dividing bacteria: mechanism B which does not require RNA and protein
synthesis and can act on bacteria unable to multiply; mechanism C requires RNA and
protein synthesis, however does not require cell division. More recent work by Chen
et al. (1996) also supports the idea of three mechanisms of cell killing. Mechanism A
12
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would be blocking of replication by the gyrase/quinolone complex, mechanism B may
be dissociation of gyrase subunits which constrain the ternary complex, and
mechanism C may correlate with trapping of topoisomerase IV complexes on DNA.
The events between DNA breakage and cell death remain unresolved.
1.2.5 The post-antibiotic effect
The method classically used to measure the bactericidal activity of antibiotics on a
given cell population is the viable count method (Hanberger et a/., 1990). This
involves removing the antibiotic from cells at time intervals after an antibiotic
challenge, plating onto suitable culture medium, and analysis of colony formation. In
fact, after antibiotic is removed from a culture, cells can maintain metabolic activity
for long periods of time. Bacterial populations begin to recover with time and
exponential growth is re-established, this time period is known as the post-antibiotic
effect (PAE).
The viable count method does not therefore give a measure ofwhether a cell is dead,
only whether it has lost colony forming ability, and these two are not necessarily
related. Post-antibiotic effect has been measured using viable counts (Hanberger et
al., 1991), microphysiology (Libby, 1998), bio-illuminescence (Hanberger et al.,
1990), however only recent studies utilising flow cytometry have given good
morphological data concerning the fate of these bacterial populations (Gottfredsson et
al., 1998; Wickens et al., 2000). Deductions concerning antibiotic action can be
gleaned from an understanding of this effect. If once challenged with an antibiotic,
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cells are condemned to death, they cannot divide again. However the fact that post¬
antibiotic effect exists show that some cells do survive, the questions of how and why
are yet to be answered. It may be that cells that survive have not undergone the death
pathway and are recoverable once antibiotic is removed, even though they cannot be
immediately cultured. Alternatively they may be present in too small numbers for
culture.
After antimicrobial treatment ((3-lactams, fluoroquinolones, trimethoprim) cells
undergo filamentation due possibly to SOS response induction (Diver & Wise, 1986;
Rolinson, 1980; Amyes & Smith, 1974). Guan and Burnham (1992) suggested that
these filamentous cells divide again after ciprofloxacin removal and proceed to normal
growth. Wickens et al. (2000) however do not support this early hypothesis and
propose that filamentous cells do not divide again. They suggest that growth after
antibiotic removal is due to a small proportion of normal sized cells present. As these
cells have not filamented it may suggest that SOS response is not yet induced, and
therefore, may be a prerequisite for cell death.
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Figure 1.3: Filamentous cells post antibiotic treatment
Morphological response ofE. coli KL16 cells to ciprofloxacin, (a) drug free control
and (b) 2h incubation with ciprofloxacin at 60mg/L (From Diver & Wise, 1986)
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1.3 Bacterial programmed cell death
As seen in the mechanisms of cell death, there is commonality in that they induce a
stress response either by activation of SOS proteins or induction of the heat shock
response. Induction of these systems may lead to a mechanism of cell death involving
bacterial "apoptosis" or "programmed cell death".
1.3.1 Addiction Modules
The bacterial toxin CcdB encoded by the F plasmid ccd locus belongs to a recently
discovered programmed cell death system (Jensen & Gerdes, 1995). This toxin kills
bacteria in an analogous manner to the quinolone antibiotics via interaction with DNA
gyrase, DNA damage and consequent SOS response induction. The presence of these
systems can be explained, as they promote plasmid carriage within cells. In plasmid
containing cells, both antidote and toxin are present, thereby the toxin is neutralised
and the cells are viable. In plasmid cured cells, however, the antidote and toxin are no
longer synthesised, and the unstable antidote is degraded by a specific protease
allowing the toxin to exert its affect (Gerdes et al., 1997). The cell is therefore
addicted to the plasmid, hence the name addiction module.
Plasmid-encoded programmed cell death systems also possess chromosomal
analogues, like the MazEF system described by Aizenman et al. (1996), consisting of
a MazE (antidote) and MazF (toxin) which form an operon with the relA gene of the
stringent response. MazEF killing is negatively regulated by 3 ,5' -bispyrophoshate
ppGpp (Aizenman et al., 1996), implying that cell death therefore also associates with
16
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the stringent response. Proteins produced during the stringent response degrade the
MazE antidote allowing the toxin to express its function. The negative regulatory
effect of ppGpp on the programmed cell death system may be responsible for bacterial
survival during post-antibiotic challenge, as seen with ppGpp effect on the stringent
response after (3-lactam treatment. The stasis response during the bacterial post¬
antibiotic effect could also therefore modulate this system meaning that bacteria are
not subjected to programmed cell death mechanism during this period. It is known
that heat shock, starvation and stress response all modulate this system (Figure 1.4).
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The stringent response blocks further production of MazEF and allows the more
stable MazF toxin to express its killing function. (From Nystrom, 1998)
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As bacteria are single cells is it difficult to imagine why they should behave in an
altruistic fashion, however work by Shapiro (1997) has challenged the conventional
view of bacterial colonies composed of identical individuals. Shapiro (1997)
demonstrated that bacterial populations constitute multi-cell structures in which
individuals may undergo genetic variation. In this context it is understandable how
programmed cell death mechanisms may exist. Under a stress (i.e. starvation,
antibiotic challenge), death of certain sub-populations may occur which may benefit
the population as a whole. The fact that bacteria also produce signals (quorum
sensing) in certain environmental conditions, allowing the population to respond
supports the hypothesis that bacterial populations have structure (Gray, 1997;
Kleerebezem et al., 1997). It may be that mutagenic systems ensure species survival
by killing or promoting adaption of a fraction of the bacterial population. The
question of whether this is the case after an antibiotic challenge remains an important
question for future research.
1.3.2 Free radical production
It has been a long accepted fact that the growth phase of a bacterial population affects
its susceptibility to certain antibiotics. Antibiotics generally exert their greatest killing
activity when a bacterial population is at log/exponential phase growth, and can have
significantly reduced effect when a bacteria are slow growing or in stationary phase
(Eng et al., 1991).These differences may be reconciled with a requirement for active
protein synthesis in bactericidal drug action, and programmed cell death may play a
part in this.
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Dodd et al. (1997) suggest that the lethal effects associated with stress and chemical
challenge can result in self-destruction of cells or "suicide", and in exponentially
growing cells suggest that this is due to an oxidative burst occurring after growth
arrest. As it is known with the post-antibiotic effect, a celf s metabolism may be active
long after growth arrest, and a build up of free radicals is thought to trigger death.
Stationary phase populations may be more resistant to death because of their low
metabolism. Lamlertthon et al. (1999) supports this hypothesis by demonstrating that
free radical scavengers can increase resistance to certain biocides. Bacterial metabolic
rate has a considerable effect on cell death, and these new insights shed light into
general death mechanism which may be applicable to bacterial reaction to a variety of




The interactions between drugs and their molecular targets are complex, and can be
heavily dependent upon the structure of the drug. Drugs may also target different
enzymes in different bacterial species. Understanding these interactions will aid better
drug design, with an emphasis on resistance minimisation.
1.4.1 Quinolones: structure-activity relationships
The first quinolone to be synthesised was nalidixic acid (Figure 1.5), discovered as a
by-product of the chloroquinine purification process (Lesher et al., 1962). This agent
was used extensively to treat urinary tract and enteric infections due to its high
potency for Enterobacteriaceae (Hooper, 1998). The basic quinolone core has
subsequently undergone numerous modifications, leading to quinolones with
increased potency, broader spectrum and improved pharmacokinetic profiles.
The most significant discovery in the development of quinolones came when it was
discovered that insertion of a fluorine atom at C-6 of the quinolone core enhanced and
broadened antimicrobial activity (Koga et al., 1980). The development of newer
quinolones with antibacterial activities a thousand times that of nalidixic acid followed
(Smith & Lewin, 1988). Structures of quinolones (Figure 1.5) have since developed
along two main pathways (Table 1.1): the napththyridones (e.g. gemifloxacin)
(containing original nalidixic acid core), and the fluoroquinolones (e.g. ciprofloxacin
Figure 1.5) in which a carbon atom is substituted for a nitrogen at position 8 of the
nucleus (Cormican & Jones, 1997; Domagala, 1994). All have a fluorine atom at
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position 6. Modifications of groups N-l, C-6, C-7 and C-8 positions have also been
particularly successful in enhancing antimicrobial activity (Chu & Fernandes, 1989)
The precise mechanisms by which these substitutions affect potency are unknown,




Figure 1.5: Structure of fluoroquinolone and napthyridone derivatives


















































trovafloxacin enhanced Gm +ve
activity, respiratory
infection,
I lib none developed gemifloxacin markedly enhanced
Gm+ve & Gm-ve
activity
Gm +ve = Gram-positive bacteria
Gm -ve = Gram-negative bacteria
From Ball (2000)
The second generation fluoroquinolones such as ciprofloxacin have a wide spectrum
of antimicrobial activity, and are particularly potent against Gram-negative infections
such as Escherichia coli (Krumpe et al., 1999). They target mainly DNA Gyrase
within the bacterial cell. They however are less effective against gram-positive
organisms, such as pneumococcal respiratory tract infection (Lee et al., 1991). This
has been addressed by the development of agents with enhanced gram-positive
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activity such as moxifloxacin (Dalhoff et al., 1996), gatifloxacin (Perry et al., 1999),
and gemifloxacin (Cormican & Jones, 1997). The second and third generation
fluoroquinolones target two bacterial enzymes, both DNA gyrase and topoisomerase
IV. Earlier fluoroquinolones such as ciprofloxacin with primarily gram-negative
activity target primarily DNA gyrase, whereas fluorquinolone with enhance gram-
positive activity target primarily topoisomerase IV in E. coli. DNA gyrase and
topoisomerase IV are secondary targets in gram-positive and negative bacteria
respectively and may also be dual and equal targets for some drugs (see section
1.5.4).
Recent studies by Dong et al. (1998) have found that substituting a C-8-methoxy
group can change the target specificity of the quinolone, and make the drug more
likely to bind to dual targets. Zhao et al., (1999) consequently demonstrated that a C-
8-methoxyl fluoroquinolone was four times more effective against Mycobacterium
tuberculosis than a C-8-H control and the fluoroquinolone ciprofloxacin (Figure 1.6).
These drugs have increased potency against first-step gyrase and topoisomerase IV
resistant mutants, and also fewer resistant mutants are selected when bacteria are
challenged with a C-8-methoxyl than with a C-8-H derivative. This has important
consequences for resistance minimisation. Alovero et al. (2000) also found that
addition of a benzenesulfonamide group to the C-7 piperazyl ring of ciprofloxacin
increase potency against Streptococcus pneumoniae, and changes target specificity of
the quinolone from DNA gyrase to topoisomerase IV.
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PD161148 - (C8-Ome) compound PD160793 (C8-H) control. The arrow indicates
the C-8 position. (From Zhao el al., 1999)
1.4.2 Quinolone -Topoisomerase Binding
There are several models of how quinolones bind to the cleavable complex formed
with DNA Gyrase and Topoisomerase IV, however a clear consensus is yet to be
reached. Most research has focused on the interaction between quinolone, DNA and




1.4.2.i Interaction between quinolone and DNA gyrase/DNA complex
Before binding studies were carried out, it was believed that quinolones bound
directly to GyrA (Gellert et al., 1977), as quinolone resistance mutations occurred in
the gyrA gene. The occurrence of quinolone resistance mutations in the gyrB gene
further suggested that the quinolone binding site may encompass both sub-units
(Yamagishi et al., 1986).
In 1985 Shen and colleagues carried out binding studies, which suggested contrary to
popular belief that quinolones do not bind to gyrase, but rather to DNA. Shen et al.
(1989) later proposed a co-operative drug binding model, in which drug binds to a
single-stranded DNA-binding pocket revealed following DNA cleavage by gyrase.
The quinolone drugs are thought to interact with the bases through hydrogen bonds
which occur between the 3-carboxy and 4-oxo groups which almost all quinolones
possess (Figure 1.7). At least 4 molecules are believed to bind per binding site and
ring stacking and hydrophobic interactions contribute to this cooperativity. Shen et al.
(1989) postulated that gyrase interacts with the C-7 position of the drug, however
Maxwell (1992) later pointed out that the C-7 group is variable in the quinolones.
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Figure 1.7: Quinolone binding model (Shen et al., 1989)
Filled and hatched boxes represent quinolone molecules inside a gyrase-induced single
stranded DNA binding site. (From Shen et al., 1989)
A later finding by Critchlow and Maxwell (1996) disputes Shen's model by
demonstrating that drugs still bind gyrase with mutations at the active-site tyrosine
(Tyr 122 —» Ser/Phe in GyrA), despite being unable to cleave DNA. They proposed
that a pre-cleavage complex between gyrase, quinolone and DNA exists, which is
converted to a perhaps more stable complex following DNA cleavage. Capranico et
al. (1993) suggest that quinolones intercalate in the space next to the cleaved
phosphodiester bond of DNA, with modelling studies by Llorente et al. (1996)
supporting this hypothesis.
Palumbo et al. (1993) proposed an alternative model which involves drug binding to
phosphates in DNA via a Mg2+ bridge, with interaction with the quinolone by ring
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stacking (Figure 1.8). Yoshida et al. (1993) believed that drugs bind in a pocket
appearing during DNA cleavage and reunion process with GyrA and GyrB sub-units
determining binding affinity. It is clear that the precise mechanism of binding between
quinolone, topoisomerase and DNA is unknown, and requires the use of high
resolution structure studies, made particularly difficult by the large size of DNA
gyrase (~ 400 kDa).




Quinolone drugs are though to bind to DNA via a Mg2^ bridge between the C-3 and
C-4 groups and phosphate groups of the DNA. Interaction between gyrase and drug
is proposed to occur via C-7 and N-l substituents on the quinolone.
1.4.3 Aminoglycosides: structure-activity relationships
The aminoglycoside group of antibiotics are biologically active bacterial secondary
metabolites. They are structurally defined by the presence of amino sugars bound by
glysosidic linkage to a dibasic cyclitol nucleus. In streptomycin the dibasic cyclitol is
streptidine, however in most of the clinically used aminoglycosides subsequently
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developed, it is 2-deoxystreptamine. Conserved elements of aminoglycosides are rings
I and II, and within ring II the amino groups at positions 1 and 3 (Figure 1.9). Drugs
with enhanced potency have been developed by substituting the 2-deoxystreptamine
ring at positions 4 and 5, as for neomycin, and positions 4 and 6, as for kanamycin,
gentamicin and tobramycin (Figure 1.9).
Aminoglycosides are active against a wide range of aerobic gram-negative bacilli,
many staphylococci and certain mycobacteria (Edson & Terrell, 1999). Streptomycin
has a particular role in the treatment of multi-drug resistant Mycobacterium
tuberculosis, and gentamicin for treating serious hospital acquired infections caused
by Enterbacteriaceae and P. aeruginosa (Edson & Terrell, 1999). Their severe
nephro and ototoxicity limit the clinical use of aminoglycosides (Kahlmeter &
Dahlager, 1984).
Attempts to make semi-synthetic aminoglycoside derivatives have focussed on drugs
which will be able to overcome aminoglycoside modifying enzymes, the main
mechanism of aminoglycoside resistance (see section 1.5 .3); for example tobramycin
lacks a crucial 3 -hydroxyl group, therefore it is no longer a substrate for APH(3 )
enzymes. Amikacin has an acetylated N-l group, which makes it a poor substrate for
a number ofmodifying enzymes.
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The A-site (530 loop) of the 16S ribosomal RNA within the 30S ribosomal complex
was identified as a main aminoglycoside target, when Moazed and Noller (1987)
demonstrated that aminoglycosides protect the region from binding to chemical
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probes. The protected area was implicated in the function of the drug, as the A-site is
involved in the decoding process, and therefore this observation corresponded with
mechanism of action.
To analyse the precise structural interaction however, X-ray analysis has been
performed. Clemons et al. (1999) obtained an X-ray structure of the 30S complex of
Ihermus thermophilus ribosomes, giving a 3-dimensional picture of the decoding site,
however the precise contacts between antibiotic and target could not be visualised. An
alternative approach has been the determination of a NMR structure of a model A-site
complexed with the aminoglycoside paromycin (Fourmy et al. 1996). The decoding
site is an irregular helix that binds antibiotic via its major groove, and contacts the
codon-anticodon complex via its minor groove. Aminoglycosides are multiply charged
compounds with high flexibility. Their positive charges are attracted to the negatively
charged RNA backbone, and their flexibility facilitates binding into the major groove.
Binding of antibiotic to RNA induces a conformational change in RNA, switching the
A-site into a high affinity state for mRNA-tRNA recognition (Fourmy et al., 1998).
This increased affinity may lead to misreading of the genetic code.
Aminoglycoside drug structure determines where the drugs bind on rRNA, with
neomycin, gentamicin and kanamycin binding to the A-site of 16S RNA in E. coli in a
similar manner (Moazed and Noller, 1987). Rings I and II of the neomycin class of
antibiotics has been shown to target binding to a unique pocket in the 16S RNA
(Fourmy et al., 1996). Alper et al. (1998) suggested that the 1,3-hydroxylamine
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moiety present in almost all aminoglycosides may also be an important recognition
motif for RNA binding.
Figure 1.10: Sequence of the decoding region A-site from E. coli rRNA
In addition to targeting the 16S ribosome there is evidence that the 12S ribosomal
subunit is also a target of aminoglycosides, with mutations in ribosomal S12 leading
to streptomycin resistance and dependence (LaCoste et al, 1977; Funatsu & Wittman,
1972; Momose & Gorini, 1971). The S12 protein has been structurally linked to the
A-site (530 region) of the 16S RNA with residues in the 530 stem protected by the
S12 protein in chemical protection experiments (Stern et al., 1988). Moazed and






Quinolones are known to target the enzyme DNA gyrase in the bacterial cell (Yoshida
et al., 1988). Sequence analysis of DNA from many bacterial species has
demonstrated resistance mutations near the active site (Tyr 122 in E. coli) in the
GyrA protein. This region, at the amino terminus between amino-acids 67 and 106,
has been named the quinolone resistance determining region (QRDR). The residues
which have been found to change correlating with an increase in MIC of quinolone
drugs are as follows: alanine-67, glycine-81, serine-83, alanine-84, aspartic acid-87
and glutamine-106 (Table 1.2) (Reece & Maxwell, 1991), however mutations in
serine-83 and aspartate-87 are known to confer the greatest reduction in quinolone
susceptibility (Hallett & Maxwell, 1991; Oram & Fisher, 1991; Yoshida et al., 1990).
Mutations at serine-83 to a leucine or tryptophan residue confer the greatest levels of
resistance (Table 1.2), and it was therefore implicated that hydrophobic residues at
these positions confer the quinolone resistance phenotype (Yoshida et al., 1990). The
bulkiness of leucine and tryptophan residues may also destabilise the quinolone gyrase
interaction and prevent access to the binding pocket. It has also been proposed that
hydrophilic residues serine-83, aspartate-87 and glutamine-106 participate in
hydrogen-binding interactions with the drug (Hallett & Maxwell, 1991). The Binding
model proposed by Shen et al. (1989), suggests that hydrogen bonding occurs
between DNA and the drug, whilst enzyme drug interactions occur with the C-7
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group of the quinolone (section 1.4.2.i). Mutations may destabilise this quinolone-
enzyme interaction.
Table 1.2: Mutations in the QRDR of the E. coli gyrA gene
Amino Acid Ammo-Acid MIC Change* Reference
Position Exchange Ciprofloxacin
(mg/L)
67 Ala—»Ser 4 Yoshida et al., 1990
81 Gly->Cys 8 Yoshida et al., 1990
81 Gly—»Asp not detectable Cambau et al., 1993
83 Ser—»Ala 4 Hallett & Maxwell,
1991
83 Ser-»Leu 32 Yoshida et al., 1990
83 Ser-»Trp 32 Yoshida et al., 1990
84 Ala—»Pro 8 Yoshida et al.,\ 990
87 Asp—»Asn 16 Yoshida et al., 1990
87 Asp—>Val 5 Yoshida et al., 1990
87 Asp->Tyr 8 Heisig et al., 1993
106 Gin—>Arg 4 Hallett & Maxwell,
1991
106 Gin—>His 4 Yoshida et al., 1990
* The change in MIC is given as the factor by which the MIC has changed to the original parent
strain. (Note: Above mutations were generated by either site-directed mutagenesis, in vitro selection
or direct analysis of clinical isolates, thereby MIC values may not be directly comparable)
The GyrB protein of DNA gyrase is also known to have a quinolone resistance
determining region (Yoshida et al., 1991), however mutations in this area are thought
to be ofminor importance, and may be at distant sites from the active site. Mutations
have been described at central residues aspartate-426 to asparagine and lysine-447 to
glutamate, and have the effects of raising quinolone MICs (Yamagishi et al., 1986).
Only a small increase in MICs of nalidixic acid, oxolinic acid and cinoxacin were
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detected for both mutations, however the change of aspartate-426 to asparagine
conferred fluoroquinolone resistance (Yamagishi et al., 1986). GyrB mutations may
lead to resistance due to different contacts with GyrA being formed, and therefore a
change in the quinolone binding pocket.
1.5.2 DNA Topoisomerase IV
Kumagai et al. (1996) have demonstrated that mutations in DNA topoisomerase IV
(topoIV) may be associated with fluoroquinolone resistance. They identified ParC
mutations (Homologous to GyrA) among quinolone resistant E. coli isolates, at
positions equivalent to Glycine-78, Serine-80 and Glutamate-84 comparable to those
in the QRDR of GyrA. In E. coli ParC mutations contribute to resistance but only in
the presence of GyrA mutations and cause no resistance in strains with wild-type
GyrA.
ParE mutations have been found in conserved regions ofParE homologous to those in
GyrB, however these mutations are not thought to be important in the acquisition of
quinolone resistance (Ruiz et al., 1997). The contribution of mutation in ParC
depends on drug structure and bacterial species, with ParC mutations selected
primarily in gram-positive organisms.
1.5.3 The plasmid dominance test
Resistance conferred by mutations in the gyrA gene are recessive to wild-type DNA
gyrase (Gellert et al., 1977). When a plasmid with a sensitive gyrase is introduced into
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a cell which contains a resistant gyrA allele, the resistant phenotype is not seen
(Nakamura et al., 1989). This character relates to the mechanism of quinolone action,
as cleaved complexes may still form in a cell with a mixture of sensitive and resistant
gyrase sub-units. Removal of these complexes would release double strand DNA
breaks in the cell, which are lethal even in small numbers (Krasin & Hutchinson,
1977). The recessive nature of gyrase resistance has been used to attribute quinolone
resistance to gyrase mutations in a number of bacteria including E. coli, Klebsiella
pneumoniae and Pseudomonas aeruginosa. (Heisig & Weiderman, 1991, Nakamura
et al., 1989). Cells that acquire quinolone susceptibility when a WT plasmid is
introduced are inferred as gyrA mutants. Care must be taken when analysing these
tests, as mutations in secondary targets may be partially complemented by plasmid
encoded wild-type alleles. This is particularly important as topoisomerase IV is also a
drug target, and resistance may be due to mutation in this enzyme.
For topoisomerase IV of E. coli, no clear dominance is seen when resistant and
sensitive alleles are both present as single copy genes. In S. aureus, where
topoisomerase IV is thought to be the primary target, wild type ParC and ParE must
be over-expressed to confer sensitivity and mutant pctrC alleles introduced on a
plasmid can confer resistance (Yamagishi et al., 1996). The difference in dominance
between gyrase and topoisomerase IV may be due to the fact that fewer
topoisomerase IV cleavage complexes are trapped on the chromosome (Chen et al.,
1996). It is clear that the consequences of interactions of quinolones differ between
topoisomerase IV and DNA gyrase.
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1.5.4 Multiple mutations: primary and secondary drug targets
Deductions from in vitro mutation studies have shown that DNA gyrase is the primary
target in Escherichia coli, with GyrA mutation selected primarily followed by
topoisomerase IV mutations at higher quinolone MICs (Chen et al., 1996, Khodursky
et al., 1995). Topoisomerase mutations do not confer resistance in the absence of
gyrase mutation. Examination of clinical isolates supports in vitro mutation studies
regarding the location of GyrA and ParC mutations, however, data from isogenic
strains showing resistance progression is lacking. Mutation of serine-83 of GyrA
protein is associated with moderate level resistance, addition of one or two ParC
protein mutations correlates with increased resistance, 3 mutations (two GyrA and
one ParC) are associated with high-level resistance and four mutations (two GyrA and
two ParC) with very high-level resistance (Table 1.3) (Vila et al., 1996).
Table 1.3: Multiple mutations in GyrA and ParC proteins in clinical E. coli
isolates (Vila et al., 1996)
GyrA ParC MIC
(ciprofloxacin) mg/L
Ser83 Asp87 Ser80 Glu84
0.007-0.25
Leu - - - 0.25
Leu - Arg - 1-4
Leu - - Lys 4
Leu Tyr - Lys 8-32
Leu Asn lie - 8-64
Leu Asn Arg - 16
Leu Asn lie Val 64
Leu Tyr He Lys 128
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In S. aureus, topoisomerase IV appears to be the primary ciprofloxacin target (Ng et
al., 1996; Ferrero et al., 1995), as S. aureus DNA gyrase is less susceptible to
inhibition than E. coli gyrase (Blanche et al., 1996). Thus ParC mutations confer low
level resistance, with higher level resistance requiring additional mutations in GyrA
Gyrase mutations do not in themselves confer resistance (Ng et al., 1996). The
situation is similar in Streptococcus pneumoniae with ciprofloxacin (Munoz & de la
Campa, 1996), however sparfloxacin selects GyrA mutants before ParC mutants in
the same organism (Pan & Fisher, 1997). It therefore appears that quinolone structure
can alter target preference. One group of quinolones i.e. ciprofloxacin selects ParC
and ParE mutations suggesting that these drugs act preferentially through
topoisomerase IV in vivo (Janoir et al., 1996), whereas a second group typified by
sparfloxacin selects GyrA mutants in the first step, consistent with gyrase being the
primary target in vivo (Fukuda & Hiramatsu, 1999). Durham et al. (1999) have also
found that GyrA mutations can be selected preferentially to ParC mutations in an in
vitro mutation study, contradicting information from previous authors. This calls into
question the way in which in vitro mutation studies are performed without
standardised criteria, and how relevant they are to the clinical situation.
1.5.5 Contribution of non-target protein mutation to fluoroquinolone resistance
In addition to mutations affecting target enzymes, resistant isolates often show
reduced drug accumulation (Everett et al., 1996). The genetic basis of this remains
however obscure. In mutants selected in vitro Mar-like (multiple antibiotic resistance
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conferring) mutations seem to occur as second step mutations preceding further
mutations in drug targets (Heisig & Tschorny, 1994; Hooper el al., 1987). There is
discrepancy between in vitro selected mutants and clinical isolates, only half of which
express a Mar phenotype (Oethinger et al., 1998).
Mutations can occur which affect expression of porins (Mortimer & Piddock, 1993),
or active efflux of quinolone from the bacterial cell (Okusu et al., 1996). Tavio el al.
(1999) demonstrated that gyrase mutations were the principal determining factor in
high-level fluoroquinolone resistance, however changes in outer membrane proteins
(OMPs) and efflux were complimentary in determining quinolone MICs in in vitro
selected E. coli isolates. These mechanisms could facilitate resistance development in
the clinic, and facilitate subsequent acquisition of target protein mutations. They also
complicate studies of the contribution of individual target protein mutations to
quinolone resistance.
1.5.6 Increasing emergence of fluoroquinolone resistance in the clinic
During the late 1980 s there was a general optimism concerning the apparent lack of
potential for resistance development to the quinolones in a majority of organisms.
Clinically significant resistance was limited to staphylococci and Pseudomonas
aeruginosa, and even amongst these species, was confined to pathogens causing
pyogenic infections in tissue sites where penetration or activity of these agents is less
than optimal (e.g. Bone, prostate or abscesses) (Ball, 1990). This picture has however
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changed significantly, as it is inevitable with increasing reliance on this group of
antimicrobial agents.
Resistance among many other bacterial species including various streptococci,
gonococci, enteropathogens and opportunist Gram-negative pathogens (e.g. Serratia
marcescens) has now been reported (Ball, 1994). Among traditionally highly
susceptible enterobacteria such as Escherichia coli, for which fluoroquinolone
minimum inhibitory concentrations (MICs) are normally < 1 mg/L, resistance has until
recently only been very rarely observed (Lopez-Brea & Alarcon, 1990). However the
frequent use of norfloxacin and ciprofloxacin in prophylaxis of patients with
neutropenia and cirrhosis, as well as in therapy of urinary tract infections seems to be
associated with the emergence of resistance in this previously fluoroquinolone
susceptible organism (Pena et al., 1995). This may have severe consequences for the
treatment of invasive illness and therefore it is imperative that we monitor this
emerging trend.
The first reports of emergence of fluoroquinolone resistance in E. coli originated from
Spain. Pena et al. (1995) observed increasing resistance to ciprofloxacin among E.
coli strains isolated in blood cultures at the Hospital de Bellvitge, Barcelona. The
rates ofE. coli bacteraemia caused by ciprofloxacin resistant strains increased steadily
from 0% to 7.5% in 1992. Carratala et al. (1995) also performed a similar study in a
teaching hospital in Barcelona and showed that 37% of E. coli bacteraemia in
neutropenic cancer patients was due to quinolone resistant strains, correlating with an
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increasing reliance on fluoroquinolones during the study period. Although the reports
of rapid increases in the prevalence of highly fluoroquinolone resistant E. coli often
appear in Spain, the extent of quinolone use in other European countries leaves no
room for complacency.
The U.K. is already beginning to experience problems with the emergence of
ciprofloxacin resistance in clinical E. coli isolates, as reported by Threlfall et al.
(1997). In the three year period Nov 1993 to Nov 1996, resistance to ciprofloxacin
was detected in isolates of E. coli from 40 patients with invasive illness or urinary
tract infection (MICs ranging from 4-256 mg/L). All the isolates were resistant to at
least one additional antimicrobial with the majority being multiply resistant (4 or more
antimicrobials). Also in Germany the prevalence of fluoroquinolone resistance among
clinical isolates of E. coli increased from <1% to 5% between 1990 and 1995
(Kresken et al., 1994). Thomson (1999) has also reported a general trend of
increasing fluoroquinolone resistance. The fact that resistance is generally
chromosomally encoded has meant that resistance spread has not been as prolific as it
could be, however the report by Martinez-Martinez et al. (1998), showing that
quinolone resistance can be transferred by a plasmid vector thereby giving the
potential for rapid spread is of great concern. Although the resistance acquired with
this plasmid was low, emergence of high-level resistant mutants was over 100-fold
higher in strains with the plasmid compared to wild-type strains.
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Epidemiological studies utilising pulsed field gel electrophoresis (PFGE) and PCR-
based typing methods have shown that clinical resistance to the fluoroquinolones
emerges as a combination of horizontal transfer of clonal strains, and individual
selection of resistant isolates (Lehn et al, 1996; Oethinger et al., 1996). However
there seems to be a prevalence of individually selected resistant strains, with clonal




1.6 Ribosomal protein mutation
Aminoglycosides are known to interact with the 30S ribosomal sub-unit of the
prokaryotic ribosome. Much knowledge about drug binding has been recently derived
from structural studies of aminoglycoside 16S RNA complexes (Fourmy et al., 1996)
Data from mutation studies have also implicated a role for ribosomal protein S12 and
16S RNA in aminoglycoside interaction. It should however be noted that these studies
generally utilise streptomycin, and resistance mutation to other aminoglycosides are
not well characterised.
1.6.1 S12 protein mutation
The rpsL gene of E. coli encodes the highly conserved S12 protein of the ribosomal
accuracy centre. The ribosomal accuracy centre is a component of the cellular
translation apparatus (Kurland & Ehrenberg, 1984), comprising of a ribosomal RNA
domain and several polypeptides of the small sub-unit including SI 2, S4 and S5. The
study of mutations in the S12 gene has provided information about aminoglycoside
binding and mode of action.
Mutations in the rpsL gene, encoding S12 have been found to generate resistance and
in some cases dependence on high-levels of streptomycin (> 25mg/L) (Funatsu &
Wittman, 1972; LaCoste et al., 1977). These mutations map to two specific regions
of the polypeptide, centred on residues 41-43 and 85-91, notably the two lysine
residues at positions 42 and 87. Mutations to any of four amino acids (lysine,
asparagine, threonine of arginine) have been found at position 42, whereas mutation
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at position 87 is typically to an arginine residue (Funatsu & Wittman, 1972). The
MICs of mutants selected in a single step generally range from 64 —» > 4000mg/L
(Bryan & van den Elsen, 1977), depending on other genetic mutations present in cells.
Clinically significant resistance to streptomycin in Mycobacterium tuberculosis is due
to rpsL mutation at positions 43 and 88 of Lys to Arg/Thr (Finken et al., 1993, Nair
et al., 1993). Streptomycin dependent strains may have changes at position Lys87
(Timms et al., 1992). Glutamine in position 42 has also been found in some
streptomycin dependent mutants (Funatsu & Wittman, 1972).
Streptomycin resistance mutations are associated with the phenotypic suppression of
nonsense mutations (Gorini, 1971), and altered expression of translationally regulated
proteins (Redaschi & Bickle, 1996). Streptomycin dependent strains exhibit hyper-
accurate translation with general growth impairment (Ruusala & Kurland, 1984),
reduced ternary complex formation and reduced translational elongation rate (Bilgen
et al., 1992; Bohman et al., 1984). The normal role of S12 seems to maintain some
slight imperfections in decoding, the mutant S12 enforces a more precise expression
of each codon in a mRNA (Bohman et al., 1984). Streptomycin resistance mutations
are likely to antagonise the effect of structural change in SI2, restoring the ribosome
to its normal position and hence permitting a low level of inaccuracy in translation.
Streptomycin dependence mutations in S12 may cause the ribosome to become too




It has been seen how a single amino-acid position mutation can confer high-level
resistance, and deductions have been implied for aminoglycoside binding. Chang &
Flaks (1972) concluded that rpsL mutants have lost a single high affinity binding site
in the ribosomal sub-unit, however can maintain low affinity binding sites. However
subsequent experiments by Lelong et al. (1974), showing that S12 antiserum does not
block streptomycin binding and therefore it may be that S12 forms part of a 3-
dimensional binding pocket influenced by several ribosomal proteins. Moazed and
Noller (1986) implicate S12 in the stabilisation of 16S ribosomal RNA (see section
1.3.4). Mutations in S12 have not been described for the other aminoglycosides, and it
would be interesting to understand their relationship with this important target
protein.
1.6.2 Mutation in 16S RNA
Structural studies have confirmed that aminoglycosides bind to the 16S ribosomal
RNA of the 30S sub-unit. Before structural studies confirmed this, some evidence for
16S RNA as a ribosomal target was deduced from studies on resistant mutants.
Although streptomycin resistance in E. coli is usually linked to mutations in the S12
ribosomal protein, Montandon et al., (1985) isolated mutants of Euglena gracilis
with streptomycin resistant chloroplasts which had a point mutation in (C876T) in the
16S RNA gene. To examine the contribution of 16S mutation to streptomycin
resistance in E. coli the authors used site-directed mutagenesis to introduce this
mutation and found that transformed cells expressed resistance (Montandon et al.,
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1986). Bonny et al. (1991) showed that point mutations in the 912-915 region of 16S
RNA can confer resistance in E. coli, however these mutations are not generally
isolated by natural means. These mutations confirm a role of the 16S rRNA in
binding, while S12 mutations may influence the availability of this site (Garvin et al.,
1974).
1.6.3 Mechanism of aminoglycoside resistance in the clinic
Unlike the situation with the fluoroquinolones, mutations in target proteins are rarely
associated with aminoglycoside resistance in the clinic. An exception to this is
streptomycin resistance caused by mutation in the 30S ribosomal segment of M.
tuberculosis. The most frequent and important mechanism of aminoglycoside
resistance are the plasmid mediated aminoglycoside modifying enzymes (Davies &
Wright, 1997; Shaw et al., 1993), which catalyse the covalent modification of amino
and hydroxyl functions, leading to chemically modified drugs which bind poorly to
ribosomes. Resistance in Enterbacteriaceae to neomycin, gentamicin, kanamycin
emerged as a result of this genetically transferable mechanism (Davies & Wright,
1997). Reduced drug uptake, mostly seen in Pseudomonas spp., is likely to be due to
membrane impermeabilisation, but the underlying molecular mechanism is largely
unknown (Chambers & Sande, 1995). Active efflux has been evidenced for neomycin,
kanamycin and hygromycin A in Escherichia coli (Edgar & Bibi, 1997), however its
clinical significance is still undetermined (Lynch et a/., 1997; Nikaido, 1996).
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1.7 The Complexity of Mutation Selection
An understanding of the way in which mutants are selected is crucial if we are to
minimise drug resistance and preserve our antimicrobial armoury. It is clear that there
are many factors involved in selecting resistant mutants, from environmental
constraints, to bacterial physiological state. It is also very highly drug structure
dependent, with those drugs aimed at targeting more than two enzymes more likely to
minimise the emergence of resistance. This is crucial knowledge for future drug
design.
1.7.1 Mutation rate
When a bacterial population is subjected to antibiotic challenge, selectively favourable
mutations occur which may lead to a visibly resistant phenotype. "Mutation rate" is
often defined as the in vitro frequency of mutant selection at a given antibiotic
concentration.
The analysis of mutation rate is complicated by the fact that mutations in different
genes produce similar antibiotic resistance phenotypes. The quinolone resistance
mutation rate is a result of a combination ofmutations of the genes that encode GyrA,
GyrB, ParC, ParE and multi-drug resistance (MDR) systems (Hooper, 1999). With
new found knowledge of the way bacterial populations behave, we are grasping the





Mutability can be defined as the probability that a mutation will produce an antibiotic
resistance phenotype, and is dependent upon the number and structure of genes in
which mutations produce resistance. These mutations must be non-lethal, not produce
a significant fitness loss, and produce resistance. The probability of this type of
mutation occurring will depend on the number of these positions in the target
enzymes. An example is in E. coli where fluoroquinolone resistance can be conferred
by changes at seven different positions in gyrA gene, however only 3 in the parC
gene, and consequently gyrA mutants are more prevalent than those in parC (Hooper,
1999). In Streptococcus pneumoniae, only 2 gyrA changes are known, however there
are 5 changes in parC, and therefore parC mutants are more frequently found.
Streptomycin resistance results from a change in one or a few nucleotides in the
ribosomal S12 gene and therefore spontaneous resistance rate is low (Bonny et al.,
1991).
1.7.3 Independent and co-operative mutations
Many genes can be involved in antibiotic action and resistance as antibiotic interacts
with the cell via 1) direct antibiotic targets, 2) access and 3) protection pathways. The
synthesis and regulatory pathways controlling target expression are thus also




Single gene mutations can give rise to antibiotic resistance, as in DNA Gyrase
mutations in quinolone resistance (Yoshida et ai, 1990). These mutations are target
protein structural changes leading to decreased binding affinity of the drug and target,
thereby elevating the MIC. Mutations controlling efflux can also increase MIC of the
antimicrobial, examples being mutations activating expression of MDR determinants
(Kohler etal., 1997).
1.7.3.H Co-operative mutation
The presence of several lethal targets in the cell would lead to the probability that
single mutations in a single drug target would be an infrequent occurrence, as
interaction with the other lethal target would ensure cell death. Mutation rate to
cefotaxime resistance (in vitro) in Streptococcus pneumoniae is higher than for
penicillin resistance, because cefotaxime has one less penicillin binding protein
(Hakenbeck, 1999). Resistance to certain fluoroquinolones in S. aureus can also only
be conferred when both gyrA and grlA mutations are present (Deplano et al, 1997). It
can be deduced from this that antimicrobials that have dual lethal targets are
favourable, knowledge that is exploited in the search for new antimicrobial
compounds. Mutations in several access pathways may also be required to prevent




As previously discussed a number of pathways from target, access and detoxification
are involved when an antibiotic interacts with a bacterial cell. A single mutation in one
of these targets will result in low-level resistance, whereas multiple mutations in
several targets will result in high-level resistance. It thereby follows that when
challenged with a low antibiotic concentration, single mutations will occur, as in
Ser83 in DNA Gyrase after quinolone challenge. Several mutations are required to
overcome challenge with high antibiotic concentrations, as seen with multiple
mutations in GyrA and ParC, along with efflux to produce a highly resistant
phenotype (Tavio et al., 1999).
Antibiotic concentration is very important in mutation selection, and a specific MIC is
often optimal for selecting specific mutation types and rate. At low antibiotic
concentrations variants may not be selected out, however if concentrations are too
high both susceptible and variant populations will be suppressed. It is also possible
that if bacterial populations are not killed effectively, the stress that the cells are under
will increase the mutation rate.
Concentrations are very important as few mutants will be recovered if antibiotic
concentrations require a cell to contain two or more concurrent mutations for growth
in the presence of drugs (current dosing protocols allow cells to grow after only one
resistance mutation) thereby aiding resistance development. With fluoroquinolones the
mutation frequency is less than 10"7and so more than 1014 bacteria would be required
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to find two target mutations. In the clinic bacterial populations may reach 1010 cells in
an infected individual, but 1014 is unlikely. This higher drug concentration required to
prevent mutant selection has been termed the "mutant prevention concentration"
(MPC) (Drlica, 2001), and may have important implications for future antibiotic
therapy regimens. The concentration between the MIC and MPC of an antibiotic is
the mutant selection window. As target preference for drugs is very much dependent
upon drug structure, understanding the interaction between drugs and targets and
altering drugs so that they may target dual enzymes may mean that in future the MPC
equals the MIC.
1.7.5 Bacterial physiological state
1.7.5.i Adaptive mutation
Early work on dividing bacteria by Lederberg & Lederberg (1952) lead to the
presumption that mutation occurs as a result of errors occurring during the DNA
replication process. Recent advances in understanding of bacterial populations has
demonstrated that mutation can occur in non-dividing cells (Rosenberg et al., 1996;
Shapiro, 1984), a process termed "adaptive" or "stress induced mutation". With this
type of mutation, the rate ofmutation selection can actually increase under starvation
conditions (Shapiro, 1984).
Adaptive mutation has been classically studied using non-lethal selection as it was
thought that lethal selection would kill bacteria before they entered starvation. Recent
work on emergence of antibiotic resistance has however yielded exciting new results.
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Quinolones, which induce the SOS response, increase the rate of emergence of
resistance to drugs in E. coli (Riesenfeld et al., 1997). Antibiotic challenge also
increases the emergence ofMDR mutants in P. aeruginosa (Alonso et al., 1999), and
E. coli exposed to streptomycin have a hypermutable phenotype (Ren et al., 1999).
This demonstrates the influence of bacterial growth conditions on mutation selection.
This stress enhanced mutation is regulated by stress-responsive error prone DNA
polymerase V (umuCD) and IV (dinB) which transiently increase mutation rate
(Radman, 1999). Bacteria growing in vivo are generally under stress (Foley et al.,
1999), contending with starvation, colonisation of hostile niches, host defences and
antibiotic challenge. The frequency ofmutation in vivo is therefore likely to be much
higher than that measured by in vitro analysis.
1.7.5.ii Mutator strains
Bacterial populations are known to contain a proportion of hypermutable or
"mutator" cells, which have a mutation rate increase from 10-10,000 times normal,
due to a defective mismatch repair system (Miller, 1996). These bacteria can evade
stressful environments such as antimicrobial treatment (Matic et al., 1997), due to
their large diversity of alleles. Antibiotic selection of mutator alleles can be the basis




Mutators are not expected to be stable in a bacterial population, as they are less fit
and may be controlled by programmed cell death systems (Mittenhuber, 1999). It can
however been seen how an environment which is fluctuating between stress and no
stress may maintain a population ofmutators. This is the environment experienced by
many pathogenic and epidemic bacterial clones, leading to the hypothesis that these
are in fact mutator strains.
1.7.5.iii Pre-existing low-level resistance
The presence of low-level antibiotic resistance mutations is likely to facilitate the
acquisition of clinical resistance when exposed to antibiotic challenge. Markham
(1999) has shown that inhibition of MDR efflux pumps in S. pneumoniae using
reserpine, reduces mutation rate and consequently resistance development. It
therefore seems that the presence of low-level antibiotic resistance mechanisms might
favour the emergence of clinically relevant antibiotic resistant bacteria. Bacteria
growing at a high density can also be considered to have low-level resistance to
antibiotic challenge (i.e. biofilms), and favour the emergence of resistant mutants.
Waters & Davies (1997) have also shown that amino-acid variation within the GyrA
sub-unit of DNA gyrase is also associated with natural non-selected resistance to
fluoroquinolones.
1.7.6 Bacterial fitness
The reason why mutants usually do not proliferate in a non-selective environment is
due to the detrimental effect mutation has on bacterial fitness (Bjorkman et al., 1998),
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however in some cases fitness can be increased (Blot et al., 1994). Reduction in
fitness can be compensated in time with mutations at other chromosomal loci
(Bjorkman et al., 2000). A recent demonstration by Bjorkman et al. (2000) that
compensatory mutations selected in vitro are different from those selected in vivo,
raises questions about the interpretation of current models of in vitro resistance
development, and the relevance of these models to the in vivo situation. Antibiotic
cycling policies rely on resistant organisms being at a disadvantage when antibiotic
pressure is removed. The presence of these compensatory mutations increasing fitness
may therefore make their benefits obsolete.
1.7.7 Selective habitat
The environment in which bacteria colonise can determine the variability of a
population and the rate at which resistance occurs (Korona et al., 1994). Structured
environments such as surfaces allow bacteria to occupy different niches and thereby
minimise competition, allowing all alleles capable of surviving selective pressure to
grow. Bacterial colonisation during infection is frequently in a heterogeneous
environment and involves attachment to various surfaces and host cells. This
environment probably allows more types of antibiotic resistant mutant selection than
in vitro tests in liquid culture medium. The size of the habitat and of the bacterial
population also alter mutation selection.
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1.8 Drug Discovery: future antibiotic targets
The antibiotics that we have in clinical use today were discovered by random
screening campaigns which started in the 1940 s. These antibiotic classes were
structurally modified when we had further knowledge of their targets to produce
many of the antibiotics of clinical use today (Figure 1.11). Empirical screening and
structural modification have limitations, and fail to produce the range of chemicals
needed to keep pace with the changing clinical situation. We are now under the threat
that drug resistant micro-organisms will overcome all of our current antibiotics, and
renewed interest from the pharmaceutical companies has meant the search for the new
class (new target) of antibiotic has begun.









The range of bacterial genome sequences now available has revolutionised the way in
which we can look for new targets. We now have tools which will enable the
discovery of essential pathways in bacterial physiology, infection process and
antibiotic induced cell death.
A particularly promising technology is that of "DNA microarrays" or "gene chips".
This technology can be used to measure the expression patterns of thousand of genes
in parallel, providing information about gene function, as well as monitoring changes
in gene expression in response to drug treatments. Identification of targets associated
with bacterial adaption /survival are crucial. The expression profiles created by micro-
arrays serve as "signatures" of the inhibitor used, and in cases where antibiotic action
is unknown can incriminate affected pathways of specific target enzymes. The
potential of this technology has excited the interest of pharmaceutical and small
biotech companies alike, and has the potential to become as essential to research as
PCR is now.
1.8.2 Analysis of drug-target interaction
The interaction between drugs and known targets is also of crucial importance in the
development of drugs which have reduced resistance potential. As previously
mentioned, drugs which simultaneously inhibit more than one target are at an
advantage, as mutations in both targets would be required to confer resistance. The
technology of site-directed mutagenesis, involving the directed substitution of amino-
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acids may prove invaluable in drug-target analysis as it allows the importance of
specific amino acids to drug-target interaction and resistance to be measured.
Understanding complex drug-target interactions and resistance may lead to the
development of antibiotics which can structurally overcome these constraints, is an aid
to future drug discovery and resistance minimisation. Revised administration of drugs,




Aims of this thesis
• To determine the mechanism of fluoroquinolone resistance in clinical Escherichia
coli isolates, concentrating on the identification of target protein (DNA gyrase and
Topisomerase IV) mutation.
• To assess the clonal diversity of clinical E. coli isolates, by restriction and PCR
based techniques.
• To employ site-directed mutagenesis, to analyse the contribution of individual
DNA gyrase (Ser83 and Asp87) mutations to fluoroquinolone resistance.
• To study the role of ribosomal S12 protein mutation, in conferring aminoglycoside
resistance, and thereby assess the role of S12 as an aminoglycoside target.
• To investigate the protein synthesis requiring, bactericidal action of the
aminoglycoside streptomycin.
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2. Materials and Methods
2.1 Bacterial Strains and Plasmids
Bacterial strains used in this study are listed in table 2.1. Fluoroquinolone resistant
clinical isolates were collected from hospitals in the Newcastle area (Supplied by Dr.
O. Murphy, Freeman Hospital, Newcastle). Plasmids used for site-directed
mutagenesis work were pUC18 supplied by Stratagene (UK), and pPH3-gyrA
(JmtacA) was a generous gift from Prof. A. Maxwell (University of Leicester).
Table 2.1: Bacterial strains
Bacterial Strain Characteristics Source
E. coli NCTC10418 Standard strain R. Paton (Edinburgh
University)
P. aeruginosa NCTC10662 Standard strain R. Paton (Edinburgh
University)
E. coli clinical isolates (n=15)
Isolated 1996
Fluoroquinolone resistant 0. Murphy (Freeman
Hospital, Newcastle)
E. coli NCTC 10418 mutants Aminoglycoside resistant This work
Epicurian Coli® XL1-Blue Supercompetent cells Stratagene, UK
E. coli KNK453 gyrA ts (42 C) mutants A. Maxwell (Leicester
University)
E. coli KNK453Asp87 gyrAAspartate 87 mutant This work
E. coli (GyrA mutants) Ser83 gyrA mutation C. J. Thomson





2. Materials and Methods
2.2 Materials
2.2.1 Antimicrobial Agents
Antimicrobial Agents, manufacturers and solubility information are listed in table 2.2.
Fresh stock solutions of all antibiotics were prepared using sterile distilled water on
the day of use.
Table 2.2: Antimicrobial agents and their solvents
Antimicrobial Agent Solvent Manufacturer / Supplier
Ampicillin Water Sigma-Aldrich
Amoxycillin Water CP Pharmaceuticals Ltd.
Amox/Clav (Augmentin) Water Smithkline Beecham
Ceftazidime Water Glaxo laboratories
Meropenem Water AstraZeneca
Trimethoprim Water + Lactic acid Sigma-Aldrich
Ciprofloxacin Water Bayer pic
Gemifloxacin Methanol/Water Smithkline Beecham
Moxifloxacin Water Bayer pic
Sparfloxacin 0.5M NaOH Rhone-Poulenc Rhorer









2. Materials and Methods
2.2.2 Chemicals, buffers and enzymes
All chemicals were purchased from Sigma-Aldrich Company Ltd.(Poole, UK) unless
otherwise stated and solutions made up with sterile distilled water. Saline was made
up with 0.85% (w/v) NaCl and sterilised before use. Buffers were made according to
Data for Biochemical Research (1974). All PCR reagents and restriction enzymes
were supplied by Promega unless otherwise stated.
2.2.3. Media
Media used in this study were Nutrient agar (NA), Nutrient Broth No. 2 (NB),
MacConkey agar, Iso-sensitest agar (1ST), Lennox L Broth (LB) and Lennox L (LB)
agar (GibcoBRL, Life Technologies Ltd., Paisley, UK), NZY broth [1L: lOg NZ
amine (casein hydrolase), 5g yeast extract, 5g NaCl (pH7.5), 12.5mL 1M MgCl2,
12.5mL 1M MgS04, 20mL 20% (w/v) glucose] and Davis Mingioli medium [1L
contains: Dipotassium hydrogen phosphate 14.0g, Potassium dihydrogen phosphate
6.0g, trisodium citrate 0.94g, Magnesium sulphate 0.2g, Ammonium sulphate 2.0g]
(Davis & Mingioli, 1950).
All media powders were obtained from Oxoid (Basingstoke, UK) and made up with
distilled water according to the manufacturer's instructions. Prior to use all media
were sterilised by autoclaving at 121°C and 15psi for 15 minutes to destroy all
vegetative cells and spores.
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2.3 Bacterial growth and maintenance
Bacterial strains were stored at -70°C in nutrient or Lennox broth (plasmid containing
strains) supplemented with glycerol to 10% (w/v). E. coli strains were subcultured on
MacConkey selective agar, whereas strains used in site-directed mutagenesis work
were subcultured on LB agar, supplemented with 50 mg/L ampicillin (plasmid
containing strains). Bacteria were routinely grown in liquid culture (NB or LB)
overnight at 37°C. Temperature sensitive mutants were routinely grown at 30°C
(permissive temperature) on LB agar or in LB broth.
2.4 Bacterial Identification
Speciation of isolates was performed by the API20NE system (BioMerieux, Marcy-
TEtoile, France) according to the manufacturer's instructions.
2.5 Antimicrobial Susceptibility Testing (MIC determination)
Antimicrobial susceptibility testing was performed on Iso-sensitest (1ST) agar
following the British Society for Antimicrobial Chemotherapy (BSAC) guidelines
(Phillips et al., 1991). Minimum inhibitory concentrations (MICs) of antibiotics were
determined by agar double dilutions of the antimicrobial agent. Antibiotic stock
solutions were freshly prepared, and agar was cooled to 50°C before mixing with
antibiotic on plates.
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Bacterial strains to be tested were inoculated into nutrient broth and incubated
overnight in an orbital shaker at 37°C. One hundred-fold dilutions of overnight
cultures were made in sterile saline solution [0.85% NaCl], to give an inoculum size
of approximately 106 colony forming units (cfu) per spot. Diluted culture was
inoculated onto plates with a Denley multi-point inoculator (Denley, Billinghurst,
Surrey). After drying, inoculated plates were incubated at 37°C for >16 hours. The
MIC of the antibiotic was defined as the lowest concentration of antibiotic to inhibit
all visible growth.
2.6 Viable Counts
To determine killing activity of a single antibiotic or antibiotic combination against E.
coli NCTC10418, dose response and time-kill experiments were performed. The
medium used for bacterial growth during and subsequent to antibiotic challenge was
generally 1ST broth and agar; however Davis-Mingioli medium and phosphate
buffered saline (PBS) [500mL: NaCl 3.4g, Na2P04 0.715g, KH2PO4 0.215g] was
substituted in some experiments, when analysing the effects of protein synthesis on
cell death. Pre-incubation with antibiotics prior to dose-response and time-kill assays
was also performed.
2.6.1 Dose response assay
To analyse killing activity of antibiotics at various concentrations dose response
experiments were performed. A single colony ofE. coli NCTC10418 was inoculated
into lOmL NB and grown overnight at 37°C. This culture was diluted 100-fold in pre-
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warmed NB and grown for 2 hours shaking until log phase. Antibiotic containing 1ST
broths (9.9mL) were inoculated with lOOpL aliquots of this culture and incubated for
3h at 37°C. After incubation lOmL of cold (4°C) NB was added to each tube before
centrifiigation at 3000rpm for 15 minutes in a Sorvall RT6000D bench-top centrifuge.
The pellet was re-suspended in lOmL NB. Aliquots of cultures: neat 10"2, 10"4, 10"6
dilutions were used to inoculate viable count plates which were incubated at 37°C
overnight. Colonies on plates were counted using an Anderman Colony counter
(Anderman, Kingston-upon-Thames, UK). Logio (cfu/mL) was plotted against
antimicrobial concentration to assess killing activity.
2.6.2 Time-kill assay
To analyse the killing activity of antibiotics over time, time-kill experiments were
performed. E. coli NCTC10418 was grown overnight in lOmL NB at 37°C. This
culture was subsequently diluted 100 fold in pre-warmed NB and grown to log phase
shaking at 37°C. One hundred microliter aliquots of this culture were used to
inoculate pre-warmed antimicrobial containing 1ST broths, which were subsequently
incubated at 37°C for periods of 0 to 3 hours. Viable counts were performed at hourly
intervals utilising the method described for dose response assays, and percentage
bacterial survival (% of viable count at time 0) was plotted against time.
2.7 Selection of aminoglycoside resistant mutants
Aminoglycoside resistant mutants were selected following the previously described
protocol by Montandon et al. (1986). E. coli NCTC10418 was grown overnight at
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37°C in NB. Two hundred microliter aliquots of this culture were spread onto 1ST
agar plates containing increasing aminoglycoside (streptomycin, gentamicin,
neomycin, tobramycin, kanamycin) concentrations. Plates were incubated at 37°C for
48h, and mutants with the highest level of resistance were used to inoculate plates for
subsequent series. Mutants were selected in a total of four series. Antibiotic
susceptibility of mutants to aminoglycosides was determined via the agar dilution
method (section 2.5).
2.8 Mutation detection via the polymerase chain reaction (PCR)
Mutations in target proteins DNA gyrase gyrA gene, Topoisomerase IV parC gene
and ribosomal S12 protein rpsL gene were detected by PCR amplification and
sequencing (section 2.13). DNA template for PCR reactions was prepared by boiling
(section 2.14). All reactions were prepared in lOOpL volumes in a Techne Cyclogene
Thermal cycler (Cambridge Biosciences, Cambridge), and all products were analysed
by agarose gel electrophoresis (section 2.9).
2.8.1 Amplification of the quinolone resistance determining region (QRDR) of
gyrA
To identify gyrA mutations two oligonucleotide primers, 5'-ATGAGCGACCTTGC
GAGAGAAATTACACCG-3' and 5'-TTCCATCAGCCCTTCAATGCTGATG
TCTTC-3' (Yoshida et al., 1988) were used to amplify a 620bp fragment of gyrA.
Reactions consisted of: 1 xPCR buffer (Advanced Biotechnologies, Dorking, Surrey),
2.5mM MgCl2, 200pM each dNPT (Boerhinger-Mannheim, Mannheim, Germany),
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lOpmoles each primer (Oswel DNA services Ltd., Southhampton), lOpL of boiled
DNA and 2U of Taq DNA polymerase (Advanced Biotechnologies, Surrey). Cycling
parameter were as follows: i) one cycle of 96°C for 30s, 50°C for 60s and 70°C for
90s; ii) 24 cycles of 96°C for 15s, 50°C for 30s and 70°C for 90s; iii) 70°C for 5 min.
2.8.2 Amplification of the QRDR ofparC
To identify parC mutations two oligonucleotide primers 5'-AAACCTGTTCA
GCGCCGCATT-3' and 5 '-GTGGTGCCGTTAAGCAAA-3' (Vila et al., 1996) were
used to amplify the fragment ofparC from nucleotides 115 to 509 (395bp). Reactions
consisted of: lxPCR buffer (Advanced Biotechnologies), 3mM MgCl2 (Advanced
Biotechnologies), lOOpM each dNTP (Boehringer-Mannheim, Mannheim, Germany),
25pmoles of each primer (Oswel), lOpL of boiled DNA and 2U of Taq DNA
polymerase (Advanced Biotechnologies, Surrey). Cycling parameter were as follows:
i) 30 cycles of 94°C for 60s, 55°C for 60s and 72°C for 60s.
2.8.3 Amplification of rpsL gene of 30S ribosomal sub-unit
Oligonucelotide primers 5'-GCAAAAGCTAAAACCAGGAGC and 5'-GGTTCTCC
GTTAAGTAAGGCC were used to amplify a 424bp region of ribosomal protein S12
(primers designed using Primer3 software (http://www.genome.wi.mit.edu/cgi-
bin/primer). Reactions consisted of: lxPCR buffer (Advanced Biotechnologies),
2.5mM MgCl2 (Advanced Biotechnologies), 200pM of each dNTP (Boerhinger-
Manheim), 25pmoles of each primer (Oswel), lOpL of boiled DNA and 2U of Taq
DNA polymerase (Advanced Biotechnologies). Cycling parameters were as follows: i)
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1 cycle of 96°C for 30s, 50°C for 60s and 70°C for 90s; ii) 24 cycles of 96°C for 15s,
50°C for 30s and 70°C for 90s; iii) 70°C for 5 min.
2.9 Analysis of DNA by agarose gel electrophoresis
Agarose gel electrophoresis ofDNA was typically performed on 1.5-4% agarose gels
(Gibco, BRL) in TAE buffer [40mM Tris-acetate (pH8.0), 2mM EDTA],
Electrophoresis was performed on horizontal gels utilising the Bio-Rad Sub-Cell® GT
agarose gel electrophoresis system. The DNA samples were mixed with loading buffer
[0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol, 30% (w/v) sucrose] at a
ratio of 5:1 prior to gel loading. Samples were electrophoresed at a constant voltage
between 70 and 100V, for a time length depending on DNA fragment size (-30-120
min). Samples were electrophoresed alongside a suitable molecular weight marker,
generally lOObp DNA ladder (Promega) of XHindill DNA (GibcoBRL, Life
Technologies Ltd., Paisley). Following electrophoresis, gels were stained in a
0.5(a,g/mL ethidium bromide solution and visualised on a UV trans-illuminator (UV
products, Cambridge). Gels were photographed with a polaroid camera containing an
orange filter. The Bio-Rad gel doc 2000 system was also latterly used to visualise and
photograph gels.
2.10 Restriction of PCR amplicons
Restriction endonuclease cutting ofPCR products was performed in volumes between
20 and lOOpL. These contained the requisite amount of DNA (usually 1-1 Opg) and
the appropriate restriction buffer (Promega) according to the manufacturer's
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instructions. Restriction enzyme was usually present in 2-5 fold excess i.e. 2-5U/pg
DNA. Final volumes were made up with distilled water and incubated at 37°C for 1-3
hours. Products were analysed by agarose gel electrophoresis (section 2.9).
2.11 Sizing plasmid DNA
The gyrA containing plasmid (pPH3) was linearised for sizing with Xhol restriction
endonuclease digestion (Promega). Restriction was carried out in total volumes of
20pL containing 5pL of plasmid DNA and 10U of restriction endonuclease according
to the manufacturer's instructions. Restrictions were incubated at 37°C for 2 hours.
Digested and undigested product was electrophoresed alongside XJHindlW DNA
(Promega) for accurate sizing of plasmid DNA.
2.12 PCR purification
PCR products were purified using a QIAquick PCR purification kit (Qiagen Ltd,
Crawley, UK) according to the manufacturer's instructions. The purified PCR
products were eluted from the column into 30p.L of elution buffer to concentrate the
DNA
2.13 DNA sequencing
The primers used for PCR amplification were also used for DNA sequencing, with
3.2pmol of primer required per sequencing sample. The DNA content of each sample
to be sequenced was determined as described in section 2.15 to ensure that it
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contained 30-90ng of DNA. An ABI Prism dRhodamine terminator cycle sequencing
ready reaction kit (PE Applied Biosystems, Warrington, UK) was used following the
manufacturer's instructions and sequencing cycles were performed on a Techne
Cyclogene Dri-Block Thermal Cycler (Cambridge Biosciences). The cycle sequencing
program consisting of 25 repetitions of 96°C for 30 seconds, 45°C for 15 seconds and
60°C for 4 minutes. Extension products were purified by the rapid ethanol
precipitation method suggested by the sequencing kit manufacturer. Automatic DNA
sequencing was determined by Edman degradation performed on an Applied
Biosystems Precise Sequencer. Analysis of sequence data was performed with
ABIView version 1 or Chromas Version 1.56 software. All results were compared to
the published sequences detailed at the European Bioinformatics institute
(http:www2.ebi. ac.uk/fasta3/).
2.14 Extraction of chromosomal DNA
Extraction of E. coli chromosomal DNA for use in PCR amplification was typically
performed by boiling. A single colony of a bacterial strain was inoculated into NB and
grown overnight at 37°C. Bacterial cells were centrifuged at 12,000rpm in a
microcentrifuge and re-suspended in 50pL of sterile water. The cells were
subsequently boiled for 5 minutes to release the DNA. Cell debris was removed by
further centrifugation at 12,000rpm and clear lysate containing DNA was used for
subsequent PCR template. Cells obtained directly from fresh agar plates (loopful)
were also boiled using the same procedure to prepare template. DNA was also
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extracted with the Qiagen DNA extraction kit (Qiagen Ltd., Crawley, UK) according
to the manufacturer's instructions.
2.15 DNA quantification
A rapid estimation of DNA concentration of PCR products was performed by
electrophoresing 1 p.L of sample DNA alongside 2(o.L of Lambday7//ra/III DNA
(Promega), each band of which is known to contain a specified DNA concentration.
After electrophoresis and ethidium bromide staining the size and thickness of sample
bands was compared with Lambda////«<7III bands to estimate DNA concentration.
DNA concentration was also measured using absorbance at A26o on a Bio-Rad
SmartSpec™ 3000.
2.16 Pulsed-field gel electrophoresis (PFGE)
Pulsed-field gel electrophoresis was carried out to type the clinical isolates by a
modification of the method described by Barrett et al. (1994). In brief: strains were
grown in 10 mL LB broth at 37°C with vigorous shaking to an optical density (O.D.)
of 1.2 at 610nm. Cells were washed twice in 75mM NaCl-25mM EDTA and
resuspended in the original volume. One half millilitre of the washed bacterial
suspension was carefully mixed with 2% low melting grade agarose (Bio-Rad
Laboratories, Herts ), and the mixture was dispensed into 1.5mm thick moulds (Bio-
Rad). Plugs were allowed to solidify for 20 minutes and then transferred to tubes
containing lysis buffer [50mM Tris (pH8.0), 50mM EDTA (pH8.0), 1%N-
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Laurylsarcosine, lmg of proteinase K/mL] and tubes were incubated at 56°C for 4
days. After lysis the clear plugs were washed 6 times in TE buffer [lOmM Tris-lmM
EDTA (pH8.0)] with 15 minute incubations at 4°C between each wash. Unless used
immediately plugs were stored at 4°C in TE buffer. Before digestion with restriction
enzyme, 3mm thick slices were removed from plugs and were washed twice with the
appropriate restriction enzyme buffer recommended by the manufacturer. Two
restriction enzymes were used to distinguish between strains: Xbal and Noil
(Promega). Restriction digests were carried out in a volume of lOOpL with 40U of
restriction endonuclease and incubated at 37°C overnight. After restriction the
reaction was stopped by the addition of 5xTris-borate EDTA (TBE) buffer (Sigma)
followed by further incubation at 4°C overnight. Restriction fragments were separated
by electrophoresis through 1% PFGE agarose (Bio-Rad) in 0.5xTBE buffer at 14°C
in a CHEF DR-II apparatus (Bio-Rad). The run time for Xbal restrictions was 20
hours at 200V, with a linearly ramped pulse time of 5 to 50 seconds. The run time for
Noil restrictions was 18 hours at 200V, with a pulse time of 10 to 30 seconds. A
Lamda ladder (50-1000kb) (Bio-Rad) was electrophoresed alongside samples. Gels
were stained with ethidium bromide (0.5p.g/mL) for 15 minutes, and destained in
0.5xTBE buffer for 30 minutes prior to UV visualisation. The gels were
photographed with the Gel-Doc 2000 system (Bio-Rad).
PFGE patterns were compared visually, and interpreted by the criteria described by
Tenover et al., (1995). Isolates were classified as indistinguishable if they had
identical PFGE patterns. Isolates with 3 differing bands were considered closely
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related, and with 4 to 6 differing bands "possibly related". Isolates were considered
unrelated if they differed by seven or more bands.
2.17 Random amplified polymorphic DNA (RAPD) typing
RAPD typing was performed essentially as described by Berg et al. (1994), with PCR
amplification of random sequences by short oligonucleotide primers 5'-AAG
AGCCCGT and 5'-GCGATCCCCA (Oswel DNA services Ltd., Southampton).
Reactions were carried out in lOOpL volumes and consisted of: lxPCR buffer
(Advanced Biotechnologies, Dorking, Surrey), 3mM MgCk (Advanced
Biotechnologies), 0.01% gelatin, 200pM each dNTP (Boehringer-Mannheim,
Germany), 200pmoles of each primer (Oswel) and 10pL of a 10 fold dilution of
boiled E. coli (section 2.14). PCR was carried out in a Techne cyclogene thermal
cycler (Cambridge Bioscience, Cambridge) with the following cycling parameters: i)
96°C for 4 min; ii) 40 cycles of 94°C for lmin, 36°C for lmin and 72°C for 2 min and
iii) 72°C for 5min. PCR products were separated by agarose gel electrophoresis
(section 2 .9) and analysed for similarity by visual comparison ofbands.
2.18 Enterobacterial repetitive intergenic consensus polymerase
chain reaction (ERIC-PCR)
The clonal diversity ofE. coli isolates was studied by amplification of template DNA
with primers for enterobacterial intergenic consensus (ERIC) sequences as described
by Dalla-Costa et al. (1998). PCR was performed with the following primer
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sequences: 5'-ATGTAAGCTCCTGGGGATTCAC-3' and 5'-AAGTAAGTGACT
GGGGTGAGCG-3' (Dalla-Costa et al., 1998). Each 50p.L reaction mixture
contained: lxPCR buffer (Promega), 4mM MgCl2 (Promega), lOOpM each dNTP
(Promega), lOOpmoles of each primer (Interactiva), 50r|g DNA(10(iL boiled DNA)
(section 2.14), and 2U of Taq DNA polymerase (Promega). PCR amplification was
carried out in a GeneAmp 9700 PCR system (PE Applied Biosystems, California)
with the protocol: i) 95°C for 5min; ii) 35 cycles of 94°C for 45s, 52°C for 60s, 70°C
for lOmin and iii) 70°C for 20min. PCR products were separated by agarose gel
electrophoresis (section 2.9), and banding patterns visually compared.
2.19 Amplified fragment length polymorphism (AFLP)
E. coli isolates were typed by the DNA fingerprinting method AFLP, with a
modification of the protocol described by Zhao et al. (2000) and the manufacturer's
kit (Perkin Elmer/Applied Biosystems Division, Foster City, CA). Genomic DNA was
extracted using the Qiagen DNA extraction kit (Qiagen Ltd., Crawley, UK) according
to the manufacturer's instructions. The AFLP protocol involved 3 steps 1) digestion
of total genomic DNA with restriction endonucleases and ligation of oligonucleotide
adaptors, 2) selective amplification of sets of restriction fragments by PCR using
fluorescently labelled primers and 3) separation of amplified DNA fragments of
denaturing polyacylamide sequencing gels.
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Table 2.3: Adaptor and primer sequences used in AFLP
Enzyme Cut site Adaptor Primer Core
EcoKl G/AATTC 5'-CTCGTAGACTGCGTACC 5'-GACTGCGTACCAATTCE
3 '-CTGACGCATGGTTAA
Msel T/TAA 5'-GACGATGAGTCCTGAG 5'-GATGAGTCCTGAGTAAE
3 '-CTACTCAGGACTGAT
2.19.1 DNA digestion and adaptor ligation
DNA restriction enzyme digestion and ligation of adapters to compatible overhanging
ends of cleaved DNAs was performed in a single step. Reactions were performed in
1 lpL volumes containing: 50qg DNA, 5U EcoKl (Promega), 1U ofMsel (Promega),
lxT4 ligase buffer (Promega), 50mM NaCl, 50p.g/mL bovine serum albumin (BSA),
1U T4 ligase (Promega), 0.04pM EcoRA and 0.4pM Msel specific adaptor pairs. The
reactions were incubated overnight at room temperature and then diluted 20 x with TE
buffer [ImM Tri-HCl. O.lmM EDTA, pH 8.0]. Products were electophoresed to
check for adequate restriction and sufficient DNA.
2.19.2 PCR amplification
£coRI primers were labelled with fluorescent dyes: 6-carboxyfluorescein (FAM;blue),
2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein (JOE;green) or N,N,N',N'-
tetramethyl-6-carboxy-rhodamine (TAMRA;yellow). Three primer combinations were
used to amplify restricted products: .EcoRI + 0 JOE/MscI+CG, EcoRl + A FAM/
Msel + CA and EcoRl + C TAMRA/ Msel + C. PCR reactions were carried out in
20pL volumes and consisted of: 3p.L of digested ligation reaction, EcoRl (0.05pM)
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and MseI (0.25pM), 0.5U Taq DNA polymerase (Promega), 1.5mM MgCb
(Promega), 200pM dNTPs (Promega) and lxPCR buffer. Temperature cycling was
performed on a GeneAmp PCR system 9600 (Perkin-Elmer) using the following
protocol: i) 94°C for 2min, 65°C for 30s and 72°C for 2min; ii) 94°C for 20s, 64°C
for 30s and 72°C for 2min. Subsequently the annealing temperature was reduced from
63°C to 56°C in increments of 1°C for each cycle. For reactions where AcoRI was
labelled with FAM or JOE, 23 cycles were performed at the lower annealing
temperature (56°C), whereas 25 cycles were performed for reactions containing
TAMRA labelled primers. PCR products from single reactions using the same DNA
template but different AFLP primer sets were pooled in the following proportion: 5pL
FAM, 7.5(iL JOE and 10pL TAMRA labelled products. DNA was precipitated by
addition of 3 volumes of cold absolute ethanol and incubation at -70°C for 10 min,
followed by centrifugation at 12,000rpm in a benchtop centrifuge to obtain a pellet.
The pellet was dried and resuspended in 5pL of HPLC grade water ready for
electrophoresis.
2.19.3 Electrophoresis
Electrophoresis was performed in 1 xTBE buffer (Sigma) at constant voltage (2500V)
for 4h at 51°C on an automated DNA sequencer (Perkin-Elmer/Applied Biosystems)
equipped with GeneScan Analysis software (version 2.1) (Perkin Elmer/Applied
Biosystems).
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2.20 Site-directed mutagenesis of DNA gyrase Ser83 and Asp87
Site-directed mutagenesis was carried out with the QuikChange™ Site-directed
mutagensis kit according to the manufacturer's instructions (Stratagene, UK). All
reagents, competent cells and plasmids were supplied by the stratagene kit unless
otherwise stated.
2.20.1 Primer design
Primers used for mutagensis are shown in table 2.4. They were designed to be
between 25 and 45 bases in length with a melting temperature (Tm) of greater or
equal to 78°C according to the following formula:
Tm = 81.5 + 0.41 (%GC) - 675/N -% mismatch
where N is the primer length in base pairs. Primers were obtained from Interactiva
Biotechnologie (Hybaid Ltd., Middlesex, UK) and were PAGE purified.
Table 2.4: Mutagenic gyrA Ser83 and Asp87 primers
Primer Sequence Base Amino-acid change
Change
SerS3 5' CATGGTGACTTGGCGGTCTATGACAC C->G Ser(TCG)->Leu (TTG)
Ser83 3' GTCTCATAGACCGCCAAGTCACCATG G->A Ser(AGC)->Leu(AAC)
Asp87 5" TCGCGCGTCTATAACACGATTGTCCG G->A Asp(GAC)-*Asn(AAC)
Asp87 3' CGGACAATCGTGTTATAGACGGCGGA C^T Asp(CTG)->Asn(TTG)
• Mutation sites are shown in bold
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2.20.2 PCR amplification
PCR reactions were carried out in a total volume of 50|iL prepared in 0.5mL
polypropylene tubes (Alpha laboratories) with a Techne Genius Dri-Block cycler
(Cambridge Biolabs, Cambs). PCR amplifications consisted of lxPCR reaction buffer
(Stratagene, UK), 5-50ng of dsDNA plasmid template (pH3 gyrA, From A. Maxwell),
125 ng of each primer (Interactiva), lOOpM each dNTP (Stratagene), and ultrapure
water to a final volume of 50pL. PfuTurbo™ (Stratagene) was then added at 2.5 U
per reaction. The cycling parameters are shown in table 2.5.
Table 2.5: Cycling parameter for plasmid amplification
Segment Cycles Temperature Time
1 1 95°C 30s
2 16 95°C 30s
55°C lmin
68°C 16min
To check for sufficient amplification lOpL of the amplified product was
electrophoresed on a 1.5% agarose gel (section 2.9).
2.20.3 Digestion with Dpnl
PCR Products were digested with 10U of Dpnl restriction enzyme per sample
reaction. The solution was mixed by pipetting, spun down in a micro-centrifuge for
lmin, and then incubated at 37°C for lh to digest the parental (non-mutated)
supercoiled dsDNA.
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2.20.4 Transformation of Epicurian Coli ® XLl-Blue supercompetent cells
For transformation into Epicurian Coli ® cells, cells were initially gently thawed on
ice for 2min. For each sample to be transformed, 50pL of competent cells were
aliquotted into prechilled glass tubes. Dpnl treated DNA (lpL) was then added, and
the reactions gently swirled before incubation on ice for 30min. The control plasmid
pUC18 (0.1ng/pL) was also added to an aliquot of the competent cells to test
transformation efficiency. The transformation reactions were heat pulsed for 45s at
42°C in a water bath and then placed on ice for 2min. Preheated NZY broth (0.5mL)
was added to each reaction and reactions were then incubated at 37°C for lh shaking
at 225-250rpm. The control and the sample reactions were then plated on LBA agar
supplemented with 10% (w/v) X-gal and 0.1 mM IPTG. Transformation plates were
incubated at 37°C for >16hours. Transformation efficiency was calculated by
analysing the number of blue colonies on X-gal plates containing pUC18
transformants.
2.21 Extraction of plasmid DNA
Small scale plasmid extraction was performed using the Hybaid Recovery™ Plasmid
Prep kit (Hybaid Ltd., Middlesex, UK) according to the manufacturer's instructions.
The extractions yielded approximately 50pg of plasmid DNA.
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2.22 Preparation of competent cells
Cells of the E. coli gyrA 13 mutant KNK453 (supplied by A. Maxwell, University of
Leicester) were made competent ready for transformation with mutageneised plasmid.
A single bacterial colony was inoculated into lOmL LB broth and grown overnight at
30°C (permissive temperature) shaking. This culture was then diluted 100 fold in LB
broth and grown at 30°C shaking until the O.D at A600 was 0.6. The cells were
placed on ice to cool rapidly and centrifuged in a Sorvall RC5B centrifuge (5000g) at
4.2K for 20 minutes at 2°C. Cells were re-suspended in TFI buffer [30mM KoAc,
lOmM CaCl2-2H20, lOOmM KC1, 15% glycerol, 50mM MnCl2] by gentle shaking.
Cells were re-centrifuged at 4.2K for 8 minutes at 2°C, and resuspended in 4 mL of
TFBII buffer [75mM CaCl2, lOmM KC1, 15% glycerol, lOmM Na-MOPs pH 7.0],
Cells were aliquotted into prechilled microfiige tubes and stored at -70°C.
2.23 Transformation ofgyrA ts Escherichia coli
Competent KNK453 cells were transformed with mutagenised plasmid. Cells were
slowly thawed on ice until just defrosted. One hundred microliter aliquots of cells
were then dispensed into pre-chilled glass tubes. Approximately lOng of plasmid
DNA was added for the transformation and the tubes were incubated on ice for
30minutes. Samples were the heat shocked at 42°C for 60 seconds, and placed back
on ice. One millilitre of pre-warmed LB broth (30°C) was added to each tube, and
they were incubated at 30°C for 2h shaking. Control transformations with pUC18
plasmid DNA to test the competent cells were performed in the same manner.
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2.24 Analysis of fluoroquinolone resistance phenotype in
temperature-sensitive mutants
Expression of plasmid gyrA in KNK453 E. coli gyrA13 mutants was confirmed by
plating transformants at 42°C in the presence and absence of the inducer IPTG.
Control plates at 30°C were also performed. Fluoroquinolone resistance conferred by
the mutant plasmid was determined by a modification of the susceptibility testing
method described in section 2.5. Cells were grown overnight at 30°C in LBA broth.
Dilutions were made of cell cultures and used to inoculate antibiotic containing LB
amp agar plates, supplemented with 0.1mM IPTG. Cells were grown at 42°C (non-
permissive temperature) for >24 hours. Control plates were also incubated at 30°C
(permissive temperature). The MIC was determined as the lowest antibiotic
concentration to inhibit all visible growth.
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3. Results: Clinical fluoroquinolone resistance
3.1 An Overview
An outbreak of ciprofloxacin resistant Enterobacteriaceae in a hospital in Newcastle,
provided a unique opportunity to study acquisition of fluoroquinolone resistance in
the clinic. Fifteen isolates were collected, identified as Escherichia coli by the API 20
NE system and designated NC-1-15 for the purpose of this study.
Antibiotic susceptibility to fluoroquinolones and other drug classes was determined by
the agar dilution method (see section 2.5). In order to assess whether this outbreak
was caused by clonal spread of resistant isolates or individual emergence of resistance,
the clonal diversity of isolates was determined by PCR and restriction-based
fingerprinting techniques (section 2.16-19). Alterations in target proteins were
identified by PCR amplification and DNA sequencing (2.8 & 2.13) of target proteins
(DNA gyrase gyr/4/Topoisomerase IVparC).
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3.2 Antibiotic Susceptibility
The MICs of ciprofloxacin, sparfloxacin, moxifloxacin and gemifloxacin against the
15 clinical E. coli isolates NC-1-15 are shown in Table 3.1.
Table 3.1: Fluoroquinolone susceptibility of clinical isolates NC-1-15 (MIC
mg/L)
Isolate Ciprofloxacin Moxifloxacin Sparfloxacin Gemifloxacin
NC-1 128 64 64 128
NC-2 0.25 2 2 1
NC-3 0.25 1 1 1
NCM 32 2 2 1
NC-5 1 8 4 4
NC-6 1 8 32 8
NC-7 0.015 0.5 0.128 0.128
NC-8 1 8 4 4
NC-9 0.25 1 1 1
NC-10 128 64 64 128
NC-11 32 64 32 32
NC-12 32 64 32 16
NC-13 8 16 8 16
NC-14 256 128 96 256
NC-15 8 32 32 16
NCTC10418 0.015 0.015 0.016 0.015
Break point 2 2 2 2
Cross-resistance was seen between the high-level fluoroquinolone resistant isolates,
with ciprofloxacin-resistant isolates being additionally resistant to moxifloxacin,
sparfloxacin and gemifloxacin (Table 3.1). Of the clinical isolates, 8/15 (53%) were
resistant to ciprofloxacin with MICs ranging from 8 to 256mg/L. Six of these isolates
had ciprofloxacin MICs of >32mg/L, an unusually high level of fluoroquinolone
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resistance in Escherichia coli. Twelve isolates (80%) were resistant to moxifloxacin, a
gram-positive targeted fluoroquinolone, 12 isolates (80%) to sparfloxacin, and 10
isolates (67%) to gemifloxacin, a new napthyridone derivative (Figure 3.1).




Cip Mox Spar Gem
Fluoroquinolone
Resistance to the fluoroquinolones was high, with a higher percentage of isolates
resistant to moxifloxacin and sparfloxacin than to gemifloxacin and ciprofloxacin,
possibly due to the difference in target proteins within drugs. These isolates had only
been previously exposed to ciprofloxacin in the clinic and therefore the resistance
mechanisms seem to be ubiquitous among the fluoroquinolones. The newer
fluoroquinolone gemifloxacin, which has been shown to have increased potency
against Enterbacteriaceae in comparison with ciprofloxacin, did not show enhanced
activity against resistant isolates. In fact 67% isolates were resistant to gemifloxacin in
comparison with 53% to ciprofloxacin.
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The MICs of trimethoprim, amoxycillin, amox/clav, gentamicin, meropenem and
ceftazidime were determined to examine the possibility that the isolates had a multi-
resistant phenotype (Table 3.2).
Table 3.2: Susceptibility of clinical isolates NC-1-15 to trimethoprim,
amoxycillin, co-amoxiclav, gentamicin, meropenem and ceftazidime
Isolate Cip Trim Amox Amox/
Clav
Gent Mer Cft
NC-1 128 32 128 8 0.5 0.12 1
NC-2 0.25 32 8 4 0.5 0.12 1
NC-3 0.25 32 128 8 0.5 0.12 1
NC-4 32 32 128 16 0.5 0.12 1
NC-5 1 32 128 8 16 0.12 1
NC-6 1 32 128 8 0.5 0.12 1
NC-7 0.015 1 128 16 0.5 0.12 1
NC-8 1 32 128 8 0.5 0.12 1
NC-9 0.25 32 128 32 0.5 0.12 1
NC-10 128 32 128 4 0.5 0.12 1
NC-11 32 32 128 8 0.5 0.12 1
NC-12 32 32 128 8 0.5 0.12 1
NC-13 8 32 128 8 0.5 0.12 1
NC-14 256 32 128 8 0.5 0.12 1
NC-15 8 32 8 4 0.5 0.12 1
NCTC10418 0.06 1 4 4 2 0.12 1
Break point 2 2 8 8 4 4 2
All of the ciprofloxacin resistant isolates showed resistance to, at least one additional
antibiotic (trimethoprim), certain isolates to two additional antibiotics (trimethoprim
& amoxycillin), and isolate NC-4 showed resistance to three additional antibiotics
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(trimethoprim, amoxycillin and amox/clav), thereby demonstrating a multi-resistant
phenotype. Ciprofloxacin sensitive isolates NC-9 and 7 were resistant to trimethoprim
and amoxycillin. Thirteen (87%) isolates were resistant to trimethoprim (Tmp), 13
isolates (87%) to amoxycillin, 3 isolates (20%) to co-amoxiclav (Amox/Clav)
combination, and 1 isolate (7%) to gentamicin (Gent). All isolates were sensitive to
meropenem (Mer) and ceftazidime (Cft) (Figure 3.2).
Figure 3.2: Proportion of isolates resistant to trimethoprim, amoxicillin,











3. Results: Clinical fluoroquinolone resistance
3.3 Isolate diversity
In order to determine whether emergence of resistant isolates was due to 1)
independent selection of resistance in individual patients, 2) clonal spread of resistant
strains, or 3) a combination of both, the genotypes of the isolates NC-1-15 were
determined.
3.3.1 PFGE typing
PFGE analysis was initially performed with restriction enzyme Xbal. Figure 3.3 shows
pulsotypes ofNC-1-15.
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Lane. 1 - DNA lambda Ladder; 2 - NC-14; 3 - NC-1; 4 - NC-10; 5 - NC-4; 6 - NC-
5; 7 - NC-11; 8 - NC-8; 9 - NC-13; 10 - NC-6; 11 - NC-9; 12 - NC-15; 13 - NC-
12; 14 - NC-2; 15 - NC-3; 16 - NC-7; 17 - DNA lambda Ladder
Xbal restriction enzyme is the enzyme of choice for typing Enterobacteriaceae,
however this failed to yield pulsotypes for 6/15 isolates (Figure 3.3). Untypable
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isolates produced smeared DNA after agarose gel electrophoresis, indicating the
possibility ofDNA breakdown during the PFGE procedure prior to restriction. In an
attempt to eliminate this effect and type isolates, PFGE parameters were altered.
Increased lysis time, increased washing and doubling restriction enzyme
concentration, along with use of enzymes to eliminate endonucleases, did not however
eliminate the problem of smearing.
Figure 3.4: PFGE of 7 isolates with Xbal
Lane: 1 - DNA lambda ladder; 2 - NC-14; 3 - NC-1; 4 - NC-10; 5 -
NC-13; 6 - NC-5; 7 - NC-11; 8 - NC-8; 9 - DNA lambda ladder
Pulsotypes were obtained for 9 isolates with Xbal, with isolates NC-14, NC-10 and
NC-1 exhibiting identical PFGE restriction patterns (PFGE type: A). The remaining 6
isolates typed were heterogeneous in nature (PFGE types: B-H), differing by 7 of
more bands and therefore deemed unrelated (Table 3.3). PFGE restriction with a
second enzyme Notl was attempted in order to type isolates which could not be typed
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by Xbal restriction. Interestingly isolates NC-8, NC-13 and NC-11, which produced
smeared DNA after Xbal restriction, also produced smeared DNA after Notl
restriction (Figure 3.5). Isolate NC-5 was the only isolate of 7 restricted to produce a
PFGE restriction pattern with Notl. Isolates NC-14, NC-10 and NC-1 which were
typed by Xbal restriction were only partially restricted by Notl (Figure 3 .5). Doubling
the restriction enzyme concentration failed to eliminate this problem.






Lane: 1 - DNA ladder; 2 - NC-14; 3 - NC-1; 4 - NC-10; 5 - NC-5; 6 - NC-13; 7 -
NC-11: 8 - NC-8; 9 - DNA lambda ladder
The failure to type 6/15 clinical isolates by PFGE led to the use of PCR-based typing
methods ofRAPD and ERIC-PCR to further differentiate isolates.
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3.3.2 RAPD-PCR
DNA from NC-1-15 was amplified using short random primers to give RAPD banding
patterns (Figure 3.6).
Figure 3.6: RAPD banding patterns of NC-1-15
1 2 3 4 5
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Lane: 1 - XHindlll DNA ladder; 2 - NC-1; 3 - NC-13; 4 - NC-3; 5 - NC-7;
6 -NC-10; 7-NC-ll; 8 - NC-6; 9 - NC-14; 10 - NC-12; 11 - NC-2; 12 -
NC-15; 13 - NC-4; 14 - NC-9; 15 - NC - 8; 16 - NC-5
Isolates NC-14, NC-10 and NC-1 which had been deemed identical by PFGE, had
identical RAPD patterns (RAPD type: RI) A further two isolates NC-4, and NC-13,
which had been untypable by PFGE were related to RI isolates with one band
difference in RAPD pattern (RAPD type: RI1). Isolates NC-11, NC-8, NC-6 and NC-
5 had identical RAPD patterns (RAPD type: RII). NC-11, NC-8 and NC-6 had been
untypable by PFGE, however NC-5 was PFGE type G. The remaining isolates were
unrelated (RAPD type: RIII to RVII), supporting results from PFGE typing.
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3.3.3 ERIC-PCR typing
A second PCR typing technique was employed to type strains and confirm RAPD
results, as PCR based techniques may lack the reproducibility and reliability of PFGE.
Clinical isolates were typed by ERIC-PCR, a technique based on the amplification of
the intergenic consensus sequence of isolates (Figure 3 .7).




Lane: 1 lOObp DNA ladder; 2 - NC-14; 3 - NC-10; 4 - NC-1; 5 - NC-4; 6
- NC-13; 7 - NC-5; 8 - NC-8; 9 - NC-11; 10 - NC-6; 11 - NC-9; 12 - NC-
15; 13 - NC-12; 14 - NC-2; 15 - NC - 3; 16 - NC-7
Isolates NC-14, NC-10 and NC-1 produced identical ERIC pattern (ERIC type: EI),
supporting results from RAPD-PCR (Type: RI) and PFGE (Type: A). Isolates NC-4
and NC-13 which were also typed Type I by RAPD-PCR, showed 2-3 band variations
with ERIC-PCR (ERIC type: I2 and I3), demonstrating that they are related but not
identical. Isolates NC-11, NC-8 and NC-5 (ERIC type: II) had identical ERIC
patterns, supporting RAPD results. Isolate NC-20 which had been identical to NC-8,
NC-5 and NC-11 by RAPD-PCR, gave a 1 band difference when typed by ERIC
(ERIC type: II1). All other isolates were unrelated (ERIC type: III to VIII),
supporting RAPD and PFGE results.
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3.3.4 AFLP typing
To overcome the small discrepancies between ERIC and RAPD-PCR techniques,
AFLP typing was performed. AFLP typing was based on restriction of DNA extracts
with a mixture of restriction enzymes, adaptor ligation and PCR amplification with
fluorescently labelled primers. Figure 3.7 shows the results ofDNA digestion with the
restriction enzyme mixture, with restricted DNA seen a smear on the agarose gel.
Figure 3.8: Restriction of NC-1-15 with enzyme mix
Lane: 1 - UiindlU DNA ladder: 2 - NC-1; 3 - NC-13; 4 - NC-3; 5 -
NC-7; 6 - NC-10; 7 - NC-11; 8 - NC-6; 9 - NC-14; 10 - NC-12; 11 -
NC-2; 12 - NC-15; 13 - NC-4; 14 - NC-9; 15 - NC - 8; 16 - NC-5
PCR amplification of restricted products produced a smear ofDNA products (Figure
3.8)
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Figure 3.9: AFLP PCR products
1 2 3 4 5 6 7 8
Lane: 1 - lOObp DNA ladder; 2 - NC-1; 3 - NC-13; 4 - NC-3; 5 - NC-
7; 6 - NC-10;7 - NC-11; 8 - NC-6
After running on GeneScan analysis software, no products could be seen, although
fluorescent primers could be seen at the bottom of the gel. The reason for this failure
is not clear. Figure 3.7 shows that there was adequate restriction ofDNA, leading to
the theory that there were problems with the PCR amplification step. Products were,
however, produced after PCR amplification (Figure 3.9), and therefore it was
unexpected that fluorescent products were not detected by GeneScan. The PCR
reaction conditions were altered, using alternative Taq polymerase, and varying DNA
starting concentrations and MgCl2 concentrations along with fresh preparation of all
reagents. Theses measures did not however affect the result, with only fluorescent
primers seen after GeneScan analysis.
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3.3.5 Summary of PFGE, RAPD and ERIC PCR typing results
Table 3.3 shows the results from the PFGE, RAPD and ERIC-PCR typing for NC-1-
15.





NC-14 256 A R-I E-I
NC-10 128 A R-I E-I
NC-1 128 A R-I E-I
NC-4 32 UD R-I1 E-I2
NC-13 8 UD R-I1 E-I3
NC-11 32 UD R-I I E-II
NC-8 1 UD R-II E-II
NC-6 1 UD R-II E-II
NC-7 0.015 UD R-III E-III
NC-9 0.25 B R-IV E-IV
NC-15 8 C R-V E-V
NC-12 32 D R-VI E-VI
NC-2 0.25 E R-VII E-VII
NC-3 0.25 F R-VIII E-VIII
NC-5 1 G R-II E-II
UD = Undetermined
PCR-based typing techniques of RAPD and ERIC-PCR were the most successful in
typing isolates. With the exception of isolates NC-15 and NC-12, resistant isolates
were typed into two groups with related isolates NC-14, NC-10, NC-1, NC-4 and
NC-13 designated TYPE I, and related isolates NC-11, NC-8, NC-6 and NC-5
designated TYPE II, based on PFGE, RAPD and ERIC-PCR. Variations in MICs
between related isolates provided the unique opportunity to study resistance
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acquisition in isogenic clinical isolates, to compare with data previously derived solely
from in vitro based studies.
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3.4 PCR amplification of the QRDR ofE. coli gyrA and parC
3.4.1 DNA gyrase gyrA
Fluoroquinolone resistance conferring mutations are known to occur in a region of
DNA gyrase known as the quinolone resistance determining region (QRDR). To
screen for mutations occurring within this region a 623bp fragment incorporating the
117bp QRDR was amplified for the 15 clinical isolates NC-1-15 (Figure 3.10).
Figure 3.10: PCR amplification of a 623bp region containing the QRDR of
DNA gyrase gyrA
Lane: 1 - NC-2; 2 - NC-3; 3 - NC- Lane: 1 - NC-4; 2 - NC-15; 3 -
9; 4 - NC-8; 5 - NC-5; 6 - NC-7; 7 NC-12; 4 - NC-14; 5 -NC- 11; 6
- NC-6; 8 - NC-13; 9 - kHindlll - NC-10; 7 - NC-13; 8 - NC-1; 9
DNA; 10 - lOObp DNA ladder - XHindUl DNA; 10 - lOObp
DNA ladder
Certain common gyrA mutations conferring quinolone resistance, for example
resulting in a substitution of amino-acid Ser83 in the QRDR ofgyrA, result in the loss
of a Hinfl G/ANTC restriction site. HinfI digestion was therefore used to screen for
the presence of this mutation in the clinical isolates.
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Restriction fragment length polymorphism's (RFLPs) were carried out on the
amplified 623bp amplicons of E. coli NC-1-15, with restriction endonuclease Hinfi
(Figure 3.11).
Figure 3.11: Restriction fragment length polymorphism's of the 623bp section of
gyrA ofNC-1-15
Lanes containing unrestricted DNA and size markers have been labelled, corresponding Hinfi
digested DNA for each isolate follows unrestricted DNA. Lane: 1 - NC-14; 2 - NC-6; 3 - NC-10; 4
- NC-4; 5 - NC-15; 6 - NC-2; 7 NC-11; 8 - NC-1; 9 - XHindlll DNA marker; 10 - NC-9; 11 - NC-
12; 12 - NC-5; 13 - NC-8; 14 - NC-7; 15 - NC-13; 16 - NC-3; 17 - XHindlll DNA marker; 18 -
lOObp DNA ladder
A control RFLP experiment was performed with 1) quinolone resistant E. coli known
to possess a GyrA change, 2) quinolone resistant E. coli with no GyrA change and
3)sensitive E. coli. To allow comparison between restriction fragment patterns these
controls were analysed alongside representative isolates of varying ciprofloxacin
MICs 0.015, 0.25, 1, 8, and 32 mg/L (Figure 3.12). Hinfi restricted DNA was run
alongside unrestricted DNA on agarose gels.
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Figure 3.12: RFLPs of the 623bp gyrA ofE. coli control strains (with and
without Ser83 mutation) and clinical isolates with ciprofloxacin MICs 0.015,
0.25,1, 8 and 32 mg/L
Lanes containing unrestricted DNA and size markers have been labelled, corresponding Hinfl
digested DNA follows unrestricted DNA. Lane: 1 - sensitive E. coli with no gyrA mutation; 2
- resistant E .coli without Ser83 mutation; 3 - Ciprofloxacin resistant E. coli with a gvrA
Ser83 mutation; 4 - NC-7 (MIC=0.015mg/L); 5 - NC-11 (MIC= 32mg/L); 6 - NC-13
(MIC=8mg/L); 7 - NC-6 (M3C=lmg/L); 8 - NC-12 (MIC=0.25mg/L); 9 - XHindlll DNA
Control E. coli isolates containing no gyrA mutation at Ser83 produced three
fragments upon restriction with Hinfl restriction endonuclease, confirming that there
was no loss of restriction site (Figure 3.12). Control E. coli containing a Ser83
mutation produced only two fragments upon restriction, demonstrating the loss of the
Hinfl restriction site G/ANTC (Figure 3.12) Fourteen of the 15 clinical isolates
showed loss of the Hinfl restriction site (2 fragments), indicating the presence ofgyrA
mutations at Ser83 in the QRDR of gyrA (Figure 3 .11). Only one isolate NC-7
produced three bands, retaining the Hinfl restriction site, and correlating with controls
with no gyrA mutations, indicating that this isolate did not possess the Ser83 gyrA
mutation. This may be expected as this isolate is highly sensitive to ciprofloxacin with
an MIC of 0.015mg/L. However we cannot conclude that ciprofloxacin sensitive
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strains with low MICs will contain no Ser83 changes, as these results indicate that
strains with ciprofloxacin MICs as low as 0.25mg/L contain gyrA changes.
3.4.2 DNA topoisomerase IV parC
Fluoroquinolone resistance conferring mutations have been described in the enzyme
Topoisomerase IV parC in a region equivalent to the QRDR of DNA gyrase gyrA.
The parC gene of NC-1-15 was analysed for mutations by PCR amplification of a
395bp region incorporating the QRDR (Figure 3.13), and subsequent DNA
sequencing (see section 3.5.2).
Figure 3.13: PCR amplification of a 395bp region ofparC
Lane: 1 - NC-14; 2 - NC-13; 3 - NC-4; 4 - NC-1; 5 - NC-10; 6 - NC-11; 7 - NC-
8; 8 - no DNA; 9 - lOObp DNA ladder
Figure 3.13 shows parC amplicons for eight clinical isolates; parC amplicons were
obtained for all 15 clinical isolates in the same way. The bands seen below the
amplified product are primer dimers, deduced as such as they are still present in the
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control sample with no DNA, ruling out non-specific DNA amplification. Unlike gyrA
mutations parC mutations could not be detected by restriction as known amino-acid
substitutions do not span a known restriction site, and therefore isolates of interest
were subsequently sequenced (Section 3.5.2).
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3.5 Sequencing of the Quinolone Resistance Determining Region
(QRDR) ofgyrA and parC genes
3.5.1 DNA gyrase gyrA
Mutations in the QRDR of gyrA of clinically sensitive and resistant isolates were
analysed by DNA sequencing. TYPE I isolates NC-13, NC-4, NC-10, NC-1 and NC-
14 with related genotypes (Section 3.3), however varying levels of ciprofloxacin
resistance (8-256mg/L) were sequenced to analyse progression to high-level
resistance. TYPE II isolates NC-8 and NC-11, which had identical genotypes, were
also sequenced to analyse progression from a clinically sensitive (lmg/L) to a resistant
phenotype (32mg/L). All sequences determined were compared to E. coli gyrA in
GenBank (http://www.ncbi.nlm.nih.gov/cgi-bin/BLAST), with accession number
(X06744), a sequence originally described by Swanberg & Wang (1987). Only the
QRDR of each sequence is shown (Figure 3.14 - 3.19) as amino acid mutations were
not found outwith this region. An exception to this was isolates NC-10 and NC-1
which had mutations outwith this region, and therefore an extended region of
sequence is shown (Figure 3 .16).
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3.5-l.i WT gyrA
The QRDR of E. coli gyrA spans the region of amino-acids from Ala67 to Glul06,
and mutation hotspots within this region are at Ser83 and Asp87. Mutations outwith
the QRDR have not been reported to confer significant effects on resistance levels.
The QRDR of the clinical isolates were compared to that ofWT gyrA QRDR found in
GenBank (Figure 3.14).
Figure 3.14: QRDR ofWT E. coli gyrA
GCT CGT GTC GTT GGT GAC GTA ATC GGT AAA
Ala Arg Val Val Gly Asp Val lie Gly Lys
67
TAC CAT CCC CAT GGT GAC TCG GCG GTC TAT
Tyr His Pro His Gly Asp Ser Ala Val Tyr
83
GAC ACG ATT GTC CGC ATG GCG CAG CCA TTC
Asp Thr lie Val Arg Met Ala Gin Pro Phe
87
TCG CTG CGT TAT ATG CTG GTA GAC GGT CAG
Ser Leu Arg Tyr Met Leu Val Asp Gly Gin
106
Mutation hotspots are shown in bold
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3.5.1.ii QRDR of DNA gyrasegyrA of RAPD type I related isolates
NC-13 and NC-4
The QRDR sequence of NC-13 (Cip MIC=8mg/L) and NC-4 (Cip MIC=32mg/L)
were found to be identical (Figure 3.15).
Figure 3.15: gyrA QRDR of NC-13 and NC-4
GCT CGT GTC GTT GGT GAC GTA ATC GGT AAA
Ala Arg Val Val Gly Asp Val lie Gly Lys
67
TAC CAT CCC CAT GGT GAC TTG GCG GTT TAT
Tyr His Pro His Gly Asp Leu Ala Val Tyr
83 85
AAC ACG ATT GTC CGT ATG GCG CAG CCA TTC
Asn Thr lie Val Arg Met Ala Gin Pro Phe
87 91
TCG CTG CGT TAC ATG CTG GTA GAC GGT CAG
Ser Leu Arg Tyr Met Leu Val Asp Gly Gin
100 106
Amino-acid substitutions are shown in red
Silent nucleotide substitutions are shown in blue
The sequence ofNC-13 and NC-4 contained two amino-acid mutations; Ser83—»Leu
and Asp87->Asn. Nucleotide substitutions which did not confer amino-acid
alterations were found at amino-acid positions 85, 91 and 100.
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NC-1 & NC-10
The QRDR sequence ofNC-1 (Cip MIC=128mg/L) and NC-10 (Cip MIC=128mg/L)
were identical (Figure 3.16).



























































































































































































































































Amino-acid substitutions are shown in red
Silent nucleotide substitutions are shown in blue
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The sequence of NC-1 and NC-10 contained amino-acid mutations: Ser83->Leu,
Asp87—»Tyr and Prol85-^Leu. Non amino-acid altering nucleotide substitutions
were found at amino-acid positions 85, 91, 100, 111 and 156.
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NC-14
The gyrA QRDR of isolate NC-14 (Cip MIC=256mg/L) is shown in figure 3.17.
Figure 3.17: gyrA QRDR ofNC-14
GCT CGT GTC GTT GGT GAC GTA ATC GGT AAA
Ala Arg Val Val Gly Asp Val lie Gly Lys
67
TAC CAT CCC CAT GGT GAC TTG GCG GTT TAT
Tyr His Pro His Gly Asp Leu Ala Val Tyr
83 85
TAC ACG ATT GTC CGT ATG GCG CAG CCA TTC
Tyr Thr lie Val Arg Met Ala Gin Pro Phe
87 91
TCG CTG CGT TAC ATG CTG GTA GAC GGT CAG
Ser Leu Arg Tyr Met Leu Val Asp Gly Gin
100 106
Amino-acid substitutions are shown in red
Silent nucleotide substitutions are shown in blue
The sequence ofNC-14 contained two mutations: Ser83^Leu and Asp87—>Tyr. Non
amino-acid altering nucleotide changes were found at positions 85, 91 and 100.
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3.5.1.iii The QRDR of DNA gyrase gyrA of type II related isolates
NC-8
The gyrA QRDR if isolate NC-8 (Cip MIC= 1mg/L) is shown in figure 3.18.
Figure 3.18: gyrA QRDR ofNC-8
GCT CGT GTC GTT GGT GAC GTA ATC GGT AAA
Ala Arg Val Val Gly Asp Val lie Gly Lys
67
TAC CAT CCC CAT GGT GAC TTG GCG GTT TAT
Tyr His Pro His Gly Asp Leu Ala Val Tyr
83 85
GAC ACG ATT GTC CGT ATG GCG CAG CCA TTC
Asn Thr lie Val Arg Met Ala Gin Pro Phe
87 91
TCG CTG CGT TAC ATG CTG GTA GAC GGT CAG
Ser Leu Arg Tyr Met Leu Val Asp Gly Gin
100 106
Amino-acid substitutions are shown in red
Silent nucleotide substitutions are shown in blue
The sequence ofNC-8 contained one amino-acid mutation: Ser83—»Leu. Non amino-
acid altering nucleotide mutations were found at positions 85, 91 and 100.
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NC-11
The gyrA QRDR sequence of isolate NC-11 (Cip MIC=32 mg/L) is shown in figure
3.19.
Figure 3.19: QRDR of NC-11
GCT CGT GTC GTT GGT GAC GTA ATC GGT AAA
Ala Arg Val Val Gly Asp Val lie Gly Lys
67
TAC CAT CCC CAT GGT GAC TTG GCG GTT TAT
Tyr His Pro His Gly Asp Leu Ala Val Tyr
83 85
AAC ACG ATT GTC CGT ATG GCG CAG CCA TTC
Asn Thr lie Val Arg Met Ala Gin Pro Phe
87 91
TCG CTG CGT TAC ATG CTG GTA GAC GGT CAG
Ser Leu Arg Tyr Met Leu Val Asp Gly Gin
100 106
Amino-acid substitutions are shown in red
Silent nucleotide substitutions are shown in blue
The sequence of NC-11 contained two amino-acid mutations: Ser83—>Leu and
Asp87-^Asn. Non amino-acid altering nucleotide substitutions were found at amino-
acid positions 85, 91 and 100.
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3.5.2 DNA topoisomerase IVparC
Sequencing of the QRDR of DNA gyrase revealed that certain isolates with varying
MICs has identical gyrA mutations, raising the theory that mutations in the
fluoroquinolone target DNA topoisomerase IV parC gene may be present and
responsible for resistance.
Mutations in the QRDR of parC of clinically sensitive and resistant isolates were
analysed by DNA sequencing. TYPE I isolates NC-13, NC-4, NC-10, NC-1 and NC-
14 with related genotype however varying levels of resistance (Cip MIC=8—>256
mg/L) were sequenced to analyse the parC changes associated with resistance
progression. TYPE II isolates NC-8 and NC-11 which had identical genotypes were
also sequenced to analyse progression from a clinically sensitive to resistant
phenotype (Cip MICs=l—>32 mg/L). Isolates NC-9 and NC-7 were sequenced to
screen for the presence ofparC mutations in isolates with MICs of <0.25 mg/L, to
assess ifgyrA ofparC mutations occur primarily because 14/15 isolates were known
to contain gyrA mutations by restriction analysis.
All sequences determined were compared to E. coli parC in GenBank (http://www
.ncbi.nlm.nih.gov/cgi-bin/BLAST), with accession number (M58408), a sequence
originally described by Kato et al. (1990).
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3.5.2.i WTparC
The QRDR of E. coli parC spans an equivalent region to that of gyrA, between
amino-acids Lys61 and Trpl06, encompassing mutation hotspots Ser80 (equivalent to
gyrA Ser83) and Glu84 (equivalent to gyrA Asp87). The QRDR sequences of clinical
isolates were compared to the WTparC sequence shown in figure 3.20.
Figure 3.20: QRDR ofE. coliWT parC
AAA AAA TCG GCC CGT ACC GTC GGT GAC GTA
Lys Lys Ser Ala Arg Thr Val Gly Asp Val
61
CTG GGT AAA TAC CAT CCG CAC GGC GAT AGC
Leu Gly Lys Tyr His Pro His Gly Asp Ser
80
GCC TGT TAT GAA GCG ATG GTC CTG ATG GCG
Ala Cys Tyr Glu Ala Met Val Leu Met Ala
84
CAA CCG TTC TCT TAC CGT TAT CCG CTG GTT
Gin Pro Phe Ser Tyr Arg Tyr Pro Leu Val
GAT GGT CAG GGG AAC TGG
Asp Gly Gin Gly Asn Trp
106
Mutation hotspots are shown in bold
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3.5.2.ii QRDR of DNA topoisomerase IVparC ofRAPD type I related isolates
NC-13
The QRDR ofNC-13 (Cip MIC=8mg/L) is shown in figure 3 .21.
Figure 3.21: parCQRDR of NC-13
AAA AAA TCG GCC CGT ACC GTC GGT GAC GTA
Lys Lys Ser Ala Arg Thr Val Gly Asp Val
61
CTG GGT AAA TAC CAT CCG CAC GGC GAT ATC
Leu Gly Lys Tyr His Pro His Gly Asp He
80
GCC TGT TAT GAA GCG ATG GTC CTG ATG GCG
Ala Cys Tyr Glu Ala Met Val Leu Met Ala
84
CAA CCG TTC TCT TAC CGT TAT CCG CTG GTT
Gin Pro Phe Ser Tyr Arg Tyr Pro Leu Val
GAT GGT CAG GGG AAC TGG
Asp Gly Gin Gly Asn Trp
106
Amino-acid substitutions are shown in red
The sequence ofNC-13 contained one amino-acid mutation; Ser80—»Ue.
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NC-4
The QRDR ofNC-4 (Cip MIC=32mg/L) is shown in figure 3.22.
Figure 3.22: parC QRDR ofNC-4
AAA AAA TCG GCC CGT ACC GTC GGT GAC GTA
Lys Lys Ser Ala Arg Thr Val Gly Asp Val
61
CTG GGT AAA TAC CAT CCG CAC GGC GAT ATC
Leu Gly Lys Tyr His Pro His Gly Asp lie
80
GCC TGT TAT GAA GCG ATG GTC CTG ATG GCG
Ala Cys Tyr Glu Ala Met Val Leu Met Ala
84
CAG CCG TTC TCT TAC CGT TAT CCG CTG GTT
Gin Pro Phe Ser Tyr Arg Tyr Pro Leu Val
GAT GGT CAG GGA AAC TGG
Asp Gly Gin Gly Asn Trp
106
Amino-acid substitutions are shown in red
Silent nucleotide substitutions are shown in blue
The sequence of NC-4 contained one amino-acid mutation; Ser80—»Ile. Nucleotide
substitutions which did not confer amino-acid alterations were found at positions 91
and 104.
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NC-1
The QRDR ofNC-1 (Cip MIC=T28mg/L) is shown in figure 3.23.




















































































GAT GGT CAG GGG AAC




Amino-acid substitutions are shown in red
The sequence of NC-1 contained amino-acid substitutions; Ser80—»Ile and
Glu84—>Lys.
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NC-10
The QRDR of isolate NC-10 (Cip MIC=T28rng/L) is shown in figure 3.24.
Figure 3.24: parCQRDR of NC-10
AAA AAA TCG GCC CGT ACC GTC GGT GAC GTA
Lys Lys Ser Ala Arg Thr Val Gly Asp Val
61
CTG GGT AAA TAC CAT CCG CAC GGC GAT ATC
Leu Gly Lys Tyr His Pro His Gly Asp lie
80
GCC TGT TAT AAA GCG ATG GTC CTG ATG GCG
Ala Cys Tyr Lys Ala Met Val Leu Met Ala
84
CAA CCG TTC TCT TAC CGT TAT CCG CTG GTT
Gin Pro Phe Ser Tyr Arg Tyr Pro Leu Val
GAT GGT CAG GGG AAC TGG
Asp Gly Gin Gly Asn Trp
106
Amino-acid substitutions are shown in red
The sequence of NC-10 contained amino-acid substitutions; Ser80->Ile and
Glu84^Lys.
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NC-14
The QRDR ofNC-14 (Cip MIC=256mg/L) is shown in figure 3.25.
Figure 3.25: parCQRDR ofNC-14
AAA AAA TCG GCC CGT ACC GTC GGT GAC GTA
Lys Lys Ser Ala Arg Thr Val Gly Asp Val
61
CTG GGT AAA TAC CAT CCG CAC GGC GAT ATC
Leu Gly Lys Tyr His Pro His Gly Asp lie
80
GCC TGT TAT AAA GCG ATG GTC CTG ATG GCG
Ala Cys Tyr Lys Ala Met Val Leu Met Ala
84
CAA CCG TTC TCT TAC CGT TAT CCG CTG GTT
Gin Pro Phe Ser Tyr Arg Tyr Pro Leu Val
GAT GGT CAG GGG AAC TGG
Asp Gly Gin Gly Asn Trp
106
Amino-acid substitutions are shown in red
The sequence contained amino-acid substitutions; Ser80—»Ile and Glu84->Lys.
114
3. Results: Clinical fluoroquinolone resistance
3.5.2.iii The QRDR ofDNA Topoisomerase IVparC of type II related isolates
NC-8
The QRDR ofNC-8 (Cip MIC=lmg/L) is shown in figure 3.26.
Figure 3.26: parC QRDR of NC-8
AAA AAA TCG GCC CGT ACC GTC GGT GAC GTA
Lys Lys Ser Ala Arg Thr Vai Gly Asp Val
61
CTG GGT AAA TAC CAT CCG CAC GGC GAT ATC
Leu Gly Lys Tyr His Pro His Gly Asp lie
80
GCC TGT TAT GAA GCG ATG GTC CTG ATG GCG
Ala Cys Tyr Glu Ala Met Val Leu Met Ala
84
CAG CCG TTC TCT TAC CGT TAT CCG CTG GTT
Gin Pro Phe Ser Tyr Arg Tyr Pro Leu Val
GAT GGT CAG GGG AAC TGG
Asp Gly Gin Gly Asn Trp
106
Amino-acid substitutions are shown in red
Silent nucleotide substitutions are shown in blue
The sequence of NC-8 contained one amino acid substitution: Ser80^Ile. A non
amino-acid altering nucleotide substitution was present at amino-acid position 91.
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NC-11
The QRDR ofNC-11 (Cip MIC=32mg/L) is shown in figure 3.27.
Figure 3.27: parC QRDR ofNC-11
AAA AAA TCG GCC CGT ACC GTC GGT GAC GTA
Lys Lys Ser Ala Arg Thr Val Gly Asp Val
61
CTG GGT AAA TAC CAT CCG CAC GGC GAT ATC
Leu Gly Lys Tyr His Pro His Gly Asp lie
80
GCC TGC TAT GTA GCG ATG GTC CTG ATG GCG
Ala Cys Tyr Val Ala Met Val Leu Met Ala
84
CAG CCA TTC TCT TAT CGT TAT CCG CTG GTC
Gin Pro Phe Ser Tyr Arg Tyr Pro Leu Val
GAC GGG CAG GGG AAC TGG
Asp Gly Gin Gly Asn Trp
106
Amino-acid substitutions are shown in red
Silent nucleotide substitutions are shown in blue
The sequence of NC-11 contained two amino acid mutations: Ser80—»Ue and
Glu84—>Val. Non amino-acid altering nucleotide substitutions were found at positions
87,91,92,95, 100, 101 and 102.
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3.5.2.iv QRDR of DNA topisomerase IV parC of isolates with ciprofloxacin
MICs of < 0.25mg/L
NC-7 and NC-9
The QRDR of NC-7 (Cip MK>0.015mg/L) and NC-9 (Cip MIC=0.25mg/L) is
shown in figure 3 .28.
Figure 3.28: parC QRDR ofNC-7 and NC-9
AAA AAA TCG GCC CGT ACC GTC GGT GAC GTA
Lys Lys Ser Ala Arg Thr Val Gly Asp Val
61
CTG GGT AAA TAC CAT CCG CAC GGC GAT AGC
Leu Gly Lys Tyr His Pro His Gly Asp Ser
80
GCC TGT TAT GAA GCG ATG GTC CTG ATG GCG
Ala Cys Tyr Glu Ala Met Val Leu Met Ala
84
CAA CCG TTC TCT TAC CGT TAT CCG CTG GTT
Gin Pro Phe Ser Tyr Arg Tyr Pro Leu Val
GAT GGT CAG GGG AAC TGG
Asp Gly Gin Gly Asn Trp
106
Mutation hotspots are shown in bold
The sequences ofNC-7 and NC-9 were identical to WT containing no amino-acid or
nucleotide substitutions.
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3.6 Summary of Progression to High-Level Resistance
In this outbreak resistance can be clearly associated with resistance mutations
occurring within target proteins DNA gyrase gyrA and Topoisomerase IV parC. All
isolates except NC-7 (Cip MIC=0.015mg/L) contained gyrA mutation at Ser83,
however NC-7 and NC-9 did not show a parC mutations. The progression to high-
level resistance in two strains Type I and II is summarised in Table 3 .4.



















4 32 1 Ser83->Leu
Asp87-»Asn
Ser80~>Ile
13 8 I Ser83-»Leu
Asp87->Asn
Ser80->Ile




8 1 II Ser83->Leu Scr80—>Ile
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4. Results: Site-Directed Mutagenesis
4.1 An Overview
Mutations at amino acids Ser83 and Asp87 were introduced into E. coli DNA gyrase
by in vitro site-directed mutagenesis. Mutagenesis was performed with the
QuikChange™ kit supplied by Stratagene, UK, and was based on the protocol shown
in figure 4.1.
Figure 4.1: Site-directed mutagenesis protocol
Step 1
Plasmid Preparation Gene in plasmid with
target site (© for mutation
Step 2
Temperature Cycling Denature the plasmid and anneal theoligonucleotide primers (A containing
the desired mutation (x)
Using the nonstrand-displacing
action of PfuTurbo DNA polymerase,
extend and incorporate the
mutagenic primers resulting





From Stratagene QuikChange Site-
Directed Mutagenesis protocol
Digest the methylated, nonmutated
parental DNA template with Dpnl
Transform the circular, nicked dsDNA
into XL1 -Blue supercompetent cells
After transformation, the XL!-Blue
supercompetent cells repair the






Mutated DNA plasmid j
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Mutated plasmids were subsequently transformed into Ts mutant KNK453 E. coli
(Kreuzer & Cozzarelli, 1979) to analyse resistance phenotype conferred by altered
gyrA genes.
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4.2 Plasmid pPH3
The gyrA containing plasmid used for mutagenesis was pPH3; a plasmid with gyrA
optimally located downstream from a tac promoter (Figure 4.2). Expression of gyrA
was therefore regulated by the inducer IPTG, in the presence of which cells show an
increased level of GyrA expression (Hallett el al., 1990). When expressed in the
gyrA15 KNK453 strain, growth was not detected at 42°C in the absence of IPTG,
whereas induction by IPTG allowed cell growth. Induction of gyrA expression by
IPTG provided additional control when expressing plasmid in gyrA18 cells.




From Hallett et al., 1990
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4.3 Extraction of plasmid DNA from JMtacA E. coli cells
Plasmid DNA was extracted from JMtacA (JM109[pPH3]) E. coli cells using the
hybaid Plasmid prep kit (Hybaid, Middlesex, UK). Electrophoresis of plasmid extracts
demonstrated a product of 8kb, the expected plasmid size, along with a larger product
of >23,000-bp (Figure 4.3) This larger unidentified band was likely as a consequence
ofplasmid concatermers, or due to the presence of contaminating chromosomal DNA.








Lane: 1 - LHindlll DNA ladder; 2 - Plasmid DNA (lpL); 3 - Plasmid
DNA (2pL); 4 - Plasmid DNA (5gL)
To eliminate possible concatermers and accurately size the plasmid DNA it was
linearised with the restriction endonuclease A7?oI, which produces a single cut in the
plasmid (Figure 4.2). Restriction of two plasmid extracts PI and P2, yielded single
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8kb products, and confirmed plasmid identity (Figure 4.4). Restriction of DNA
eliminated the 23kb band, thereby demonstrating that this was plasmid concatermers,
and not contaminating chromosomal DNA. The concentration of plasmid in extracts
was estimated to be 30r|g/pL utilising comparison with ////?r/III/Lamda DNA.
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4.4 Verification of the Ts phenotype of E. coli KNK453 mutants
E. coli Ts mutants KNK453 (gyrA43 polA thyA uvrA phxA) carry a temperature
sensitive gyrA allele and were found to be viable at 30°C, but not at 42°C. Upon
arrival cells were replica plated at 30°C and 42°C; 90% were found to have retained
their Ts phenotype. Ts mutants and were stored at -70°C or on plates for further
experimentation.
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4.5 Mutagenesis of Ser83 and Aps87 amino-acids
PCR amplification of gyrA containing plasmid template utilised DNA template
concentrations of 15r|g, 30r|g and 60r|g. Initial amplification with Ser83 mutagenic
primers was successful (Figure 4.5), however amplification failed with Asp87
mutagenic primers. For Ser83 amplification reactions, the DNA template of 15r|g
gave the most specific amplification product (Figure 4.5). As starting concentration
was increased from this, PCR specificity decreased (Figure 4.5). Ser83 plasmid
products were subsequently transformed into Epicurian Coli® cells (see section 4.6).
Figure 4.5: PCR amplification of pPH3 with Ser83 mutagenic primers
8kb
Lane: 1- XHindlll DNA ladder; 2- S83 (15r|g); 3 - S83 (30rig); 4- S83
(60r|g)
PCR amplification with Asp87 mutagenic primers required further optimisation as
PCR amplification with staring template of 15-60 r|g was unsuccessful. Increasing
DNA starting concentration to 90r|g was successful however yielded non-specific
DNA products (Figure 4.6a). To increase specificity, annealing temperature was
increased from 50°C to 52°C; this increased specificity gave product, however DNA
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yield remained low (Figure 4.6b). The optimal product was obtained by retaining this
increased annealing temperature, decreasing DNA concentration to 60r|g, and
increasing the number ofPCR cycles (Figure 4.6c).








Lane: 1 - UHindlW DNA Lane: 1- XHindlll DNA Lane: 1 - XHindUl
ladder; 2 - A87 (90r|g) ladder; 2 - A87 (90r|g) DNA ladder; 2 - A87
(60r|g); 3 - A87 (90-qg)
Asp87 mutated plasmid products were subsequently transformed into Epicurian Coli®
cells (Section 4.6).
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4.6 Transformation of Epicurian Coli® XL-1 Blue super-competent
cells
Nicked mutant plasmid DNA and control pUC 18 plasmid DNA was transformed into
Epicurian Coli® (recAl endA I gyrA96 thi-1 hsdRJ7 supE44 relAl /ac[F' proAB lacP
ZM15 Tn70(Tef)] cells. These cells are known to allow repair of the nicks in plasmid
created during the DNA restriction step (Figure 4.1). Transformants were selected on
LB amp plates, substituted with IPTG and X-gal for pUC18 control.
A control transformation was initially performed using the plasmid pUC18.
Transformation with the pUC18 plasmid should optimally yield >250 colonies (108
cfu) with 98% having the blue phenotype (QuikChange protocol). Transformation of
cells with pUC18 however yielded only 15 cells with 10 having the blue phenotype,
showing that transformation efficiency was 6% of the expected value. This raised
questions about the efficiency of the Epicurian Coli® cells. Cells had been stored in
the freezer for 6 months, and may have undergone temperature variations during this
time and upon arrival. As these cells are extremely sensitive, these factors may have
affected their efficiency and ability to uptake plasmid DNA.
Transformation with Asp87 and Ser83 mutant plasmids yielded slowly growing
transformants > 48 hours. Transformants should be selected in approximately 16
hours, and therefore there is a possibility that cells seen after 48 hour selection were
selected for ampicillin resistance (ampicillin resistance revertants), and selection may
not be due to a plasmid containing the bla (ampR) resistance gene. Attempts to extract
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plasmid from these cells failed, supporting that they may not be carrying the desired
plasmid, however did not rule out the possibility that there were faults with the
plasmid extraction technique.
As transformation of the mutant plasmid failed in Epicurian Coli®, the transfer of
plasmid directly into KNK453 gyrA^ E. coli cells was attempted. Transformants were
selected with low efficiency, with pUC18 control yielding only 20 transformants.
Transformation with mutant plasmids yielded —10 transformants per sample (50%
pUC18 control). Plasmid extraction from transformants also failed, however in this
system it was also possible to analyse plasmid carriage by the phenotype of the cells in
a Ts environment. Transformants were selected on ampicllin containing plates, and
transformants replica plated at 30°C and 42°C, in the presence and absence of IPTG.
Plasmids extracts transformed were Wild-type (Wl, W2), Ser83 (SI, S2) and Asp87
(Al, A2). The results are shown in table 4.1.
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+ IPTG -IPTG +IPTG -IPTG
W1 + + + -
W2 + + + -
SI + + - -
S2 + + - -
A1 + + - -
A2 + + - -
CgyrA* + + - -
+ = growth
- = no growth
These results indicated that there was successful transformation ofWT plasmid into
Ts mutants. Plasmid was subsequently extracted from WT transformants. The fact
that Asp87 and Ser83 mutant transformants did not grow at 42°C indicated that these
cells did not contain plasmid. Over 100 transformants were tested in a the same
manner, and all failed to grow at 42°C independent of the presence or absence of
IPTG. Stimulation of plasmid gyrA expression by IPTG in broth was attempted before
plating, however this also failed yield plasmid or a complementary phenotype. The
failure to transform into Ts mutants was possibly due to the fact that endonucleases
within these cells would break down the nicked plasmid DNA, before repairs to the
plasmid could be completed. Epicurian coli® cells are engineered to repair DNA
damage and limit DNA breakdown.
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As original Epicurian Coli® transformation failure pointed to a loss of efficiency in
competent cells, a fresh batch ofEpicurian Coli® were obtained for use in subsequent
transformation reactions. Transformation of the second batch ofEpicurian Coli® with
pUC18 yielded 210 cfu out of expected 250 cfu, 87% of the expected value,
compared to the 6% of transformation into original Epicurian Coli®. This indicated
that original transformation failure had been due to loss of efficiency in competent
cells, rather than a problem with plasmid or experimental procedure. Transformation
of these cells with control pUC18, WT, Ser83 and Asp87 mutated plasmid also
yielded transformants with increased efficiency in comparison with original
transformation reactions (Table 4.2).
Table 4.2: Transformation efficiency of Epicurian Coli ® cells









% transformation efficiency was calculated by a comparison of the number of sample
transformants with number of control pUC18 transformants. Transformation of pUC18
plasmid was designated 100% efficient.
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An 8kb plasmid was extracted from -60% of transformants from each transformation
experiment, and used for subsequent transformation ofTs gyrA mutants (see section
4.8).
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4.7 PCR amplification of the QRDR of DNA gyrase gyrA
A 620bp region of DNA gyrase gyrA incorporating the QRDR of WT, Ser83 and
Asp87 plasmid gyrA were amplified (Figure 4.7), and sequenced to confirm correct
mutation incorporation.
Figure 4.7: gyrA amplification ofWT, Ser83 and Asp87 plasmid DNA
1 2 3 4 5 6 7
Lane: 1- 100-bp DNA ladder; XHindlll DNA ladder; WT gyrA: 5 -
A1 gyrA; 6 - SI gyrA; 7 - S2 gyrA; S3 gyrA
GyrA amplification was performed on twenty plasmids, 7 Ser83, 7 Asp87 and 6 WT
transformants, however only 5 amplifications were successful, shown in figure 4.7.
Four of the amplification products were of the expected size of~ 620bp, whereas one
product was ~ 50bp larger, suggesting that an insertion has taken place. All 5
products were consequently sequenced.
132
4. Results: Site-directed mutagenesis
4.8 Sequencing of plasmid gyrA QRDRs
Sequences of the 620bp gyrA amplicons ofWT, Ser83(Sl-3) and Asp87 (Al-2) were
compared with E. coli gyrA found in GenBank (http://www.ncbi.nlm.nih.gov: 80/
blast/Blast.cgi) with accession number (X06744.1), a sequence originally determined
by Swanberg & Wang (1987). Figures 4.8-4.11, show sequences of the QRDR only,
as mutations were not found out with these regions.
4.8.1 Wild-type
The nucleotide and amino acid sequence of the QRDR region ofWT plasmid encoded
gyrA is shown in figure 4.8.
Figure 4.8: Sequence of the QRDR ofWT E. coli gyrA
GCT CGT GTC GTT GGT GAC GTA ATC GGT AAA
Ala Arg Val Val Gly Asp Val lie Gly Lys
67
TAC CAT CCC CAT GGT GAC TCG GCG GTC TAT
Tyr His Pro His Gly Asp Ser Ala Val Tyr
83
GAC ACG ATT GTC CGC ATG GCG CAG CCA TTC
Asp Thr lie Val Arg Met Ala Gin Pro Phe
87
TCG CTG CGT TAT ATG CTG GTA GAC GGT CAG
Ser Leu Arg Tyr Met Leu Val Asp Gly Gin
106
Mutation hotspots are shown in bold
No mutations were present within the sequence, and therefore this plasmid provided
an accurate starting template for mutagenesis, as well as a control for phenotypic
analysis ofmutant plasmids.
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4.8.2 Ser83 mutant
Sequence of Ser83 mutants was expected to contain a Ser83—»Leu mutation
(TCG—>TTG) to confirm successful mutagenesis. Three mutants SI-3 were
sequenced, figure 4.9 shows the sequence of mutants SI and S2, and figure 4.10
shows the sequence of S3.
Figure 4.9: Sequence of Ser83 mutants SI & S2
GCT CGT GTC GTT GGT GAC GTA ATC GGT AAA
Ala Arg Val Val Gly Asp Val lie Gly Lys
67
TAC CAT CCC CAT GGT GAC TCG GCG GTC TAT
Tyr His Pro His Gly Asp Ser Ala Val Tyr
83
AAC ACG ATT GTC CGC ATG GCG CAG CCA TTC
Asn Thr lie Val Arg Met Ala Gin Pro Phe
87
TCG CTG CGT TAT ATG CTG GTA GAC GGT CAG
Ser Leu Arg Tyr Met Leu Val Asp Gly Gin
106
Mutations are shown in red
These strains contained Asp87->Asn mutations shown in red (Figure 4.9) This result
was unexpected as the primer used should have created a Ser83 mutation. This
mutation may have occurred naturally, however as there was no quinolone selection
pressure this also seems an unlikely scenario. It may be that errors occurred during the
PCR step and primer annealing, as this amino acid occurs at the end of the primer
sequence.
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Figure 4.10: Sequence of Ser83 mutant S3
GCT CGT GTC GTT GGT GAC GTA ATC GGT AAA
Ala Arg Val Val Gly Asp Val lie Gly Lys
67
TAC CAT CCC CAT GGT GAC TTG GCG GTC TAT
Tyr His Pro His Gly Asp Ser Ala Val Tyr
83
GAC AC/C MS SIS ACI JGG CGG ICT MS AC£
Asp Thr Met Val Thr Trp Ara Ser Met Ifar
87
ATG GTG ACT TGG CGG TCT ATG A£A CGA TTG
Met Val Thr Trp Ara Ser Met Thr Arg Leu
TCC GCA TGG CGC AGC CAT TCT CGC TGC GTT
Ser Ala Trp Arg Ser His Ser Arg Cys Val
ATA TGC TGC TAG ACG GTC AGG
He Cys Cys - Thr Val Arg
Introduced mutations are shown in red ; Altered reading frame is shown in green
Inserted primer sequence is underlined: - = STOP codon
This strain contained the desired mutation of Ser83->Leu (TCG-»TTG), however it
also contained a 50bp insertion concurrent with the greater product size on the
electrophoresis gel (Figure 4.7). This insertion consisted of two additional primer
sequences, inserting after amino-acid Asp87 (Figure 4.11), and changed the reading
frame of the gene.
Figure 4.11: Map of primer insertions
primer




Primer inserts are shown in green
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As the insertion changed the reading frame of the gene and a stop codon was
incorporated, gyrA expression would be interrupted, thus preventing use of this
mutant plasmid for further experimentation. Four separate attempts of Ser83 PCR
reactions yielded problems with mutagenesis. Unfortunately this meant that Ser83
mutant plasmid could not be used for subsequent phenotypic analysis.
4.8.3 Asp87 mutant
The expected sequence of A1 for a successfully mutagenised plasmid should contain a
mutation ofAsp87—>Asn (GAC—»AAC). The sequence ofA1 is shown in figure 4.12.
Figure 4.12: Sequence ofAsp 87 mutant A1
GCT CGT GTC GTT GGT GAC GTA ATC GGT AAA
Ala Arg Val Val Gly Asp Val lie Gly Lys
67
TAC CAT CCC CAT GGT GAC TCG GCG GTC TAT
Tyr His Pro His Giy Asp Ser Ala Val Tyr
83
AAC ACG ATT GTC CGC ATG GCG CAG CCA TTC
Asn Thr lie Val Arg Met Ala Gin Pro Phe
87
TCG CTG CGT TAT ATG CTG GTA GAC GGT CAG
Ser Leu Arg Tyr Met Leu Val Asp Gly Gin
106
Introduced mutations are shown in red
This transformant contained the desired mutation of Asp87-»Asn (GAC—>AAC), and
was subsequently expressed in the gyr^ system
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4.9 Expression of mutant phenotype in a temperature-sensitive
system
WT plasmid extracted from JM109 cells, and mutant Asp87 plasmid extracted from
Epicurian cells was successfully transformed into competent KNK453 Ts mutant E.
coli cells. Transformation with pUC18 control yielded 70 transformants, whereas
transformation with mutant Asp87 plasmid yielded 50 (71%). The transformants were
grown at 30°C and 42°C on LB amp selective agar in the presence and absence of
IPTG. The WT cells and Asp87 mutants grew at 42°C in the presence of IPTG.
Growth was seen after16 hours and cells were amp selected suggesting that they were
plasmid containing. Plasmid was successfully extracted from them.
137
4. Results: Site-directed mutagenesis
4.10 Fluoroquinolone MICs
The minimum inhibitory concentrations of nalidixic acid, ciprofloxacin, gemifloxacin,
moxifloxacin and sparfloxacin were determined (Table 4.2) using the agar dilution
method. Bacteria were grown at 42°C on IPTG containing plates to ensure expression
of plasmid gyrA.
Table 4.3: MICs ofWT and Asp87 mutant containing E. coli for a range of
quinolones




Nalidixic acid 0.01 2 7
Ciprofloxacin 0.007 0.04 3
Sparfloxacin 0.01 0.03 2
Moxifloxacin 0.05 0.06 <2
Gemifloxacin 0.005 0.04 3
The presence of plasmid encoded Asp87—»Asn gyrA mutation increased quinolone
MICs from < 2-7 fold (Table 4.2). Resistance was greatest with nalidixic acid, with
newer fluoroquinolones concurring only 2-3 fold increases in MICs. The levels of
resistance concurred remained below levels of clinically significant resistant levels,
indicating that this mutation alone could not be responsible for high-level quinolone
resistance.
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5.1 An Overview
Mutations in two conserved regions between amino-acids (41 & 43) and (85 & 91) of
E. coli ribosomal protein S12 are known to confer high-level streptomycin resistance,
with MICs exceeding 1500mg/L. The role of mutations in the S12 protein in
conferring resistance to other members of the aminoglycoside group of antibiotics has
not been previously characterised.
This work characterised the sequential progression to high-level aminoglycoside
resistance via a stepwise mutation study, analysing resistance progression for a range
of aminoglycosides. Mutants of E. coli NCTC10418 were selected in four steps
(Series 1-4) on plates with increasing aminoglycoside (streptomycin, neomycin,
gentamicin, kanamycin and tobramycin) concentrations. Cross-resistance between
different antibiotics was determined, to analyse whether resistance mechanisms
between aminoglycosides are common to all drugs, and hence whether these drugs
share common targets. The nucleotide sequence of ribosomal rpsL\2 encoding S12,
was determined for resistant mutants to analyse whether mutation in this target
contributes to resistance to aminoglycosides other than streptomycin resistance, and
whether the ribosomal S12 protein is a common target for all of the aminoglycosides.
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5.2 Selection of aminoglycoside resistant mutants
Mutants of E. coli NCTC10418 were selected in four steps (Series 1-4) on plates
containing increasing aminoglycoside concentrations. The mutation frequencies and
MICs ofmutants at each subsequent step is shown in table 5.1.
Table 5.1: MICs and mutation frequencies of aminoglycoside resistant mutants
selected in four series (1-4)
Drug Series (MIC mg/L and mutation frequency)
1 2 3 4
Streptomycin (S) 25 (lxlCT6) 100 (lxl0*4) 1000 (lxlO'3) 1500 (lxlO"3)
Neomycin (N) 10 (1x10"®) 25 (lxl0"6) 50 (1x10'®) 50 (lxlO"6)
Tobramycin (T) 10 (lx 10"®) 20 (lxl 0"6) 50 (1x10®) 50 (1x10"®)
Kanamycin (K) 10 (lxl 0"6) 20 (1 x 10"3) 50 (1x10"®) 50(1x10"®)
Gentamicin (G) 2 (lxlO"5) 4(1x10'®) 10 (lxl0~®) 10 (1x10 ®)
Streptomycin resistant mutants were selected with increasing frequency with each
selection step (1 in 106—>1 in 103), the first mutation being the most infrequent;
however after selection of this initial mutant, subsequent mutants were more readily
selected (Table 5.1). Resistance to streptomycin was not selected at levels greater
than lOOOmg/L until the third step, which was unexpected, as previous work has
documented streptomycin resistance of greater than 1500mg/L selected in a single
step. In this experiment four selection steps were required to achieve this level of
resistance. The levels of streptomycin resistance achieved after four series was higher
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than resistance to the other aminoglycosides. Resistance to kanamycin, tobramycin,
and neomycin progressed in a similar manner with each selection step, giving final
resistance levels of 50-100mg/L with the 4th step selection. Excluding kanamycin
which had a higher mutation frequency on the second step selection (1 in 103),
mutation frequencies remained low (1 in 106) and constant throughout the four
selections. Gentamicin resistance levels were the lowest after four selections, at
lOmg/L, with mutation frequencies remaining low and constant throughout the four
selections.
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5.3 Aminoglycoside cross-resistance
The levels of cross-resistance between streptomycin (S), neomycin (N), tobramycin
(T), kanamycin (K) and gentamicin (G) resistant mutants were determined (Figures
5.1 to 5.5).
Streptomycin resistance was only seen in mutants previously selected on streptomycin
plates, with resistance rising to 1500mg/L within four selection steps (Figure 5.1).
Tobramycin, neomycin, gentamicin and kanamycin-selected mutants remained
sensitive to streptomycin, indicating that the mutational changes and, therefore, drug
targets between of streptomycin appear different to the other aminoglycoside groups.
This is also confirmed in figures 5.2 to 5.5, where it can be seen that streptomycin
selected mutants remain sensitive to all other aminoglycosides tested.
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High-level resistance (lOOmg/L) to neomycin was seen in neomycin, kanamycin and
tobramycin selected mutants (Figure 5.2). Gentamicin mutants also showed resistance
to neomycin to a level of 30mg/L. Streptomycin mutants remained sensitive to
neomycin. Cross-resistance was significant between neomycin, kanamycin and
tobramycin and could be due to the fact that these antibiotics have similar structures
and therefore share common target proteins.




N S K T G
Aminoglycoside Mutant
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The greatest levels of resistance to tobramycin was seen in tobramycin and neomycin
selected mutants, with resistance levels reaching lOOmg/L. Gentamicin and kanamycin
showed similar levels of resistance (25mg/L), whereas mutants selected by
streptomycin remained sensitive (Figure 5.3).
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High-level resistance to kanamycin was seen in neomycin, kanamycin and tobramycin
and gentamicin mutants (50-100mg/L) (Figure 5.4). Streptomycin mutants remained
sensitive. Interestingly, neomycin, tobramycin and gentamicin-selected mutants had
greater or equal levels of kanamycin resistance, than mutants selected on kanamycin
plates. This again indicates the possibility of shared target proteins and hence
resistance mutations conferring aminoglycoside cross-resistance.




K S N T G
Aminoglycoside Mutant
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Resistance to gentamicin was lower than other aminoglycosides rising to 25mg/L for
tobramycin and kanamycin 4th step mutants (Figure 5.5). Gentamicin resistance in
gentamicin-selected mutants rose to lOmg/L, a lower level than for neomycin,
kanamycin and tobramycin selected mutants. Neomycin, tobramycin and kanamycin
may therefore be more effective in selecting mutations that lead to aminoglycoside
cross-resistance. Streptomycin selected mutants remained sensitive to gentamicin.
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5.4 PCR amplification and sequencing of the rpsL 12 gene
The gene encoding ribosomal protein S12 (rpsL 12) encompassing mutation hotspots
(41-43 and 85-91) was amplified by PCR, producing a 424bp PCR amplicon (Figure
Figure 5.6: A 424bp rpsL amplicon of aminoglycoside resistant mutants
Lane 1: lOObp DNA ladder; 2 - S-100; 3 - S-25; 4 - S-1000; 5 - S-1500; 6 - G-2;
7 - G-l(2nd); 8 - G-l(3rd); 9 - G-10; 10 - N-5; 11 - N-25; 12 - N-50; 13- N-100;
14 - T-10; 15 - T-50; 16 - T-100; 17 - K-5; 18 - K-10; 19; K-50 (see table 5.1)
Mutational changes within the rpsL genes were analysed by automated DNA
sequencing and compared with the E. coli S12 sequence in GenBank with accession
number V00355, originally described by Post & Namura, (1980) (Figure 5.7).
Mutations have been previously described in the two main areas, which are shown in
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Figure 5.7: Wild-type E. coli rpsL sequence
ATG GCA ACA GTT AAC CAG CTG GTA CGC AAA
Met Ala Thr Val Asp Gin Leu Val Arg Lys
CCA CGT GCT CGC AAA GTT GCA AAA AGC AAC
Pro Arg Ala Arg Lys Val Ala Lys Ser Asn
GTG CCT GCG CTG GAA GCA TGC CCG CAA AAA
Val Pro Ala Leu Glu Ala Cys Pro Gin Lys
CGT GGC GTA TGT ACT CGT GTA TAT ACT ACC
Arg Ala Val Cys Thr Arg Val Tyr Thr Thr
ACT CCT AAA AAA CCG AAC TCC GCG CTG CGT
Thr Pro Lys Lys Pro Asn Ser Ala Leu Arg
41 43
AAA GTA TGC CGT GTT CGT CTG ACT AAC GGT
Lys Val Cys Arg Val Arg Leu Thr Asn Gly
TTC GAA GTG ACT TCC TAC ATC GGT GGT GAA
Phe Glu Val Thr Ser Tyr lie Gly Gly Glu
GGT CAC AAC CTG CAG GAG CAC TCC GTG ATC
Gly His Asn Leu Gin Glu His Ser Val lie
CTG ATC CGT GGC GGT CGT GTT AAA GAC CTC
Leu lie Arg Gly Gly Arg Val Lys Asp Leu
85 87
CCG GGT GTT CGT TAC CAC ACC GTA CGT GGT
Pro Gly
Q1
Val Arg Tyr His Thr Val Arg Gly
GCG
J7 I
CTT GAC TGC TCC GGC GTT AAA GAC CGT
Arg Leu Asp Cys Ser Gly Val Lys Asp Arg
AAG CAG GCT CGT TCC AAG TAT GGC GTG AAG
Lys Gin Ala Arg Ser Lys Tyr Gly Val Lys
CGT CCT AAG GCT TAA
Arg Pro Lys Ala -
123
Mutation hotspots are shown in bold
- STOP
Sequencing of the rpsL gene of S-1500, N-50, K-50, T-50 and G-10 series 4 (S-
1500) mutants revealed mutation in the rpsL gene of the streptomycin resistant
mutant only. The other sequences mimicked that of wild-type rpsL (Figure 5.7). The
sequence of S-1500 is shown in Figure 5.8.
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Figure 5.8: S-1500 streptomycin mutant rpsL sequence
ATG GCA ACA GTT AAC CAG CTG GTA CGC AAA
Met Ala Thr Val Asp Gin Leu Val Arg Lys
CCA CGT GCT CGC AAA GTT GCA AAA AGC AAC
Pro Arg Ala Arg Lys Val Ala Lys Ser Asn
GTG CCT GCG CTG GAA GCA TGC CCG CAA AAA
Val Pro Ala Leu Glu Ala Cys Pro Gin Lys
CGT GGC GTA TGT ACT CGT GTA TAT ACT ACC
Arg Ala Val Cys Thr Arg Val Tyr Thr Thr
ACT CCT AAA AAA CCG AAC TCC GCG CTG CGT
Thr Pro Lys Lys Pro Asn Ser Ala Leu Arg
41 43
AAA GTA TGC CGT GTT CGT CTG ACT AAC GGT
Lys Val Cys Arg Val Arg Leu Thr Asn Gly
TTC GAA GTG ACT TCC TAC ATC GGT GGT GAA
Phe Glu Val Thr Ser Tyr lie Gly Gly Glu
GGT CAC AAC CTG CAG GAG CAC TCC GTG ATC
Gly His Asn Leu Gin Glu His Ser Val lie
CTG ATC CGT GGC GGT CGT GTT GAA GAC CTC
Leu lie Arg Gly Gly Arg Val Glu Asp Leu
85 87
CCG GGT GTT CGT TAC CAC ACC GTA CGT GGT
Pro Gly
Q1
Val Arg Tyr His Thr Val Arg Gly
GCG
%f i
CTT GAC TGC TCC GGC GTT AAA GAC CGT
Arg Leu Asp Cys Ser Gly Val Lys Asp Arg
AAG CAG GCT CGT TCC AAG TAT GGC GTG AAG
Lys Gin Ala Arg Ser Lys Tyr Gly Val Lys
CGT CCT AAG GCT TAA
Arg Pro Lys Ala -
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Amino-acid substitutions are shown in red
An amino-acid substitution of Lys87—>Glu was found in this sequence (S-1500). To
analyse at which point during mutation selection over the four series (1-4) this
mutation had occurred, Series l(25mg/L), 2(100mg/L) and 3(1000mg/L) mutants
were sequenced. The Lys87—»Glu mutation was present in all four series of mutants
(Streptomycin MICs 25—»1500mg/L), indicating that this mutation was not
responsible for the extremely high-level resistance found in streptomycin-resistant
mutants (1500mg/L).
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The lack of S12 mutations in tobramycin, gentamicin, kanamycin and neomycin
mutants suggested that the S12 protein encoded by rpsL may be a target unique to
streptomycin, with target preference closely associated with drug structure. The lack
of additional mutations in streptomycin resistant mutants, indicated the role of other
ribosomal proteins /targets in streptomycin action.
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6.1 An Overview
Antibiotics which interfere with bacterial protein synthesis machinery are known to
exert both bacteriostatic and bactericidal effects on cells. For example,
chloramphenicol which interacts with the bacterial 70S ribosome, is bacteriostatic, as
is spectinomycin, an aminocyclitol which is structurally closely related to the
aminoglycosides. Streptomycin, an aminoglycoside which interacts with the 30S
ribosomal sub-unit, exerts rapid bactericidal activity upon bacterial populations. The
reason why the aminoglycosides are bactericidal, whereas other protein synthesis
inhibitors are bacteriostatic remains to be determined. The way in which
aminoglycosides exert their killing effect in stationary phase populations, under
conditions of amino-acid starvation, or when protein synthesis is inhibited by drug
intervention may provide important new evidence essential for understanding these
differences.
This work investigated streptomycin induced cell death in log phase E. coli
NCTC10418 populations when challenged with single antibiotics, or antibiotic
combinations. The requirement of protein synthesis in streptomycin-induced cell death
was additionally analysed by challenging cell populations in minimal media, under
various growth conditions, and in the presence of bacteriostatic protein synthesis
inhibitors. Both dose-response and time-kill activity were examined, by assays
utilising 3-hour incubations of E. coli populations with a specific drug or drug
combination.
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6.2 Activity of streptomycin, spectinomycin, chloramphenicol and a
streptomycin/spectinomycin combination against log-phase E. coli
The activity of streptomycin, spectinomycin and chloramphenicol were assessed
against a log-phase E. coli population (Figure 6.1). Streptomycin is thought to
paradoxically require protein synthesis for its bactericidal activity. As spectinomycin is
a bacteriostatic protein synthesis inhibitor, cells were also challenged with a
streptomycin/spectinomycin combination, to examine any possible antagonistic
activity caused by spectinomycin halting putative protein synthesis required for cell
death (Figure 6.1).
—■ — Streptomycin
- -X - Spectinomycin
— Chloramphenicol
- - -X- • - Strep/Spec
Figure 6.1: Activity of streptomycin, spectinomycin, chloramphenicol, and a
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The aminoglycoside streptomycin exerted a rapid bactericidal effect at concentrations
below its MIC (lOmg/L), with bactericidal activity directly proportional to dose.
Chloramphenicol (MIC=2mg/L) and the aminocyclitol spectinomycin
(MIC=100mg/L) exerted a principally bacteriostatic effect, with some initial killing in
comparison with the original viable count (Figure 6.1). At low doses (below MIC) the
streptomycin effect was antagonised by the presence of spectinomycin; however
streptomycin can still exert its maximum bactericidal effect at three times higher
concentrations than without spectinomycin. This indicates that incubation with this
protein synthesis inhibitor did prevent death at low concentrations; however at high
streptomycin concentrations, streptomycin may not be reliant on protein synthesis for
cell death. Spectinomycin was however only added at time Oh in this experiment,
thereby some protein synthesis would have proceeded before spectinomycin exerted
its effect. Therefore, although streptomycin still exerted its effect at high
concentrations, the antagonistic effect of spectinomycin on streptomycin induced cell
death, suggested that there was a requirement for some protein synthesis in cell death.
153
6. Results: Bactericidal antibiotic action
6.3 Effect of chloramphenicol on streptomycin activity
The activity of streptomycin against E. coli in the presence of the bacteriostatic
protein synthesis inhibitor chloramphenicol was investigated. Chloramphenicol was
added at Time Oh and at lh prior to streptomycin addition, to analyse the effect of a
more prolonged protein synthesis inhibition before streptomycin action (Figure 6.2).
Figure 6.2: Bactericidal activity of streptomycin against E. coli treated with
chloramphenicol (lOmg/L) at time Oh and lh previous to streptomycin addition
Streptomycin exerted a potent bactericidal activity, with cell populations reduced
more than seven fold when treated with lOmg/L (lxMIC) and higher concentrations.
A bi-phasic response, as is seen for fluoroquinolones, where cell viability begins to
increase after an optimal bactericidal concentration was not seen, with cell death
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response, after an initial phase of cell death. Chloramphenicol reduced bactericidal
killing 1-2 fold, and pre-incubating cells with chloramphenicol for lh previous to
streptomycin addition had no effect on cell death.
The bactericidal activity of streptomycin (S) in the presence of increasing
chloramphenicol (C) concentrations over a three hour time period was assessed
(Figure 6.3). Log-phase E. coli populations were pre-incubated for lh with
chloramphenicol (5mg/L to 40mg/L), before subsequent addition of lOOmg/L
streptomycin. This dose was chosen, as it is would give a maximal bactericidal effect.
Figure 6.3: Bactericidal activity of streptomycin against E. coli pre-treated with








Streptomycin activity was proportionally reduced against E. coli pre-incubated with
increasing chloramphenicol concentrations, with chloramphenicol-5mg/L providing
the least antagonistic effect, and chloramphenicol at 40mg/L being the most
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antagonistic. Streptomycin (lOOmg/L) alone produced rapid bactericidal cell death in
lh with cell population reduced 6-fold after three hours. Chloramphenicol alone
(40mg/L), produced a principally bacteriostatic effect, with cell populations
decreasing by less than 0.5-fold. These results indicated that streptomycin-induced
cell death, required protein synthesis. The contrasting finding between this experiment
and that of figure 6.2, may be due to an insufficient chloramphenicol concentration,
and therefore incomplete protein synthesis inhibition in the previous experiment.
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6.4 Effect of amino-acid starvation on streptomycin activity
The previous findings had indicated that protein synthesis was an integral requirement
for streptomycin-induced cell death. To add weight to this hypothesis, streptomycin
activity was analysed against cells incubated in media lacking a carbon source. The
media used for these challenge experiments were Davis-Mingioli (DM) minimal media
and phosphate buffered saline. Cells were also challenged in nutrient broth and Davis-
Mingioli medium containing glucose as controls (Figure 6.4).

































■ - - Strept + Glu (DM)
— Streptomycin (DM)
The activity of streptomycin against E. coli in minimal media (DM and PBS) was
reduced 1-2 fold in comparison with cells in carbon-rich media (NB and DM +
glucose). This reduction was therefore not significant with killing levels 5-fold, in
comparison to the 1-fold reduction seen when streptomycin acts upon
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chloramphenicol-treated cells. This result, however, does not necessarily contradict
the result found with chloramphenicol antagonism, as amino-acid starvation
conditions may still produce residual amino-acids, which upon protein breakdown
provide the supply necessary for streptomycin-induced cell death. Breakdown of these
residual amino-acids may explain the difference between streptomycin challenge ofE.
coli in amino-acid starvation, compared with that under chloramphenicol treatment.
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6.5 The role of streptomycin as a protein synthesis inhibitor -
mechanism of bactericidal cell death ?
Streptomycin is known to exert effects on ribosomal proteins leading to the inhibition
of protein synthesis. The role of this protein synthesis inhibition in cell death is not
well characterised. We have seen that other ribosome interacting antibiotics such as
chloramphenicol and spectinomycin are bacteriostatic, leading to the hypothesis that
although streptomycin interacts with the ribosome and interferes with protein
synthesis, it is not the effect on protein synthesis that leads to cell death. The fact that
streptomycin requires protein synthesis for bactericidal activity, shown by the
antagonistic effects of chloramphenicol, suggests that other mechanisms may be
responsible for cell death.
The protein synthesis inhibiting action of streptomycin was investigated in
experiments in which E. coli populations pre-treated with low streptomycin
concentrations, were challenged with a higher bactericidal streptomycin dose. This
was based upon the hypothesis that at low concentrations streptomycin would exert
its effects as a protein synthesis inhibitor, and therefore consequently could inhibit its
own bactericidal protein synthesis requiring mechanism at higher streptomycin
concentrations.
Log-phase E. coli populations were pre-treated with chloramphenicol (1Omg/L) as a
control, and various concentrations of streptomycin (10, 5, lmg/L). Controls
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challenging cells with streptomycin and chloramphenicol alone were also performed
(Figure 6.5).
Figure 6.5: Bactericidal activity of streptomycin against E. coli pre-treated with















— A - — Strep (1 00mg/L)-rChlor
(40mg/L)
- X — Strep (100mg/L)+
Strep(1 mg/L)
—*- — Strep (1 00mg/L)+Strep
(5mg/L)
------ - Strep (100mg/L)+Strep
(10mg/L)
Streptomycin (lOOmg/L) induced a rapid bactericidal cell death within lh, with cell
viability reduced to <0.0001% at 3h. Pre-incubation with chloramphenicol
significantly reduced the bactericidal activity indicating a requirement of protein
synthesis in cell death. Substituting lmg/L streptomycin for chloramphenicol gave a
similar significant reduction in bactericidal activity. Pre-incubation with 5 or lOmg/L
streptomycin conferred a reduced effect on the killing rate of streptomycin
(lOOmg/L). These results indicated that at sub-lethal concentrations streptomycin acts
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as a protein synthesis inhibitor which subsequently blocked its own bactericidal
activity.
The length of time protein synthesis needed to be halted before addition of the second
streptomycin dose was assessed (Figure 6.6). E. coli were pre-incubated with
streptomycin (lmg/L) for various time points (30-180min), before subsequent
addition of streptomycin (lOOmg/L).
Figure 6.6: Bactericidal activity of streptomycin (lOOmg/L) against E. coli pre-
treated with streptomycin (lmg/L) for 30-180 minutes
1000
-♦ S (1 mg/L)
■ » - -30min
— -A — 60min
—O 90min




The length of streptomycin (lmg/L) pre-incubation time correlated directly with
subsequent inhibition of streptomycin activity. The inhibition of streptomycin killing
was most prominent with a pre-incubation time of >120minutes. Streptomycin
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(lOOmg/L) alone as expected had rapid bactericidal activity, and streptomycin
(lmg/L) exerted a bacteriostatic effect.
In order to rule out the possibility that the three hour pre-incubation with
streptomycin was not producing a streptomycin resistant population, leading to the
subsequent survival of cells when challenged with a higher bactericidal dose, the
experiment was repeated substituting streptomycin pre-incubation for gentamicin pre¬
incubation. Log-phase E. coli cells were pre-incubated with low concentrations of
gentamicin (0.125, 0.25 and 0.5mg/L) for 2 hours prior to the addition of a
bactericidal streptomycin (lOOmg/L) dose (Figure 6.7).
Figure 6.7: Bactericidal activity of streptomycin against E. coli pre-treated with













—■ Strep (100mg/L) +Gent
(0.125mg/L)
—A Strep (100mg/L) +Gent (0.25mg/L)
- X- - - Strep (1OOrng/L) +Gent (0.5rrg/L)
Streptomycin (lOOmg/L) induced a rapid bactericidal cell death within lh, with cell
viability reduced to <0.0001% at 3h. Substituting gentamicin (0.125mg/L) for
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streptomycin (lmg/L) gave a similar significant reduction in bactericidal activity as
seen in figure 6.5. Pre-incubation with or 0.25 and 0.5mg/L gentamicin had no effect
on the killing rate of streptomycin (lOOmg/L). These results indicated that at sub¬
lethal concentrations aminoglycosides act as a protein synthesis inhibitors which
subsequently blocked its own cell death when challenged with a higher bactericidal
dose. This result demonstrates that pre-incubation with low doses of streptomycin is
not creating a population of cells which are more readily resistant to streptomycin, but
that it is the effect on protein synthesis inhibition that reduced the bactericidal action




Analysis of the way in which target proteins mutate to confer antibiotic resistance
provides a clearer understanding of bacterial resistance mechanisms. It also sheds light
on the important antibiotic-target protein interaction, an understanding of which is
crucial ifwe are to elucidate the complex mechanisms of antibiotic-induced bacterial
cell death. The deduction of primary and secondary bacterial targets is of special
significance for the future of antimicrobial drug design and resistance minimisation, as
is an understanding of pathways of cell death not directly related to the initial drug-
target interaction. Indeed there may be commonality between cell death induced by
drugs, which have very different initial targets, as there is differentiation in cell death
induced by drugs that share target proteins, for example those which target ribosomal
protein synthesis machinery. This thesis presents results on mutations in the target
proteins of two bacterial drug classes; the fluoroquinolones, which target the enzymes
DNA gyrase and DNA topoisomerase IV, and the aminoglycosides, which target the
ribosomal proteins. In addition, the role of protein synthesis requiring cell death was
examined for the aminoglycoside streptomycin.
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7.1 Fluoroquinolone resistance in clinical E. coli isolates
Resistance to the fluoroquinolones in clinical E. coli isolates has until recently been
rarely observed in the U. K.; however, the situation is now an emerging phenomenon
of increasing concern. This study characterised the resistance profile of 15 clinical E.
coli isolates obtained from a hospital in Newcastle in 1996. Of the 15 viable isolates
obtained in this study, 8/15 were found to have high-level ciprofloxacin resistance
with MICs ranging from 8 to 256mg/L. The MICs of six of these isolates was
>32mg/L, an unusually high level of quinolone resistance for E. coli isolates.
Reports of increasing levels of fluoroquinolone resistance in Europe has been
previously limited to Spain, where lack of antibiotic control and increased usage has
led to resistance levels rising alarmingly from 0% in 1988 to 7.5% in 1992 in E. coli
bacteraemias (Pena et al., 1995). Carratala et al. (1995), also demonstrated that 37%
of bacteraemias in neutropenic cancer patients were due to quinolone resistant strains.
This rise in fluoroquinolone resistance demands the use of tight restrictions on
prescribing, which Spain lacks. The high-level ciprofloxacin resistance in this study
suggests that the U.K may not be exempt from a problem of emerging
fluoroquinolone resistance, and support evidence from Threlfall et al. (1997), who
detected high-level ciprofloxacin resistance in E. coli isolates from patients with
invasive illness or urinary tract infection (MICs=4-256mg/L) during the period 1994-
1997. Taken together, these results suggest that the UK is not exempt from the
problem of increasing fluoroquinolone resistance, and raise serious concerns over the
future use of ciprofloxacin, and the promotion of fluoroquinolone resistance. It should
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however be noted that a majority of E. coli strains (95%) isolated in the UK remain
sensitive to the fluoroquinolones (Thomson, 1999).
Although only 8/15 isolates were clinically resistant, 14/15 isolates showed increased
levels of fluoroquinolone resistance, when compared to the control strain E. coli
NCTC10418. These strains with underlying low to moderate levels of resistance may
represent a bacterial population poised to become highly resistant upon further drug
treatment. These underlying resistance levels are rarely detected by the techniques
employed in the clinical microbiology departments, which rely heavily on breakpoint
sensitivities. Indeed MIC breakpoints may provide a false sense of security and
thereby contribute to the selective enrichment of antibiotic resistant mutants by
encouraging the use of marginal compounds as monotherapy. We may be facing a
widespread population of low-level resistance strains, which will pose major problems
for future antimicrobial therapy.
In addition to determining the resistance levels of ciprofloxacin, the activity of new
second and third generation fluoroquinolones against isolates in this outbreak was
also investigated. Many new fluoroquinolones have been modified to enhance
potency, and certain substitutions are known to enhance dual target, rather than single
target binding. It was, therefore, of particular interest to examine the activity of these
new compounds against isolates that already show wide ranging levels of
ciprofloxacin resistance. Surprisingly, high-level resistance to the new
fluoroquinolones moxifloxacin, sparfloxacin and gemifloxacin was demonstrated in
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the Newcastle isolates, with resistance levels correlating closely with ciprofloxacin
resistance. In fact a greater percentage of the clinical isolates were resistant to
sparfloxacin and moxifloxacin.
These results have important consequences for the future use of the new
fluoroquinolones, and highlight their limitations. These new quinolones have not been
introduced into clinical practice in the UK. The results of this study thereby indicate
that resistance mechanisms between ciprofloxacin and these new drugs are shared.
Although the new compounds may have been engineered to have greater potency and
hence may slow the initial selection of antibiotic mutants in the clinic (Zhao et al.,
1997), they do not appear to be any more active against clinical strains, which have
low and high-levels of previously selected fluoroquinolone resistance.
Drugs with a C-8 methoxy substitution such as moxifloxacin have been reported to be
more active against strains which have an initial gyrase mutation (Zhao et al., 1999;
Dong et al., 1998; Zhao et al., 1997), however this was not the case against the
clinical isolates in this study. Moxifloxacin a generation Ilia, gram-positive targeted
fluoroquinolone was no more effective against resistant strains than ciprofloxacin.
There are however high hopes that third generation quinolones will provide a class of
antibiotics, which are effective even against resistant strains. A greater percentage of
isolates were resistant to gemifloxacin, a generation Illb napthyridone, with
exceedingly high-levels of gemifloxacin seen in correlation with the levels of
ciprofloxacin resistance (256mg/L). The correlation between MIC levels of the
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fluoroquinolones suggest that resistance mechanisms between these drugs are
ubiquitous, shared, and therefore selecting resistance to one of these antibiotics will
inevitably lead to resistance upon treatment with another drug of the same class. This
has not been the case for other antimicrobial classes, in which infections resistant to a
first generation (3-lactam (penicillin), are often successfully treated with a third
generation drug (cefotaxime). This is because of the differences in P-lactamases
required to overcome these drugs.
Gemifloxacin has been modified to enhance potency, and therefore may be less
effective at selecting out bacterial resistance in the first place, as once a drug with
increased potency is used, the frequency of mutation selection will be reduced.
However, once mutations are selected, the results in this thesis suggest that
gemifloxacin, and the newer fluoroquinolones will be no more effective than the
second generation ciprofloxacin. The fact that moxifloxacin resistance was generally
higher may have been due to the fact that this drug has different target specificity than
the other fluoroquinolones, which have increased activity against gram-negative
organisms (Ball, 2000; Pestova et al., 2000).
All of the fluoroquinolone resistant isolates were found to be resistant to at least one
additional antimicrobial; trimethoprim, the majority were additionally resistant to
amoxycillin, with one isolate demonstrating a multi-resistant phenotype, showing
resistant to three antimicrobials (trimethoprim, amoxycillin and co-amoxiclav). These
results support those of Threlfall and colleagues (1997), who found that the
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fluoroquinolone-resistant strains they isolated expressed a multiply resistant
phenotype. This raised concerns for the possibility of treatment failure in these E. coli.
Sensitivity of isolates in the current study to ceftazidime and meropenem,
demonstrated that there were however treatment options for patients infected with
these organisms. The multiple antibiotic resistant phenotype in these isolates
implicated the involvement of plasmid mediated resistance mechanisms, which confer
resistance to penicillins and trimethoprim. Changes in outer membrane proteins
(OMPs) and efflux, are also known to confer resistance to numerous drug classes
(Charvalos et al., 1995; Li et al., 1994; Hooper et al., 1992; Cohen et al., 1989). The
MICs of fluoroquinolones, did not, however correlate with resistance against
aminoglycosides, suggesting that changes in the OMPs were of minor importance.
Cohen et al. (1989) demonstrated cross-resistance to fluoroquinolones in multiple
antibiotic resistant (Mar) E. coli, and Okusu et al. (1996) showed that the AcrAB
efflux pump plays a major role in the antibiotic resistant phenotype ofMar mutants.
The clonal diversity of strains was determined to assess whether the outbreak had
been due to clonal spread of resistant strains, implicating defective infection control
measures, or due to individual selection of resistance in patients. A variety of typing
techniques were employed to achieve the most accurate result, along with an
assessment of the value of restriction and PCR based techniques in typing E. coli.
Genotyping by PFGE has been shown to be a powerful tool for the study of the
genetic diversity ofE. coli strains from related lineage, and accordingly offers a high
level of discriminatory power (Arbeit et al., 1990). Interestingly, several strains
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among the fluoroquinolone resistant isolates in this study were nontypable. The exact
reasons for this nontypability are unknown. Nontypable strains showed smeared DNA
fragments between 40 and 270kb. And there was no indication that these smeared
DNA fragments were due to DNAase activity. Typing was attempted utilising two
separate enzymes Xbal and Notl. Xbal produced restriction for 9/15 isolates, with 6
remaining untypable. Attempts to restrict these untypable isolates using the enzymes
Notl also failed, yielding the same pattern of DNA fragment as found when restricted
with Xbal. Interestingly Notl was also not effective in typing strains which has been
previously restricted with Xbal, yielding only partially restricted DNA fragments.
Doubling Notl concentration failed to eliminate this problem and for economical
reasons, attempts to type with this enzyme were discontinued.
Failure to type fluoroquinolone resistant E. coli isolates by PFGE has previously been
reported by Oethinger el al. (1996), who found that of 23 isolates, only 16 were
typable by PFGE. The nontypbable isolates produced smeared DNA fragments similar
to those seen in this study. Oethinger et al. (1996) found that nontypability of his
strains correlated with their high-level fluoroquinolone resistance, whereas the
nontypable stains in this study were a mixture of sensitive and resistant isolates. This
supports results from other authors, who found nontypability in some stains of
fluoroquinolone sensitive E. coli (Berg et al., 1994).
The Tenover criteria were used to assess the band differences between restriction
patterns (Tenover et al., 1995) generated by PFGE typed isolates. These criteria are
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intended for us in clinical hospital laboratories with small sets of isolates (typically no
more than 30) which are related to putative disease outbreaks, and therefore were
applicable to this study. The interpretation criteria are based on fragment differences
expected within PFGE patterns that have undergone a defined number of "genetic
events". These may be point mutations that result in the creation or loss of restriction
sites, and insertions and deletions of DNA. PFGE that differ by two or three
fragments are deemed closely related as fragment differences have arisen due to a
single genetic event. Restriction patterns that differ by four to six fragments, are
interpreted a possibly related, and PFGE with less than 50% fragments in common are
considered unrelated, indicative of three ofmore genetic events that result in seven of
more fragment differences. Based on these criteria the PFGE of 9 of the clinical E.
coli isolates revealed 7 pulsotypes (Type A-G), with three highly resistant strains NC-
14, NC-10 and NC-1 exhibiting identical PFGE restriction patterns (Type A), and the
remaining PFGE typed isolates heterogenous in nature (B-G), differing by more than
7 bands.
PFGE has been considered the gold standard of bacterial fingerprinting, however the
failure of this technique to type six of the clinical isolates led to the employment of
PCR based typing techniques. Unlike PFGE, there are no standardised criteria for the
interpretation of PCR generated fingerprints. These techniques additionally suffer
from a high sensitivity to reaction conditions, DNA quality and PCR temperature
profiles, leading to problems of reproducibility. PCR based techniques have however
been successfully employed to type a range of bacteria (Versalovic el al., 1991), and
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specifically used in previous cases to type fluoroquinolone resistant
Enterobacteriaceae (Oethinger et al., 1996), where PFGE has failed. Short random
primers were initially used to amplify genomic fragments by RAPD-PCR, with
fingerprints produced for clinical isolates NC-1-15. The correlation between strain
diversities of PFGE and RAPD-PCR was found acceptable although incomplete.
RAPD-PCR typed strains into seven types (RI-RVII), with isolates NC-14, NC-10
and NC-1, which were deemed identical by PFGE having identical RAPD patterns
(RI). A further two isolates NC-4 and NC-13 which were untypable by PFGE were
related to RI isolates with one band difference in RAPD pattern (RI1). Isolates NC-
11, NC-8, NC-6 and NC-5 had also identical RAPD patterns (RII). All but one of the
high-level resistant isolates were typed within type RI or RII, indicating that clonal
spread of resistant isolates was responsible for the high-level resistance observed.
Identical isolates showed varying levels of fluoroquinolone resistance, and therefore a
combination of clonal spread followed by subsequent further selection of resistance
within individual patients was likely to be responsible for the selection of resistance.
The treatment regimen, and patient data for these strains were unfortunately
unavailable, however it is likely that drug selection was associated with increases in
resistance. The remaining isolates were typed as unrelated (RIII to RVTII), supporting
results from PFGE.
Due to the lack of standardised interpretation criteria for RAPD results, a second
PCR based typing method was employed, which relied upon the amplification of
enterobacterial intergenic consensus (ERIC) sequences, as described by Gillings &
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Holley (1997). The results from ERIC-PCR typing supported those from RAPD-
PCR. Isolates NC-4, and NC-13, which were RAPD type I (RI), showed 2-3 band
difference with ERIC-PCR (EI2 & EE), demonstrating a degree of relativity but that
the strains were not identical. Isolate NC-11 which was RAPD type II, differed by one
band from this type by ERIC. All other isolates were deemed unrelated (EIII to
EVII), supporting PFGE and RAPD results.
The small discrepancies between RAPD-PCR and ERIC-PCR based typing methods,
led to the use of a new technique, AFLP, which is based on the detection of genomic
restriction fragments by PCR amplification, and thereby combines the reliability of
RFLP technique with the power of the PCR technique (Vos et al., 1995). This typing
method however failed to yield results. The reason for this failure was unapparent, as
restriction products were produced, and PCR amplification appeared to produce
strong products upon agarose gel electrophoresis, however, after running the
genescan analysis, only fluorescent primers were seen on gels. This led to the
hypothesis that the PCR stage of the technique had failed, however several attempts at
optimisation with a variety of reagents failed to solve this problem. One conclusion
from this typing method in comparison with the simple PCR based techniques of
RAPD and ERIC was that it was time consuming and costly, and therefore the PCR
based typing would be recommended for future use of clinical E. coli strains, even
though a comparison of two different techniques yielded small discrepancies. Much is
dependent upon interpretation of the result, something which can be aided by
computer software such as diversity database, however even software is dependent
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upon detection of bands by the eye, and therefore is dependent upon the perception of
the investigator. The benefits of the PCR-based typing methods employed in this
study were the fact that they were user friendly, inexpensive to run, and yielded rapid
results.
From a comparison of the types obtained from the three typing methods (PFGE,
RAPD/ERIC-PCR) the Newcastle isolates were typed into eight strains, with two
stains TYPE-I and TYPE-II of major importance in the dissemination of resistance.
The spread of resistant strains and individual emergence of resistance has been
previously found by Oethinger et al. (1996) who studied E. coli strains among
hospitalised cancer patients from different geographic locations. Other reports have
demonstrated independent emergence of resistance in isolates from a single unit (Lehn
et al., 1996), with Kern et al. (1994) demonstrating combination of horizontal spread
and individual emergence of resistance in E. coli isolates. Clonal diversity among the
resistant strains from Newcastle was less than that of the non-resistant strains, but the
low-level resistance seen between heterogeneous isolates may reflect an increasing
background colonisation of strains with low-levels of fluoroquinolone resistance.
These subtle epidemiological changes may have developed unrecognised within the
background colonisation of the population at large, and it is conceivable that in such a
situation, patients at high risk for bacterial infection, and frequently treated with
fluoroquinolones are the first in which clinically significant fluoroquinolone resistance
would develop. This would fit the hypothesis that resistance development requires
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more than one mutational steps, and therefore may be potentially minimised by a
change in dosing policy.
The studies performed to date analysing the chromosomal mutations responsible for
increases in fluoroquinolone resistance have concentrated on selection of mutant
bacteria in an in vitro situation, and in individually isolated clinical strains (Tavio et
al., 1999; Heisig, 1996; Vila et al., 1996; Heisig & Tschorny, 1994; Yoshida et al.,
1990; Nakamura et al., 1989). The existence of this isogenic population of resistant
strains with varying levels of fluoroquinolone resistance from Newcastle, provided a
unique opportunity to compare the clinical situation with that found in vitro.
Preliminary data indicate that highly resistant laboratory generated mutants have
impaired viability, as indicated by significantly increased doubling times compared to
that of the parent strain, or random clinical isolates carrying a similar gyrA or parC
mutation (Heisig, 1996, Heisig & Tschorny, 1994). Under in vivo conditions, i.e., at
the site of infection, variations in the global gene expression pattern might also cause
alterations in the response to environmental stimuli, and thus affect the type of
mutation preferentially selected. As a consequence, mutations selected in vitro would
differ from those selected in vivo, as was observed by Bagel et al., 1999, however
there have not been previous opportunities to study resistance selection in the clinic.
In an in vivo environment, bacteria are constantly under conditions of stress forcing a
population of bacteria to mutate, and hence rapidly evolve to cope with this stressful
environment. Bjorkman et al. (2000) have shown that compensatory mutations
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selected in vivo can differ form those selected in vitro. This is of concern as most of
the data to date about the emergence of quinolone resistance come from in vitro
mutation studies, and therefore raises questions about the data deduced from these
studies providing an accurate model of the clinical situation.
The most commonly found change in DNA gyrase, a mutation at amino-acid position
Ser83 (Everett et al., 1996; Heisig, 1996; Ruiz et al., 1995), results in the loss of a
Hinfl restriction enzyme recognition sequence. This allows for fast screening for
mutations by digestion of the PCR products with Hinfl to detect mutation at codon
82 of 83 (Fisher et al., 1989). This loss was detected in 14/15 (CIP MIC range 0.25
to 256mg/L) clinical isolates in this study, indicating the presence of a Ser83 gyrase
mutation. This is in concordance with both in vitro and clinical resistance isolates
described by other investigators (Tavio et al., 1999, Evertt et al., 1996; Heisig, 1996;
Ruiz et al., 1995; Vila et al., 1994), who show that low level resistant isolates most
frequently carry a single gyrA mutation altering Ser83->Leu. Because several
different point mutations may contribute to this change ofHinfl. recognition sequence
and additional mutations cannot be identified in this way, the complete QRDR was
sequenced for a selection of low, moderate and high-level resistant isolates. The fact
that this mutation was present at such low resistance levels suggested that it was the
primarily selected mutation, as parC mutations were not present in isolates with an
ciprofloxacin MIC as low as 0.25mg/L.
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There has been some controversy over the primary and secondary fluoroquinolone
target proteins in gram-negative and gram-positive bacteria. The generally accepted
view is that in gram-negative bacteria DNA gyrase is the primary ciprofloxacin target
(Chen et al., 1996), whereas ciprofloxacin targets topoisomerase IV initially in gram-
positive organisms (Ng et al., 1996; Ferrero et al., 1995). There has however been
conflicting evidence using clinically selected gram-positive fluoroquinolone resistant
bacteria which showed that DNA gyrase mutations were selected primarily (Durham
et al., 1999). This brought into question the value of data deduced from in vitro
mutation studies when analysing primary and secondary fluoroquinolone targets. The
data from the clinical isolates in this study support the evidence form in vitro mutation
studies, indicating that in gram-negative organisms DNA gyrase mutations are
selected prior to those in topoisomerase IV, and therefore DNA gyrase was confirmed
as the primary fluoroquinolone target.
In addition to confirming DNA gyrase as the primary ciprofloxacin target in E. coli,
the resistance progression with subsequent additional target mutation acquisition
supported data observed in previous in vitro mutation studies with gram-negative
bacteria (Heisig, 1996; Khodursky et al., 1995; Yoshida et al., 1990). Resistance-
levels increased progressively with the accumulation of target enzyme mutations in
both TYPE-I and TYPE II isolates, demonstrating the requirement for multiple
selection steps for the acquisition of high-level resistance (Cip MIC=>4mg/L) (Table
3.4). The clinically sensitive isolate NC-8 (Cip MIC=lmg/L) contained a single
mutation in DNA gyrase (Ser83—>Leu) and topoisomerase IV (Ser80->Ile). The
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presence of two gyrase mutations in low-level clinical resistant isolates has been
previously documented (Truong et al., 1995; Vila el al., 1994), but the presence of a
topoisomerase IV mutation at these low levels of resistance is not common (Vila et
al., 1996). Mutations affecting the Ser80 and Glu84 amino-acids in ParC are generally
associated with high-level resistance (Heisig, 1996; Kumagai et al., 1996; Vila et al.,
1996). The fact that mutation was found in topoisomerase IV at such low levels
suggested that Topoisomerase IV target may be more equal to DNA gyrase as a
fluoroquinolone target in gram-negative bacteria than previously thought. Progression
to high-level clinical resistance (Cip MIC=32mg/L) in this strain resulted in second
step mutations in each enzyme at DNA gyrase Asp87—vAsn and Topoisomerase IV
Glu84—»Val. This indicated that second step mutations in each enzyme had the
important role of conferring high level resistance, rather than mutations in one enzyme
being more responsible for resistance than the other. Mutation progression in Type I
isolates showed similar results, however in this case two gyrase mutations
(Ser83—vLeu and Asp87—vAsn) and one topoisomerase IV mutation (Ser80—»Ile)
conferred a ciprofloxacin MIC of 8-32mg/L, with acquisition of the second
topoisomerase IV mutation (Glu84-»Lys) conferring levels of resistance to
>128mg/L.
Isolates NC-13 (Cip MIC=8mg/L) and NC-4 (Cip MIC=32mg/L) had identical target
enzyme mutation profiles (GyrA Ser83—»Leu; Asp87—»Asn; ParC Ser80—>Ile)
suggesting that resistance mechanisms other than those identified were responsible for
the 3-fold difference in ciprofloxacin MIC between the two isolates. This difference
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can also be seen between isolate NC-11 (Cip MIC=32mg/L) and isolates NC-14 (Cip
MIC=256mg/L), with both isolates containing the four identified target mutations,
although in NC-14 Asp87 is replaced with tyrosine rather than asparagine, and Glu84
is replaced with a lysine rather than the valine seen in NC-11. This indicates that the
amino-acid replaced may play an important role in determining resistance, rather than
just the simple loss of a crucial ammo-acid at these positions. As well as changes in
amino-acids, resistance mechanisms such as efflux, changes in outer membrane
proteins (OMPs), or perhaps alterations in the genes gyrB or parE may contribute to
variation in resistance between strains with the same GyrA and ParC target protein
mutations. The fact that strains with four mutations have a range of resistances from
32 to 256mg/L, indeed suggest that these mechanisms may play a major role in
resistance acquisition, however the genetic basis of these resistance mechanisms were
not investigated in this study.
In in vitro selected mutants, non-target gene mutations accumulate in second and
third-step mutants upon exposure to the fluoroquinolone and include, but are not
limited to, mutations that occur in the mar and sox regulons (Kern et al., 2000; Bagel
et al., 1999). Many high-level fluoroquinolone resistant isolates show a multiple
antibiotic resistance (Mar) phenotype and increased tolerance to organic solvents
(Conrad et al., 1996; Everett et al., 1996). They accumulate less ciprofloxacin than
reference strains, and or lack outer membrane protein OmpF (Everett et al., 1996),
however the lack of cross-resistance to gentamicin seen in the clinical isolates in this
study does not implicate OMP loss as a major resistance mechanism. Mar mutations
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seem to play an important early step in resistance selection in vitro (Piddock et al.,
1991; Cohen et al., 1988; Hooper et al., 1987), however Manneewannakul & Levy
(1996), found that this mutation was present in less than 15% clinical fluoroquinolone
resistant E. coli isolates. Mar mutations don't therefore seem to be the predominant
mutations affecting quinolone resistance in clinical isolates, nonetheless, reduced
accumulation has been detected in several clinical isolates (Everett et al., 1996;
Oethinger et al., 1996), with the genetic basis remaining obscure. The contribution of
mutational changes in the gyrB and parE genes were not investigated, as they have
been previously found to be absent or confer insignificant changes in fluoroquinolone
MIC (Tavio et al., 1999; Ruiz et al., 1997; Vila et al., 1994).
Isolate NC-10 which contained a Pro 185 mutation in addition to two gyrA and two
parC mutations had a lower MIC than strain NC-14, which did not contain this
mutation. This indicated that this mutation was likely to be a back mutation, altering
enzyme conformation to confer fluoroquinolone sensitivity. Combining the results
from clinical isolates in this study, it was possible to deduce a model for ciprofloxacin
resistance progression in the clinic, shown in Figure 7.1.
Figure 7.1: Mutational changes conferring ciprofloxacin resistance (mg/L) in
clinical E. coli
0.25 1 8 >32
GyrA Ser83 GyrA Ser83 GyrA Ser83 GyrA Ser83
ParC Ser80 ParC Ser80 ParC Ser80




This model demonstrates the requirement for three target protein mutations to enable
strains to overcome the clinically detected resistant breakpoint (Cip MIC=2mg/L),
again emphasising the dangers of low level selection. This model predicts the lowest
resistance levels conferred by the specified amino-acid alterations. It must be noted
that isolates with increased MIC values may have the same pattern of resistance
mutations.
DNA gyrase and topoisomerase IV mutations confer resistance to the new
fluoroquinolones, gemifloxacin, moxifloxacin and sparfloxacin in a similar manner to
that of ciprofloxacin allowing for a 2-fold difference in MIC (Table 7.1). A Second
parC mutation had a greater effect of increasing MICs of these drugs compared to
ciprofloxacin which may reflect a greater ParC specificity of the new compounds.
Also a second gyrA mutation did not seem to effect these drugs to the same extent as
that of gyrase. Third generation fluoroquinolones such as gemifloxacin have enhanced
greater potential to target DNA gyrase and topoisomerase IV equally, with certain
substitutions enhancing activity against resistant organisms (Zhao et a!., 1999).
Table 7.1: Effect of target protein mutation in resistance (MIC mg/L) to new
fluoroquinolones, gemifloxacin, moxifloxacin and sparfloxacin




Ciprofloxacin 0.25 1 8 >32
Gemifloxacin 1 4 16 >32
Moxifloxacin 1 8 16 >64
Sparfloxacin 1 4 8 >32
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The step-wise nature of resistance development observed in this study has
implications for more effective drug design. Compounds that attack both gyrase and
topoisomerase equally would be ideal, as there would be no concentration at which
mutant having only one resistant target as seen here with ciprofloxacin selection could
arise (Ng et al., 1996; Pan et al., 1996). Drugs such as gemifloxacin have been
deemed to be more effective against strains which have a first step gyrase mutation for
example, and therefore a second mutation would be required to achieve resistance.
A C-8 methoxyl substituent as is found in moxifloxacin, was found to facilitate attack
against first-step gyrase mutant against Mycobacterium tuberculosis (Dong et al.,
1998). This was not the case for E. coli in this study, where moxifloxacin MICs were
similar to those of ciprofloxacin against low-level resistant mutants, suggesting that
the clinical isolates have resistance mechanisms that are not selected in vitro. This has
implications about the deductions of the effectiveness of these drugs for use in vivo
against strains which are already ciprofloxacin resistant. The C-8Me substituent
increase lethal action against E. coli, and also recovery of resistant mutants was three
fold less than observed with compounds lacking a methoxyl group at C-8 (Zhao et al.,
1997). Clinical isolates of.E. coli that are highly resistant to C-8 methoxy group have
been isolated in this study. Therefore due to the heavy use of fluoroquinolones and
sequential acquisition of mutations in DNA gyrase and topoisomerase IV genes, it is
unlikely that these new agents will encounter a fully susceptible WT population. The
optimism displayed by authors about the potential of these new fluoroquinolones may
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not hold true in the clinical environment (Zhao et al., 1997). As newer quinolones are
brought into clinical practice it has been suggested that use of older drugs such as
ciprofloxacin should be limited as this will limit the use of the newer drugs. This
indeed may be the case, as the newer drugs may be less likely to select for resistance,
however strains which are already resistant by enzyme mutation will be resistant to the
newer fluoroquinolones.
This study has shown that three mutations are required to over come the ciprofloxacin
breakpoint in clinical isolates. The question therefore is posed as to why so many
isolates now becoming resistant to ciprofloxacin (Threlfall et al., 1997; Goldstein &
Acar, 1995; Kern et al., 1994). The fact that 14/15 isolates contained a gyrA mutation
suggests that the probability is that in the bowel 1st and perhaps 2nd and 3rd mutations
persist for long periods of time in the absence of selective pressure. The reasons why
these mutants can persist maybe due to compensatory mutations which occur in the
clinical environment (Levin et al., 2000), for example defective mutant gyrase may be
compensated for by mutation in topoisomerase I (Hooper et al., 1998). The course of
quinolone treatment may select for further mutations, which allow resistance to
overcome the breakpoint. Susceptibility to fluoroquinolone can no longer be taken for
granted, and this study demonstrates the need to prevent further spread of resistant
strains, which appear to persist in the absence of selective pressure.
This study has indicated the that 14/15 strains contained low-level resistant mutants,
which would not be detected by breakpoint sensitivity testing. The presence of such
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low-level resistant mutants may be overcome if we reassess dosing policy for the
fluoroquinolones, a consideration if we are to preserve these potent compounds. If
bacteria are not killed effectively by a fluoroquinolone, then the stress induced within
the bacteria will increase mutation rate (Ren et a/., 1999; Phillips et al., 1987),
facilitating further selection of resistant isolates. Current dosing protocols allow cells
to grow after only one resistance mutation, and thereby aid resistance development,
poising the population for further resistance selection. However, as seen in this study,
more than three mutations are required to achieve clinically significant resistance. The
mutation frequency of fluoroquinolones is less than 10"7, and so more than 1014
bacteria would be required to find two consecutive target mutations. In the clinic,
bacterial populations may reach 1010 cells in an infected individual, but 1014 is
unlikely. Treating patients with higher drug concentrations would prevent initial
selection of single mutations. The engineering of new drugs should also concentrate
on lowering the concentration required to prevent mutant selection, by engineering
dual targets, therefore at least two consecutive mutations would be required for
resistance. However, as we have seen even these engineered changes will not have
greater effects against organisms which already possess target site mutations through




In order to assess the contribution of single amino-acid changes to the phenotype of
fluoroquinolone resistance, specific amino-acid mutations were introduced into the
fluoroquinolone target protein DNA gyrase by site-directed mutagenesis. The
attribution of resistance to specific amino-acid changes has previously been
investigated by complementation tests (Heisig & Wiedermann, 1991; Yoshida et al.,
1990; Nakamura et al., 1989). These involve the introduction of plasmids conferring
sensitive gyrA gene into a resistant bacteria, and assessing the decrease in resistance
conferred by WT plasmid. Although many authors have attributed resistance to
specific mutations in gyrA by this manner (Khodursky et al., 1995), this test is not
completely reliable. With the discovery of the parC target, we cannot rule out the fact
that part of the resistance being complemented is due to mutations in the parC gene,
especially as these are not expressed in the absence ofgyrA mutation.
As was seen in the clinical isolates, increased fluoroquinolone MICs did not
necessarily correlate with mutational changes in the target enzymes DNA gyrase and
topoisomerase IV, probably due to the presence of complicating factors such as efflux
and outer membrane proteins. The contribution of these factors to resistance can
make it difficult to assess the direct role of chromosomal mutations in changing
fluoroquinolone MIC. The presence of efflux mechanisms has been demonstrated by
the use of efflux pump inhibitors CCCP and reserpine, however these experiments
lack reproducibility and cannot be transferred among species (Schmitz et al., 1998; Li
et al., 1994). Mutations in OMPs have also been demonstrated (Everett et al., 1996;
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Hooper et al., 1992), however they are usually found in the presence of additional
target protein mutation changes.
A direct assessment of the contribution of individual target protein alterations to
fluoroquinolone resistance was performed by the introduction of the single clinically
demonstrated gyrase mutations, Ser83—»Leu and Asp87->Asn into WT gyrA,
expressed on plasmid pPH3. Unfortunately this protocol yielded problems with the
PCR annealing of the Ser83 mutant primer, due to double insertions during the PCR
stage of the reactions. Due to time constraints when these experiments were
performed, this could not be repeated.
A mutation of Asp87-»Asn, the second-step gyrase mutation was however
successfully introduced into gyrA on the plasmid pPH3, allowing the contribution of
this mutation in the absence of complicating factors to be assessed. Expression of the
plasmid encoded gyrA was achieved in a temperature sensitive (Ts) gyrA KNK453
strain (Kreuzer & Cozzarelli, 1979) which grew at 30°C, but not at 42°C. The use of
Ts strain was necessary as the DNA gyrase sensitive allele has been shown to be
dominant to the resistant allele in phenotypic expression studies (Soussy et al., 1993;
Power et al., 1992). This is likely a consequence of the fluoroquinolone mechanism of
action. They act like poisons and therefore interaction with a sensitive target will form
complexes leading to cell death, even if there is also interaction with resistant target.
Therefore if the pPH3 plasmid containing mutant gyrA was expressed in cells which
expressed sensitive gyrA, the resistance phenotype would not be conferred. The
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plasmid was additionally under the tight control of the tac promoter, which therefore
only induced expression of gyrA in the presence of the inducer IPTG, providing
additional control in the experiment.
Sequencing of the plasmid gyrA confirmed the presence of the desired single
Asp—>Asn mutation at position 87. The contribution to fluoroquinolone resistance
conferred by this amino-acid alteration was assessed in the Ts KNK453 mutant at
42°C by calculating MICs for a range of fluoroquinolones. The greatest increase in
MIC was seen for the older quinolone nalidixic acid, which showed a 7-fold resistance
increase compared to WT, whereas resistance for ciprofloxacin and the new
fluoroquinolones gemifloxacin, moxifloxacin and sparfloxacin increased only 2-3 fold
in comparison with the WT strain. Acquisition of an Asp87—>Asn mutation in the
clinical selection model in Figure 7.1, conferred a jump from clinically sensitive to a
resistant phenotype (Cip MIC lmg/L-»8mg/L), and was the third target mutation
selected. Therefore, the site-directed mutagenesis correlated well with the increase in
fluoroquinolone resistance seen with the acquisition of an Asp87 mutation in the
clinic, suggesting that at this point in resistance selection the roles of efflux and OMPs
had not been important in the clinical isolates. Although the Asp87-»Asn mutation
was crucial in increasing MIC of clinical isolates to resistance levels above their
clinically detected breakpoints, the results of the site-directed mutagenesis,
demonstrate that the Asp87->Asn mutation alone does not confer an increase in
resistance large enough to be detected by clinical means and therefore is acting
cumulatively with other mutations to confer this increase in MIC. As previously
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demonstrated mutations in GyrA Ser83 confer less than 0.25 mg/L ciprofloxacin
resistance, and single ParC mutations are not seen, therefore clinical resistance by any
one mutational change is highly unlikely, confirming results of the predicted model
that three target protein mutations are required for clinical resistance.
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7.3 Ribosomal protein mutation
Along with investigating the fluoroquinolone target proteins, this thesis presented data
on how aminoglycoside target protein S12 can mutate to confer aminoglycoside
resistance. Ribosomal S12 protein has been previously implicated in streptomycin
resistance (Toivonen et al., 1999; Funatsu & Wittmann, 1972; Ozaki et al., 1969),
however the importance of ribosomal SI2 protein in conferring resistance to other
members of the aminoglycoside family has not been previously assessed.
This study characterised the role of S12 mutation in stepwise progression to
resistance for aminoglycosides neomycin, gentamicin, tobramycin and kanamycin in
addition to streptomycin, thereby providing insights into specific drug targets and
mechanism of resistance acquisition. Aminoglycoside resistant mutants were selected
at a low frequency (1 x 10"6), suggesting the number of possible mutation hotspots for
resistance was small. Mutants were selected in four selection steps, with streptomycin
resistant mutants conferring the largest increase in resistance after the four step
selection. Streptomycin (4th step = MIC 1500mg/L) mutants remained sensitive to all
other aminoglycosides tested, indicating that resistance was not due to a membrane
permeability change or mutation in a shared aminoglycoside target. The antibiotics
neomycin, tobramycin and kanamycin mutants showed cross-resistance, implicating a
common target protein and shared mechanism of action. The cross-resistance seen
between these drugs could be influenced by their structure, as neomycin, kanamycin,
gentamicin and tobramycin have a deoxy-streptamine ring, whereas streptomycin has
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a streptidine ring, and therefore indicates the importance this structural determinant
alteration in drug binding.
Analysis of the sequence of the entire streptomycin S12 gene, demonstrated a novel
Lys87—>Glu mutation in all streptomycin resistant mutants (Strep MIC=25-
1500mg/L), confirming the importance of ribosomal S12 protein as a streptomycin
target. Previous authors have described mutations in areas 41-43 and 85-91 of the
S12 protein (Timms et al., 1992; Lui et al., 1989; Funatsu & Wittman, 1972),
however a glutamic acid substitution at position 87 ofE. coll rpsL gene has not been
previously demonstrated. A previously described Lys87—»Arg mutation can confer
resistance levels of 1500mg/L in a single step selection (Timms et al., 1992), however
the Lys87^Glu mutation in this study conferred resistance to a level of 25mg/L.
Conversion ofLys87 to a basic rather than an acidic residue therefore seems to have a
great deal of influence on target site availability and drug binding. Recent NMR
studies have demonstrated that aminoglycosides bind to the tRNA site of the 16S
ribosomal sub-unit (Moazed & Noller, 1996), with S12 having a suggested role in
stabilising the pseudoknot structure of 16S RNA (Stern et al., 1988).
The lack of additional S12 target protein mutations in 2nd (Strep MIC=100mg/L) to
4th step (Strep MIC=T500mg/L) selections, implicated other resistance mechanisms in
these mutants. If resistance increase was due to an outer membrane effect, then cross-
resistance between the other aminoglycosides would be expected in 3rd and 4th step
resistant mutants, which was not demonstrated. A second target protein was therefore
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implicated in streptomycin binding, supporting the hypothesis that S12 may either
form part of a binding pocket, or control access to a target protein.
S12 mutations were not present in neomycin, kanamycin, tobramycin and gentamicin
resistant mutants, demonstrating that S12 is not likely to be the primary target of
these antibiotics. Mutations in other ribosomal targets such as 16S rRNA have been
implicated in resistance (Montandon et al., 1985). The strong cross-resistance
between the drugs suggest a common target, and thus may be a consequence of close




7.4 Bactericidal antibiotic action
Bactericidal drugs such as the fluoroquinolones are known to require protein synthesis
to exert their killing activity (Lewin et al., 1991). This requirement has explained why
fluoroquinolones have a bi-phasic dose-response curve, with high concentrations of
antibiotic inhibiting protein synthesis and thereby decreasing cell death (Smith, 1986).
This protein synthesis requirement is not wholly understood, with investigators
postulating the possible roles of SOS response proteins in cell death (Piddock et al.,
1990; Lewin et al., 1989; Walters et al., 1989). The (3-lactam antibiotics are also
known to require protein synthesis in cell death (Tuomanen, 1986), and Novak et al.
(2000) have demonstrated the role of signal transduction cascades in cell death.
Although we may understand the complex interaction between drugs and their initial
bacterial targets, it is important to look beyond these initial target interactions if we
are to understand cell death and consequently design the antimicrobials of the future.
This thesis investigated the putative protein synthesis requirement in streptomycin
induced cell death, in order to assess whether the aminoglycosides like the
fluoroquinolones require protein synthesis for bactericidal action.
The activity of streptomycin in the presence of protein synthesis inhibitors was initially
determined, in order to characterise the protein synthesis requirement in cell death.
Chloramphenicol and spectinomycin produced a principally bacteriostatic effect
against log-phase E. colt populations, exerting some initial killing activity.
Streptomycin acting alone against a log-phase bacterial population exhibited
bactericidal activity below its defined MIC of lOmg/L, with cell death at its maximum
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at and above this concentration. Streptomycin activity directly correlated with drug
concentration, and no bi-phasic response was demonstrated. Treatment of a log-phase
E. coli population with a streptomycin/spectinomycin combination resulted in
antagonism of streptomycin action, however this antagonism was not demonstrated at
high drug concentrations. The protein synthesis inhibition by
spectinomycin/chloramphenicol may not have been fast enough to prevent synthesis of
proteins required for cell death. The antagonism observed at low drug concentrations,
suggested that death required protein synthesis, whereas at high concentrations death
progresses independently of protein synthesis.
One may speculate at a dual mechanism of cell death, which would tie in with
hypothesis by Hancock (1981) and Matsunaga et al. (1986) who have suggested that
alternative targets such as DNA synthesis inhibition can be involved in cell death. It is
not certain whether all protein synthesis was inhibited by spectinomycin, and pre¬
incubation with this drug may have been more effective in inhibiting the streptomycin
effect. The fact some antagonism was shown suggested a role for protein synthesis in
cell death. The bacteriostatic protein synthesis inhibitor chloramphenicol was shown
to have a greater effect at antagonising streptomycin action; however, streptomycin
was still able to exert its action in the presence of this protein synthesis inhibitor.
These results were indicative of more than one mechanism of cell death, raising the
question of whether the aminoglycosides share similarity with the fluoroquinolones,
which have protein synthesis dependent and independent pathways of killing. To
account for the possibility of residual protein synthesis, streptomycin activity was
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assessed over a three hour period in the presence of increasing chloramphenicol
concentrations. The higher the chloramphenicol concentration, the more bacteriostatic
the effect of streptomycin became, demonstrating a clear requirement for protein
synthesis in cell death.
The activity of streptomycin against bacteria in amino-acid starvation conditions was
subsequently investigated. Streptomycin still elicited cell death against bacteria in
these conditions, thereby contradicting results previously demonstrated, that
streptomycin required protein synthesis for cell death. Breakdown of proteins within
the cell under amino-acid starvation conditions to provide a residual supply of amino-
acids may account for this result. This supports the mechanism of bactericidal cell
death proposed by Davis (1987), who suggest that the incorporation of mistranslated
proteins into the bacterial membrane accounts for cell death. Death would therefore
proceed in amino-acid starvation, as this misreading would be increased under these
conditions. The Davis hypothesis does not however explain a mechanism of cell death,
outwith that of prolonged protein synthesis inhibition.
The action of streptomycin as a protein synthesis inhibitor is well demonstrated
(Brimacombe et al., 1988; Hausner et al., 1988), with this thesis providing supporting
evidence that streptomycin exerts its effect by interaction with ribosomal protein SI2.
Additionally the results demonstrated with the antagonism of streptomycin activity in
the presence of protein synthesis inhibitors implicate a protein synthesis requirement
in cell death. Based upon this knowledge the hypothesis that streptomycin acting as a
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protein synthesis inhibitor could inhibit its own cell death was investigated. This study
demonstrated that bactericidal streptomycin activity was significantly reduced, when
acting upon a bacterial population pre-treated for 3 hours with a low concentration
(lmg/L) streptomycin. The low streptomycin concentration (lmg/L) exerted a
bacteriostatic effect on cells, and therefore was acting as a protein synthesis inhibitor
in a similar manner to chloramphenicol and spectinomycin. Streptomycin pre¬
incubation inhibited subsequent bactericidal streptomycin dose (lOOmg/L) in a similar
manner to pre-incubation with chloramphenicol. These results suggested that at low
concentrations streptomycin can act as a protein synthesis inhibitor, which inhibits a
second yet unidentified protein synthesis dependent mechanism of cell death. The
action of streptomycin as a protein synthesis inhibitor is therefore separate to the
reason for drug lethality. The reason why pre-incubation with slightly higher
concentrations of streptomycin (5, lOmg/L) failed to yield the same antagonistic
activity is unknown.
An alternative hypothesis to explain why bacteria survive streptomycin challenge after
cells have been treated with a low concentration of streptomycin, would be if a
bacterial population had adapted and therefore become a more resistant population of
hypermutators. Under conditions of stress such as antibiotic treatment, the mutation
rates in a bacterial population are increased. Taddei et al. (1997) have demonstrated
that an antibiotic treated cell population can turn into a population of hypermutators,
which is subsequently more resistant to bacterial challenge. This adaption generally
takes more than three hours, and therefore makes this an unlikely hypothesis to
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explain the result seen in this study. Nonetheless to rule out adaption, an E. coli
population was pre-treated with gentamicin prior to subsequent streptomycin
challenge. Streptomycin induced cell death was inhibited confirming that it is likely the
inhibition of protein synthesis rather than a streptomycin adapted population which
results in the reduction in streptomycin activity.
The effectiveness of antimicrobials are usually measured by their ability to inhibit or
kill bacteria. However, tests of this ability are usually performed on log-phase bacteria
or those in rapid growth phase, in media supplying all the necessary nutrients for
optimum growth. Clinically, some infected tissues may be walled off quickly by host
leukocytes, followed by fibrin deposits, and thus growth of bacteria may be less than
optimal, and controlled by the limited access to nutrition. The dormant state of
bacteria could be responsible for it escaping antibiotic therapy. Cells in vivo are less
likely to be killed than cells growing in vitro log-phase.
The results of these experiments show that analysing the initial target protein
interaction, although of crucial importance for future engineering of more potent
antimicrobial compounds, is not sufficient to elucidate the complex mechanisms of cell
death. Investigators must focus their energy on understanding complex cellular
machinery and feedback cascades which may represent these protein synthesis




A model for the development of fluoroquinolone resistance due to mutational change
in target enzymes DNA gyrase GyrA and Topoisomerase IV ParC in clinical E. coli
isolates was deduced : GyrA Ser83 (Cip M3C=0.25mg/L) —> ParC Ser80 (Cip
MIC=lmg/L) GyrA Asp87 (Cip MIC=8mg/L) -> ParC Glu84 (Cip MI032mg/L).
Three target protein mutations were required to achieve clinical resistance (Cip
MIC=>2mg/L). DNA gyrase was confirmed as the primary fluoroquinolone target in
E. coli, with first step GyrA mutations demonstrated in the absence of mutations in
Topoisomerase IV ParC. Resistance varied between strains with the same target
protein mutation profile, demonstrating the additional role of putative efflux
mechanisms and changes in outer membrane proteins in conferring resistance. The
demonstration ofGyrA mutations in 14/15 isolates with ciprofloxacin MICs as low as
0.25mg/L, indicated that these mutations are maintained undetected in the population
poised for consequent selection to resistance upon further antimicrobial treatment.
The new fluoroquinolones sparfloxacin, moxifloxacin and gemifloxacin were equally
ineffective at treating these ciprofloxacin selected resistant isolates. This calls into
question the future value of these new compounds, which as demonstrated here are
highly unlikely to face a fully susceptible wild-type population.
Site-directed mutagenesis demonstrated that a single Asp87-^Asn mutation in DNA
gyrase GyrA cannot confer clinically significant levels of resistance, confirming results
found with the clinical isolates that resistance requires accumulation of several
mutations. The three-fold increase in resistance compared to wild-type seen with the
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Asp87^Asn mutation correlated closely with progression seen in the clinic,
demonstrating that resistance from changes in OMPs and efflux were unlikely to have
a major role in this selection step.
This thesis additionally analysed the role of ribosomal S12 in conferring resistance to
the aminoglycoside antibiotics. Ribosomal S12 protein was demonstrated to be
involved in streptomycin action, however was unlikely to be a primary target of
gentamicin, kanamycin, neomycin and tobramycin. In vitro selected streptomycin
resistant mutants (Strep MIC=25—»!500mg/L) had a novel Lys87—>Glu mutation.
Previous work had demonstrated a Lys87—»Arg mutation conferred resistance to
levels of 1500mg/L in a single step selection, and therefore results form this study
imply that replacement with a basic rather than acidic amino-acid residue confers a
greater level of resistance. The lack of additional mutations in ribosomal S12 protein
for 2nd to 4th step streptomycin selected mutants (Strep MIOIOO—»1500mg/L)
suggested the involvement of alternative targets in streptomycin action, with S12
possibly forming only part of a streptomycin binding pocket. S12 mutations were not
demonstrated in four generations of neomycin, kanamycin, tobramycin and gentamicin
selected mutants, indicating that this protein is not a target of these antibiotics.
Streptomycin mutants lacked cross-resistance to other aminoglycosides again
suggesting that S12 is involved exclusively in streptomycin action. Cross-resistance
was demonstrated between neomycin, tobramycin, kanamycin and gentamicin
resistant mutants, indicating a common target, most probably a facet of their shared
structural similarity.
7. Discussion
The results from this thesis suggested that streptomycin has a protein synthesis
dependent mechanism of cell death, beyond initial target binding. The action of
streptomycin as a protein synthesis inhibitor is well documented, however this fails to
explain why it is bactericidal to cell, when other common protein synthesis inhibitors
do not exert a bactericidal effect. Chloramphenicol and spectinomycin were
demonstrated to have an antagonistic effect on streptomycin activity, indicating a
protein synthesis requirement in cell death. Streptomycin was shown to inhibit its own
activity by acting as a bacteriostatic protein synthesis inhibitor at low concentrations.
The action of streptomycin as a protein synthesis inhibitor is therefore not responsible
for cell death, with action dependent upon a yet unidentified protein synthesis
requiring bactericidal pathway.
An understanding of bacterial targets will allow drugs to be modified which may not
select resistance in the same fashion. Knowledge of how resistance emerged in the
clinic will allow better drug use and dosing policies. The deduction that drug-target
interaction does not explain the consequent bactericidal cell death, suggests that the
future of antimicrobial design is dependent upon looking beyond initial target protein
interactions to understand complex cellular dynamics, to elucidate the pathways of




Data for Biochemical Research (1974) 2nd edn. Dawson, R.M.C., Elliot, DC, Elliot,
W.H., Jones, K.M. (editors) Oxford University Press.
Alonso, A., Campanario, E. and Martinez, J.L. (1999) Emergence of multi-drug
resistant mutants is increased under antibiotic selective pressure in Pseudomonas
aeruginosa. Microbiology 145, 2857-2862.
Alovero, F.L., Pan, X.S. Morris, J.E., Manzo R.H. and Fisher L.M. (2000)
Engineering the specificity of antibacterial fluoroquinolones: Benzenesulfonamide
modifications at C-7 of ciprofloxacin change its primary target in Streptococcus
pneumoniae from topoisomerase IV to DNA gyrase. Antimicrob. Agents Chemother.
44, 320-325.
Alper, P.B., Hendrix, M., Sears, P. and Wong, C.Et. (1998) Probing the specificity of
aminoglycoside-ribosomal RNA interactions with designed synthetic analogs. J. Am.
Chem. Soc. 120, 1965-1978.
Aizenman, E., Engelberg-Kulka, H. and Glaser, G. (1996) An Escherichia coli
chromosomal addiction module regulated by 3',5'-bispyrophosphate: A model for
programmed bacterial cell death. Proc. Natl. Acad. Sci. USA 93, 6059-6063.
Amyes, S.G.B. and Smith, J.T. (1974) Trimethoprim action and its analogy with
thymine starvation. Antimicrob. Agents Chemother. 5, 169-178.
Anderson, V., Gootz, T. and Osheroff, N. (1998) Topoisomerase IV catalysis and the
mechanism of quinolone action. J. Biol. Chem. 274, 17879-17885.
200
Bibliography
Arbeit, R.D., Arthur, M., Dunn, R., Kim, C., Selander, R.K. and Goldstein, R. (1990)
Resolution of recent evolutionary divergence among Escherichia coli from related
lineages: the application of pulsed-field electrophoresis to molecular epidemiology. J.
Infect. Dis. 161, 230-235.
Bagel, S., Hullen, V., Wiedemann, B. and Heisig P. (1999) Impact ofgyrA and parC
mutations on quinolone resistance, doubling time, and supercoiling degree of
Escherichia coli. Antimicrob. Agents Chemother. 43, 868-875.
Bakker, E.P. (1992) Aminoglycoside and Aminocyclitol antibiotics: hygromycin B is
an atypical bactericidal compound that exerts effects on cells of Escherichia coli
characteristic for bacteriostatic aminocyclitols. J. Gen. Microbiol. 138, 563-569.
Ball, P. (1990) Emergent resistance to ciprofloxacin amongst Pseudomonas
aeruginosa and Staphylococcus aureus: clinical significance and therapeutic
approaches. J. Antimicrob. Chemother. 26, (Suppl F) 165-179.
Ball, P. (1994) Bacterial resistance to fluoroquinolones: lessons to be learned.
Infection 22, (Suppl. 2) S140-S147.
Ball, P. (2000) Quinolone generations: natural history of natural selection ? J.
Antimicrob. Chemother. 46, 17-24.
Barrett, T.J., Lior, EL, Green, J.H., Khakhrria, R., Wells, J.G., Bell, B P., Greene,
K.D., Lewis, J. and Griffin, P.M. (1994) Laboratory investigation of a multi-state
food-borne outbreak of Escherichia coli 0157:H7 by using pulsed-field gel
electrophoresis and phage typing. J. Clin. Microbiol 32, 3013-3017.
Berg, D.E., Akopyants, N.S. and Kersulyte, D. (1994) Fingerprinting microbial
genomes using the RAPD or AP-PCR method. MethodsMol. Cell. Biol. 5, 13-24.
201
Bibliography
Bilgin, N., Claesens, F., Pahverk, H. and Ehrenberg, M. (1992) Kinetic properties of
Escherichia coli ribosomes with altered forms of S12. J. Mol. Biol. 224,1011-1027.
Blanche, F., Cameron, B., Bernard, F.X., Maton, L., Manse, B., Ferrero, L., Ratet,
N., Lecoq, C., Goniot, A., Bisch, D. and Crouzet, J. (1996) Differential behaviours of
Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.
Antimicrob. Agents Chemother. 40, 2714-2720.
Blot, M., Hauer., B. and Monnet, G. (1994) The Tn5 bleomycin resistance gene
confers improved survival and growth advantage on Escherichia coli. Mol. Gen.
Genet. 242, 595-601.
Bjorkman, J., Hughes, D., and Andersson, D.I. (1998) Virulence of antibiotic-
resistant Salmonella typhimurium. Proc. Natl. Acad. Sci. USA 95, 3949-3953.
Bjorkman, J., Nagaev, I., Berg, O.G., Hughes, D. and Andersson D.I. (2000) Effects
of environment on compensatory mutations to ameliorate costs of antibiotic
resistance. Science 287, 1479-1482.
Bohmann, K., Ruusala, T., Jelenc, P.C. and Kurland, C.G. (1984) Kinetic impairment
of restrictive streptomycin-resistant ribosomes. Mol. Gen. Genet. 198, 90-99.
Bonny, C., Montandon, P.E., Martin, S.M. and Stutz E. (1991) Analysis of
streptomycin-resistance of Escherichia coli mutants. Biochim. Biophys. Acta 1089,
213-219.
Brimacombe, R., Atmadja, J., Stiege, W. and Schuler, D. (1988) A detailed model of
the 3-dimensional structure of Escherichia coli 16-S Ribosomal-RNA in situ in the
30-S sub-unit. J. Mol. Biol. 199, 115-136.
202
Bibliography
Bryan, L.E. and van den Elzen, H.M. (1977) Effects of membrane-energy mutations
and cations on streptomycin and gentamicin accumulation by bacteria: a model for
entry of streptomycin and gentamicin in susceptible and resistant bacteria. Antimicrob.
Agents Chemother.12, 163-177.
Busse, H., Wostmann C., and Bakker E.P. (1992). The bactericidal action of
streptomycin: membrane permeabiliization caused by the insertion of mistranslated
proteins into the cytoplasmic membrane ofEscherichia coli and subsequent caging of
the antibiotic inside the cells due to degradation of these proteins. J. Gen. Microbiol.
138, 551-561.
Cambau, E., Bordon, F., Colatz, E., and Gutmann, L. (1993) Novel gyrA point
mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to
nalidixic acid. Antimicrob. Agents Chemother. 37, 1247-1252.
Capranico, G., Tinelli, S., Zunino, F., Kohn, K.W., Pommier, Y. (1993) Effects of
base mutations on topoisomerase II DNA cleavage stimulated by mAMSA in short
oligomers. Biochemistry 32, 145-152.
Carratala, J., FernandezSevilla, A., Tubau, F., Callis, M. and Gudiol, F. (1995)
Emergence of quinolone resistant Escherichia coli bacteremia in neutropenic patients
with cancer who have received prophylactic norfloxacin. Clin. Infect. Dis. 20, 557-
560.
Cashel, M., Gentry, DR., Hernandez, V.J. and Vinella, D. (1996) The stringent
response. In Escherichia coli and Salmonella: cellular and molecular biology,
Neidhardt, F.C., Curtis III, R., Ingraham, J.L., Lin, E.C.C., Low, K.B., Magasanik,
B., Reznikoff, W.S., Riley, M., Schaechter, M. and Umbarger, H.E. (editors.)
(Washington, D. C.: ASM Press)
203
Bibliography
Chambers, H.H. and Sande, M.A. (1995) Antimicrobial agents: the aminoglycosides,
p 1103-1121. In Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W. and
Goodman Gilman A. (Editors). The pharmacological basis of therapeutics. McGraw-
Hill, New York, N. Y.
Chang, F.N. and Flaks. J.G. (1972) Binding of dihydrostreptomycin to Escherichia
coli ribosomes: characteristics and equilibrium of the reaction. Antimicrob. Agents
Chemother. 2, 294-307.
Charvalos, E., Tselentis, Y., Hamzehpour, M.M., Kohler, T. and Pechere, J.C. (1995)
Evidence for an efflux pump in multi-drug resistant Campylobacter jejuni.
Antimicrob. Agents Chemother 39, 2019-2022.
Chen, C.R., Malik, M., Snyder, M. and Drlica, M. (1996) DNA gyrase and
topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J.
Mol. Biol. 258, 627-637.
Chu, D.W.T. and Fernandes, P.B. (1989) Structure-activity relationships of the
fluoroquinolones. Antimicrob. Agents Chemother. 33, 131-135.
demons, W.C.J., May, J.L.C., Wimberly, B.T., McCutcheon, J.P., Capel, M.S. and
Ramakrishnan, V. (1999) Structure of a bacterial 3OS ribosomal subunit at 5.5 A
resolution. Nature 400, 833-840.
Cohen, S., Hooper, D C., Wolfson, J.S., Souza, K.S., McMurry, L.M. and Levy, S.B.
(1988) Endogenous active efflux of norfloxacin in susceptible Escherichia coli.
Antimicrob. Agents Chemother. 32, 1187-91.
Cohen, S., McMurry, L.M., Hooper, D C., Wolfson, J.S. and Levy, S B. (1989)
Cross-resistance to fluoroquinolones in multiple antibiotic-resistant (Mar) Escherichia
coli selected by tetracycline or chloramphenicol - Decreased drug accumulation
204
Bibliography
associated with membrane changes in addition to OmpF reduction. Antimicrob.
Agents Chemother. 33, 1318-1325.
Conrad, S., Oethinger, M., Kaifel, K., Klotz, G., Marre, R. and Kern, W.V. (1996)
gyrA mutations in high-level fluoroquinolone resistant Escherichia coli clinical
isolates. J. Antimicrob. Chemother. 38, 443-455.
Cormican, M.G. and Jones, R.N. (1997) Antimicrobial activity and spectrum of
LB20304, a novel fluoronapthyridone. Antimicrob. Agents Chemother. 41, 204-211.
Critchlow, S.E. and Maxwell, A. (1996) DNA cleavage is not required for the binding
of quinolone drugs to the DNA gyrase-DNA complex. Biochemistry 35, 7387-7393.
Dabbs, E.R. (1980) A new class of mutations altering the response of the ribosome to
streptomycin. Mol. Gen. Genet. 178, 361-366.
Dalhoff, A., Petersen, U. and Endermann, R. (1996) In vitro activity of BAY 12-
8039, a new 8-methoxyquinolone. Chemotherapy 42, 410-425.
Dalla-Costa, L.M., Irino, K., Rodrigues, J., Rivera, I.N.G. and Trabulsi, L.R. (1998)
Characterisation of diarrhoeagenic Escherichia coli clones by ribotyping and ERIC-
PCR. J. Med. Microbiol 47, 227-234.
Davies, J. and Wright, G.D. (1997) Bacterial resistance to aminoglycoside antibiotics.
TrendsMicrobiol. 5, 234-240.
Davis, B.D. (1987) Mechanism of Bactericidal Action of Aminoglycosides.
Microbiological Reviews 51, 341-350.
Davis, B.D. and Mingioli, E.S. (1950) Mutants of Escherichia coli requiring
methionine or vitamin B!2. J. Bacteriol. 60, 17-28.
205
Bibliography
Deplano, A., Zekhnini, A. Allali, N. Couturier, M. and Struelens M.J. (1997)
Association of mutations in grlA and gyrA topoisomerase genes with resistance to
ciprofloxacin in epidemic and sporadic isolates ofmethicillin-resistant Staphylococcus
aureus. Antimicrob. Agents Chemother. 41, 2023-2025.
Diver, J.M. and Wise, R. (1986) Morphological and biochemical changes in
Escherichia coli after exposure to ciprofloxacin. J. Antimicrob. Chemother. 18
(Suppl.D),31-41.
Dodd, C.E.R., Sharman, R.L., Bloomfield, S.F., Booth, I.R. and Stewart, G.S.A.B.
(1997) The inimical process: bacterial self destruction and sub-lethal injury. Trends
Food Sci. Technol. 8, 238-241.
Domagala, J.M. (1994) Structure-activity and structure-side effect relationships for
the quinolone antibacterial. J. Antimicrob. Chemother. 33, 685-706.
Dong, Y.Z., Xu, C., Zhao, X.L., Domagala, J. and Drlica K. (1998) Fluoroquinolone
action against mycobacteria: Effects of C-8 substituents on growth, survival and
resistance. Antimicrob. Agents Chemother. 42, 2978-2984.
Drlica, K. (2001) A strategy for fighting antibiotic resistance. ASMNews 67, 27-33.
Drlica, K. and Zhao, X. (1997) DNA gyrase, topoisomerase IV and the 4-quinolones.
Microbiol. Mol. Biol. Rev. 61, 377-392.
Durham, E.J., Thomson, C.J., Dahloff, A and Amyes, S.G.B. (1999) Preferred targets
ofmoxifloxacin in Staphylococcus aureus. Moxifloxacin in Practice 1, 63-69.
206
Bibliography
Edelmann, P. and Gallant, J. (1977) On the transitional error theory of ageing. Proc.
Natl. Acad. Sci. USA 74, 3396-3398.
Edgar, R. and Bibi, E. (1997) Mdfa, an Escherichia coli multi-drug resistance protein
with an extraordinarily broad spectrum of drug recognition. J. Bacteriol. 179, 2274-
2280.
Edson, R.S. and Terrell, C.L. (1999) The aminoglycosides. Mayo Clinic Proc. 74,
519-528.
Eng, R.H.K., Padberg, F.T., Smith, S.M., Tan, E.N. and Cherubin, C.E. (1991)
Bactericidal effects of antibiotics on slowly growing and non growing bacteria.
Antimicrob. Agents Chemother. 35, 1824-1828.
Everett, M.J., Jin, Y.F., Ricci, V., and Piddock L.J.V. (1996) Contribution of
individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains
isolates from humans and animals. Antimicrob. Agents Chemother. 40, 2380-2386.
Ferrero, L., Cameron, B. and Crouzet, J. (1995) Analysis ofgyrA and grlA mutations
in stepwise selected ciprofloxacin resistant mutants of Staphylococcus aureus.
Antimicrob. Agents Chemother. 39,1554-1558.
Finken, M., Kirschner, P., Meier, A., Wrede, A. and Bottger, E.C. (1993) Molecular
basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the
ribosomal protein S12 gene and point mutations within a functional 16S ribosomal
RNA pseudoknot. Mol. Microbiol. 9, 1239-1246.
Fisher, L.M., Lawrence, J.M., Josty, I.C., Hopewell, R., Margerrsion, E.E. and
Cullen, M.E. (1989) Ciprofloxacin and the fluorquinolones - new concepts on the
mechanism of action and resistance. Am. J. Med. 87,S2-S8.
207
Bibliography
Foley, I., Marsh, P., Wellington, E.M.H., Smith, A.W. and Brown, M.R.W. (1999)
General stress response master regulator rpoS is expressed in human infection: a
possible role in chronicity. J. Antimicrob. Chemother. 43, 164-165.
Fourmy, D., Recht, M.I., Blanchard S C., and Puglisi J.D. (1996) Structure of the A-
site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside
antibiotic. Science 274, 1367-1371.
Fourmy, D., Yoshizawa, S. and Puglisi, J.D. (1998) Paromomycin binding induces a
local conformational change in the A-site of 16S rRNA. J. Mol. Biol. 277, 333-345.
Fukuda, H. and Hiramatsu, K. (1999) Primary targets of fluoroquinolones in
Streptococcuspneumoniae. Antimicrob. Agents Chemother. 43, 410-412.
Funatsu, G. and Wittman, H.G. (1972) Ribosomal proteins XXXIII. Location of
amino-acid replacements in protein S12 isolated from Escherichia coli mutants
resistant to streptomycin. J. Mol. Biol. 68,547-550.
Gardner, A.D. (1940) Morphological effects of penicillin on bacteria. Nature 146,
837-838.
Garvin, R.T., Biswas, D.K. and Gorini, L. (1974) The effect of streptomycin of
dihydrostreptomycin binding to 16S RNA of to 30S ribosomal subunits. Proc, Natl.
Acad. Sci. USA 71, 3814-3818.
Gellert, M., Mizuuchi, K., O'Dea, M.H., Itoh, T., Tomizawa, J.I. (1977) Nalidixic
acid resistance: a second genetic character involved in DNA gyrase activity. Proc.
Natl. Acad. Sci. USA 74, 4772-4776.
Gerdes, K., Jacobsen, J.S. and Franch, T. (1997) Plasmid stabilisation by post-
segregational killing. Genet. Eng. 19,49-61.
208
Bibliography
Gillings, M. and Holley, M. (1997) Repetitive element PCR fingerprinting (rep-PCR)
using enterobacterial repetitive intergenic consensus (ERIC) primers is not necessarily
directed at ERIC elements. Appl. Microbiol. Letts. 25, 17-21.
Goldstein, F.W. and Acar, JF. (1995) Epidemiology of quinolone resistance: Europe
and North and South America. Drugs 49 (Suppl. 2), 36-42.
Gorini, L. (1971) Ribosomal discrimination of tRNAs. Nature New Biol. 234, 261-
264.
Gorini, L. (1974) Streptomycin and misreading of the genetic code. In: Nomura M.,.
Tissieres A., and Lengyel P. (Eds.) Ribosomes, pp.791-803. Cold Spring Harbor
Laboratory, Cold Spring Harbor. N. Y.
Gottfredsson, M., Erlendsdottir, H., Sigfusson, A. and Gudmundsson, S. (1998)
Characteristics and dynamics of bacterial populations during post-antibiotic effect
determined by flow cytometry. Antimicrob. Agents Chemother. 42, 1005-1011.
Gray, K.M. (1997) Intracellular communication and group behaviour in bacteria.
TrendsMicrobiol. 5, 184-188.
Guan, L. and Burnham, J.C. (1992) Post-antibiotic effect of CI-960, enoxacin and
ciprofloxacin on Escherichia coli, effect on morphology and haemolysin activity. ./.
Antimicrob. Chemother. 29, 529-538.
Hakenbeck, R. (1999) Beta-lactam resistant Streptococcus pneumoniae.
epidemiology and evolutionary mechanism. Chemotherapy 45,83-94.
209
Bibliography
Hallett, P., Grimshaw, A.J., Wigly, D.B. and Maxwell, A. (1990) Cloning of the DNA
gyrase genes under tac promoter control: over production of the gyrase A and B
proteins. Gene 93, 139-142.
Hallett, P. and Maxwell, A. (1991) Novel quinolone resistance mutations of
Escherichia coli DNA gyrase A-protein - enzymatic analysis of the mutant proteins.
Antimicrob. Agents Chemother. 35, 335-340.
Hanberger, H., Nilsson, L.E., Kihlstrom, E and Mailer, R. (1990) Post-antibiotic
effects of (f-lactam antibiotics on Escherichia coli evaluated by bio-illuminescence
assay ofbacterial ATP. Antimicrob. Agents Chemother. 34, 102-106.
Hanberger, H., Nilsson, L.E., Mailer, R. and Nilsson., M. (1991) Pharmaco-dynamics
of beta-lactam antibiotics on gram-negative bacteria: initial killing, morphology and
post-antibiotic effect. Scand. J. Infect. Dis. Suppl. 74, 118-123.
Hancock, R.E.W. (1981) Aminoglycoside uptake and mode of action- with special
reference to streptomycin and gentamicin II. Effects of aminoglycosides on cells. J.
Antimicrob Chemother 8, 429-445.
Hausner, T.P., Geigenmuller U. and Nierhaus K.H. (1988) The allosteric three-site
model for the ribosomal elongation cycle. New insights into the inhibition mechanisms
of aminoglycosides, thiostrepton, and viomycin. J. Biol. Chem. 263, 13103-13111.
Heisig, P. (1996) Genetic evidence for a role ofparC mutations in development of
high-level fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents
Chemother. 40, 879-885.
Heisig, P., Schledletzky, H., and Falkensteinpaul, H. (1993) Mutations in the gyrA
gene of a highly fluoroquinolone resistant clinical isolate of Escherichia coli.
Antimicrob. Agents Chemother. 37, 696-701.
210
Bibliography
Heisig, P. and Tschorny, R. (1994) Characterisation of fluoroquinolone resistant
mutants of Escherichia coli selected in vitro. Antimicrob. Agents Chemother. 38,
1284-1291.
Heisig, P. and Wiedemann, B. (1991) Use of a broad host range gyrA plasmid for
genetic characterisation of fluoroquinolone resistant gram-negative bacteria.
Antimicrob. Agents Chemother. 35, 2031-2036.
Hipkiss, A.R. and Kogut M. (1973) Stimulation of protein breakdown in Escherichia
coli by dihydrostreptomycin. Trans. Biochem. Soc. 1,594-596.
Hooper, D.C. (1998) Clinical applications of quinolones. Biochim. Biophy. Act. 1400,
45-61.
Hooper, D.C. (1999) Mechanisms of fluoroquinolone resistance. Drug Resist.
Updates 2, 38-55.
Hooper, D.C., Wolfson, J.S., Ng, E.Y. and Swartz, M.N. (1987) Mechanism of
action and resistance to ciprofloxacin. Am. J. Med. 82,12-20.
Hooper, D C., Wolson, J.S., Bozza, M.A., Ng, E.Y. (1992) Genetics and regulation
of outer-membrane protein expression by quinolone resistance loci nfxB, nficC and
cfxB. Antimicrob. Agents Chemother 36, 1151-1154.
Janoir, C., Zeller, V., Kitzis, M., Moreau, J. and Gutmann, L. (1996) High-level
fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC
and gyrA. Antimicrob. Agents Chemother. 40, 2760-2764.
Jawetz, E., Gunnison J.B. and Bruff J.B. (1952) Studies on antibiotic synergism and
antagonism. J. Bacteriol. 64, 29-39.
211
Bibliography
Jensen, R.B. and Gerdes, K. (1995) Programmed cell death in bacteria - proteic
plasmid stabilisation systems. Mol. Microbiol. 17, 205-210.
Kahlmeter, G. and Dahlager, J.I. (1984) Aminoglycoside toxicity - a review of clinical
studies published between 1975 and 1982. JAntimicrob. Chemother. 13 (Suppl A),
9-22.
Kato, J., Nishimura, Y., Imamura, R., Niki, H., Hiraga, S., Suzuki, H. (1990) New
topoisomerase essential for essential for chromosome segregation in E. coli. Cell 63,
393-404.
Kern, W.V., Andriof, E., Oethinger, M., Kern, P., Hacker, J. and Marre, R. (1994)
Emergence of fluoroquinolone-resistant Escherichia coli at a cancer centre.
Antimicrob. Agents Chemother. 38,681-687.
Kern, W.V., Oethinger, M., Jellen-Ritter, AS. and Levy, S.B. (2000) Non-target
gene mutations in the development of fluoroquinolone resistance in Escherichia coli.
Antimicrob. Agents Chemother. 44, 814-820.
Khodursky, A.B., Zechiedrich, E.L. and Cozzarelli, N.R. (1995) Topoisomerase IV is
a target of quinolones in Escherichia coli. Proc. Natl. Acad. Sci. USA 92,11801-
11805.
Kleerebezem, M., Quadri, L.E., Kuipers, O.P. and de Vos, W.M. (1997) Quorum
sensing by peptide pheromones and two component signal-transduction systems in
gram-positive bacteria. Mol. Microbiol. 24, 895-904.




Koga, H., Itoh, A., Murayama, S., Suzue, S. and Irikura, T. (1980) Structure activity
relationships of antibacterial 6,7- and 7,8-disubstituted l-alkyl-l,4-dihydro-4-
oxoquinoline-3-carboxylic acids. J. Med. Chem. 23, 1358-1363.
Kohler, T., Michea-Hamzehpour, M., Plesiat, P., Kahr, A.L. and Pechere, J.C. (1997)
Differential selection of multidrug efflux systems by quinolones in Pseudomonas
aeruginosa. Antimicrob. Agents Chemother. 41, 2540-2543.
Korona, R., Nakatsu, C.H. Forney, L.J. and Lenski, R.E. (1994) Evidence for
multiple adaptive peaks from populations of bacteria evolving in a structured habitat.
Proc. Natl. Acad. Sci. USA 91, 9037-9041.
Krasin, F and Hutchinson, F. (1977) Repair of DNA double strand breaks in
Escherichia coli, which requires recA function and the presence of a duplicate
genome. J. Mol. Biol. 116, 81-98.
Krueger, J.H. and Walker, G.C. (1984) groEL and dnaK genes of Escherichia coli
are induced by UV irradiation and nalidixic acid in an htR' -dependent fashion. Proc.
Natl. Acad. Sci. USA 81, 1499-1503.
Rresken, M., Hafner, D., Mittermayer, H., Verbist, L., Bergogneberezin,
E.,Giamarellou, H., Esposito, S., Vanklingeren, B., Kayser, F.H. et al. (1994)
Prevalence of fluoroquinolone resistance in Europe. Infection 22 (Suppl. 2), 90-98.
Kreuzer, K.N. and Cozzarelli, N R. (1979) Escherichia coli mutants thermosensitive
for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid
replication, transcription, and bacteriophage growth. J. Bacteriol 140, 424-435.
Krumpe, P.E., Cohn, S., Garreltes, J., Ramirez, J., Coulter, H., Haverstock, D.
(1999) Intravenous and oral mono- of combination therapy in the treatment of severe
213
Bibliography
infections: ciprofloxacin versus standard antibiotic therapy. J. Antimicrob.
Chemother. 43 (SuppI A), 117-128.
Kumagai, Y., Kato, J., Hoshino, K., Akasaka, T., Sato, K. and Ikeda, H. (1996)
Quinolone-resistant mutants of Escherichia coli DNA topoisomerase IV parC gene.
Antimicrob. Agents Chemother. 40, 710-714.
Kurland, C.G. and Ehrenberg, M. (1984) Optimisation of translation accuracy. Prog.
Nucleic AcidRes. Mol. Biol. 31, 191-219.
LaCoste, L., Lacaille, M. and Brakier-Gingras, L. (1977) The role of misrepair
processes in the isolation of new types of streptomycin-resistant mutants in
Escherichia coli. Mol. Gen. Genet. 157, 313-318.
Lamlertthon, S., Miles, R.J. and Bloomfield, S.F. (1999) Common factors affecting
biocide resistance in Escherichia coli. J. Appl. Microbiol. 87 (Suppl.), 11-12.
LeClerc, J.E., Li, B., Payne, W.I. And Cebula, T.A. (1996) High mutation frequencies
among Escherichia coli and Salmonella pathogens. Science 274, 1208-1211.
Lederberg, J. and Lederberg E.M. (1952) Replica plating and indirect selection of
bacterial mutants. J. Bacteriol. 63, 399-406.
Lee, B.L., Padula, A.M., Kimbrough, R.C., Jones, S.R., Chaisson, R.E., Mills, J.,
Sande, M.E. (1991) Infectious complications with respiratory pathogens despite
ciprofloxacin therapy. N. Eng. J. Med. 325, 520-521.
Lehn, N., StowerHoffmann, J., Kott, T., Strassner, C., Wagner, H., Kronke, M. and
SchneiderBrachert, W. (1996) Characterisation of clinical isolates ofEscherichia coli
showing high-levels of fluoroquinolone resistance. J. Clin. Microbiol. 34, 597-602.
214
Bibliography
Lelong, J.C., Gros, D., Gros, F., Bolen, A., Maschler, R. and Stoffler, G. (1974)
Function of individual 3OS subunit proteins of Escherichia coli. effect of specific
immunoglobulin fragments (Fab) on activities of ribosomal decoding sites. Proc. Natl.
Acad. Sci. USA 71, 248-252.
Lesher, G.Y., Froelich, E.J., Gruett, M.D., Bailey J.H., and Brundage, R.P. (1962)
1,8-Napthyridine derivatives. A new class of chemotherapeutic agents. ./. Med.
Pharm. Chem. 5, 1063-1065.
Levin, B.R., Perrot, V. and Walker, N. (2000) Compensatory mutations, antibiotic
resistance and the population genetics of adaptive evolution in bacteria. Genetics 154,
985-997.
Levine, C., Hiasa H. and Marians K. (1998) DNA gyrase and topoisomerase IV:
biochemical activities, physiological roles during chromosome replication, and drug
sensitivities. Biochim. Biophys. Acta 1400, 29-43
Lewin, C.S. and Amyes, S.G.B. (1991) The role of the SOS response in bacteria
exposed to zidovudine or trimethoprim. J. Med. Microbiol. 34, 329-332.
Lewin, C. S., Howard, B. M. A., Ratcliffe, N. T. and Smith, J. T. (1989) 4-quinolones
and the SOS response. J. Med. Microbiol. 29, 139-144.
Lewin, C.S., Howard, B.M.A. and Smith, J.T. (1991) Protein and RNA-synthesis
independent bactericidal activity of ciprofloxacin than involves the A subunit ofDNA
gyrase. J. Med Microbiol. 34, 19-22.
Li, X., Livermore, D.M. and Nikaido, H. (1994) Role of efflux pump(s) in intrinsic
resistance of Pseudomonas aeruginosa: Resistance to tetracycline, chloramphenciol
and norfloxacin. Antimicrob. Agents Chemother. 38, 1732-1741.
215
Bibliography
Libby, J.M. (1998) Post-antibiotic effect in Escherichia coli determined with Real-
Time Metabolic monitoring. Antimicroh. Agents Chemother. 42, 78-82.
Liu, X.Q., Gillham, N.W. and Boynton, J.E. (1989) Chloroplast ribosomal protein
gene rps\2 ofChlamydomonas hardtii: wild type sequence, mutation to streptomycin
resistance, and dependence and function in Escherichia coli. J. Biol. Chem. 264,
16100-16108.
Llorente, B., Leclerc, F. and Cedergreen, R. (1996) Using SAR and QSAR analysis to
model the activity and structure of the quinolone-DNA complex. Bioorg. Med. Chem.
4,61-71.
Lopez-Brea, M. and Alarcon, T. (1990) Isolation of a fluoroquinolone-resistant
Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter. Eur.
J. Clin. Microbiol. Infect. Dis 9, 345-347.
Lynch, C., Courvalin, P. and Nikaido, H. (1997) Active efflux of antimicrobial agents
in wild-type strains ofEnterococci. Antimicrob. Agents Chemother. 41, 869-871.
Lynch, S.R., Recht, M.I. and Puglisi, J.D. (2000) Biochemical and Nuclear Magnetic
resonance studies of aminoglycoside-RNA complexes. Meth. Enymol. 317, 240-261.
Maneewannakul, K. and Levy, S.B. (1996) Identification of mar mutants among
quinolone-resistant clinical isolates of Escherichia coli. Antimicrob. Agents
Chemother. 40, 1695-1698.
Marians, K.J. and Hiasa, H. (1997) Mechanism of quinolone action - a drug-induced
structural perturbation of the DNA precedes strand cleavage by topoisomerase IV. J.
Biol. Chem. 272, 9401-9409.
216
Bibliography
Markham, P.N. (1999) Inhibition of the emergence of ciprofloxacin resistance in
Streptococcus pneumoniae by the multi-drug efflux inhibitor reserpine. Antimicrob.
Agents Chemother. 43, 988-989.
Martinez-Martinez, L., Pascual, A. and Jacoby, G.A. (1998) Quinolone resistance
from a transferable plasmid. Lancet 351, 797-799.
Matic, I., Radman, M., Taddei, F., Picard, B., Doit, C., Bingen, E., Denamur E. and
Elion, J. (1997) Highly variable mutation rates in commensal and pathogenic
Escherichia coll. Science 277, 1833-1834.
Matsunaga, K., Yamaki H., Nishimura T. and Tanaka N. (1986). Inhibition of DNA
Replication Initiation by Aminoglycoside Antibiotics. Antimicrob. Agents Chemother.
30, 468-474.
Maxwell, A. (1992) The molecular basis of quinolone action. J. Antimicrob.
Chemother. 30,409-416.
Metzger, S., Dror, IB., Aizenman, E., Schreiber, G., Toone, M., Friesen, J.D.,
Cashel, M. and Glaser, G. (1988) The nucleotide sequence and characterisation of the
relA gene ofEscherichia coli. J. Biol. Chem. 263, 15699-15704.
Miller, J.H. (1996) Spontaneous mutators in bacteria: insights into pathways of
mutagenesis and repair. Annu. Rev. Microbiol. 50, 625-643.
Mittenhuber, G. (1999) Occurrence ofMazEF-like autolysin/toxin systems in bacteria.
J.Mol. Biotechnol. 1, 295-302
Moazed, D. and Noller, H.F. (1986) Transfer RNA shields specific nucleotides in 16S
ribosomal RNA from attack by chemical probes. Cell 47, 985-994.
217
Bibliography
Moazed, D. and Noller, H.F. (1987) Interaction of antibiotics with functional sites in
16S ribosomal RNA. Nature 327, 389-394.
Momose, H. and Gorini, L. (1971) Genetic analysis of streptomycin dependence in
Escherichia coli. Genetics 67, 19-38.
Montandon, P.E., Nicolas, P., Schurmann, P. and Stutz, E. (1985) Streptomycin
resistance in Euglena gracilis chloroplasts - identification of a point mutation in the
16S ribosomal RNA gene in an invariant position. Nucleic Acids Res. 13, 4299-4310.
Montandon, P.E., Wagner, R. and Stutz, E. (1986) E. coli ribosomes with a C912 to
U base change in the 16S rRNA are streptomycin resistant. EMBO 5, 3705-3708.
Moreillon, P., Markiewicz, Z., Nachman, S. and Tomasz, A. (1990) Two bactericidal
targets for penicillin in pneumococci: autolysis-dependent and autolysis-independent
killing mechanisms. Antimicrob. Agents Chemother. 34, 33-39.
Mortimer, P.G. and Piddock, L.J.V. (1993) The accumulation of five antibacterial
agents in porin-deficient mutants of Escherichia coli. J. Antimicrob. Chemother.
32,195-213.
Muir, M.E., Van Heeswyck R.S. and Wallace B.J. (1984) Effect of growth rate on
streptomycin accumulation by Escherichia coli and Bacillus megaterium. J. Gen.
Microbiol. 130, 2015-2022.
Munoz, R. and De La Campa, A G. (1996) ParC subunit ofDNA topoisomerase IV
of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates




Nair, J., Rouse, D.A., Bai, G.H. and Morris, S.L. (1993) The rpsL gene and
streptomycin resistance in single and multiple drug-resistant strains ofMycobacterium
tuberculosis. Mol. Microbiol. 10, 521-527.
Nakamura, S., Nakamura, M., Kojima, T. and Yoshida, H. (1989) GyrA and GyrB
mutations in quinolone-resistant strains of Escherichia coli. Antimicrob. Agents
Chemother. 33, 254-255.
Ng, E.Y., Trucksis, M., and Hooper, D C. (1996) Quinolone resistance mutations in
topoisomerase IV: Relationship to the flqA locus and genetic evidence that
topoisomerase IV is the primary target and DNA gyrase is the secondary target of
fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40,
1881-1888.
Nichols, WW. (1989) The enigma of streptomycin transport. J. Antimicrob.
Chemother. 22, 673-676.
Nikaido, H. (1996) Mutidrug efflux pumps of gram-negative bacteria. J. Bacteriol.
178, 5853-5859.
Novak, R., Charpentier E., Braun, J.S. and Tuomanen E. (2000) Signal transduction
by a death signal peptide: Uncovering the mechanism of bacterial killing by penicillin.
Molecular Cell 5, 49-57.
Novak, R., Henriques, B., Charpentier, E., Normark, S. and Tuomanen, E. (1999)
Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 399, 590-
593.
Nystrom, T. (1998) To be or not to be: the ultimate decision of the growth-arrested
bacterial cell. FEMSMicrobiol. Rev. 21, 283-290.
219
Bibliography
Oethinger, M., Conrad, S. Kaifel, K., Cometta, A., Bille, J., Klotz, G., Glausner, M.
P., Marre, R. and Kern, M.V. (1996) Molecular epidemiology of fluoroquinolone-
resistant Escherichia coli bloodstream isolates from patients admitted to European
cancer centres. Antimicrob. Agents Chemother. 40, 387-392.
Oethinger, M., Podglajen, I., Kern, W.V. and Levy, S.B. (1998) Overexpression of
the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia
coli. Antimicrob. Agents Chemother. 42, 2089-2094.
Okusu, H., Ma, D. and Nikaido, H. (1996) AcrAB efflux pump plays a major role in
the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic resistance
(Mar) mutants. J. Bacteriol. 178, 306-308.
Oram, M. and Fisher, L.M. (1991) 4-Quinolone resistance mutations in the DNA
gyrase of Escherichia coli clinical isolates identified by using the polymerase chain
reaction. Antimicrob. Agents Chemother. 35, 387-389.
Ozaki, M., Mizushima, S. and Nomura, H. (1969) Identification and functional
characterisation of the protein controlled by the streptomycin-resistant locus in E.
coli. Nature 222, 333-339.
Palumbo, M., Gatto, B., Zagotto, Z. and Palii, G. (1993) On the mechanism of action
of quinolone drugs. Trends inMicrobiol. 1, 233-235.
Pan, X.S. and Fisher, L.M. (1997) Targeting of DNA gyrase in Streptococcus
pneumoniae by sparfloxacin: Selective targeting of gyrase of topoisomerase IV by
quinolones. Antimicrob. Agents Chemother. 41, 471-474.
Pan, X.S., Ambler, J., Mehtar, S., Fisher, L.M. (1996) Involvement of topoisomerase
IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.
Antimicrob. Agents Chemother. 40, 2321-2326.
220
Bibliography
Pena, C., Albareda, J., Pallares, R., Pujol, M., Tubau, F.E. and Anza, J. (1995)
Relationship between quinolone use and emergence of ciprofloxacin resistant
Escherichia coli in bloodstream infections. Antimicroh. Agents Chemother. 39, 520-
524.
Perry, C P., Barman Balfour, J.A. and Lamb, H.M. (1999) Gatifloxacin. Drugs 58,
683-696.
Pestova, E., Millichap, J.J., Noskin, G.A. and Peterson, L.R. (2000) Intracellular
targets of moxifloxacin: a comparison with other fluoroquinolones. J. Antimicrob.
Chemother. 45, 583-590.
Phillips, I. (1991) A guide to sensitivity testing. J. Antimicrob. Chemother. 27
(Suppl. D), 1-50
Phillips, I., Culebras, E., Moreno, F. and Baquero, F. (1987) Induction of the SOS
response by new 4-quinolones. Antimicrob. Agents Chemother. 20, 631-638.
Piddock, L.J.V., Hall, M.C. and Walters, R.N. (1991) Phenotypic characterisation of
quinolone-resistant mutants ofEnterobacteriaceae selected from wild type, gyrA type
and multiply-resistant (marA) type strains. J. Antimicrob. Chemother. 28, 185-198.
Piddock, L.J.V., Walters R.N. and Diver J.M. (1990) Correlation of quinolone MIC
and inhibition ofDNA, RNA and protein synthesis and induction of the SOS response
in Escherichia coli. Antimicrob. Agents Chemother. 34, 2331-2336.
Piddock, L.J.V. and Walters, R.N. (1992) Bactericidal activities of five quinolones for
Escherichia coli strains with mutations in genes encoding the SOS response or cell
division. Antimicrobi. Agents Chemother. 36, 819-825.
221
Bibliography
Piddock L.J.V. and Wise, R. (1987) Induction of the SOS response in Escherichia
coli by 4-quinolone antimicrobial agents. FEMSMicrobiol. Lett. 41, 289-294.
Pine, M.J. (1978) Comparative effects of incorporated amino-acids analogs in
Escherichia coli. Antimicroh. Agents Chemother. 13, 676-685.
Post, L.E. and Nomura, M. (1980) DNA sequences from the str operon of
Escherichia coli. J. Biol. Chem. 255, 4660-4666.
Powell, J.K. and Young, K.D. (1991) Lysis ofEscherichia coli by beta-lactams which
bind penicillin binding proteins 1A and IB - inhibition by heat shock proteins. J
Bacteriol. 173, 4021-4026.
Power, E.G., Munoz Bellido, J.L. and Phillips, I. (1992) Detection of ciprofloxacin
resistance in Gram-negative bacteria due to alterations in gyrA. J. Antimicrob.
Chemother. 29, 9-17.
Radman, M. (1999) Enzymes of evolutionary change. Nature 401, 866-887.
Redaschi, N. and Bickle, T.A. (1996) Post-transcriptional regulation of EcdPl and
EcoP 15 restriction activity. J. Mol. Biol. 257, 790-803.
Reece, R.J. and Maxwell, A. (1991) DNA gyrase - structure and function. Critical
Rev. Biochem. Mol. Biol. 26, 335-375.
Ren, L., Rahman, M.S. and Humayun, M.Z. (1999) Escherichia coli cells exposed to
streptomycin display a mutator phenotype. J. Bacteriol. 181, 1043-1044.
Riesenfeld, C., Everett, M., Piddock, L.J. and Hall, B.G. (1997) Adaptive mutations
produce resistance to ciprofloxacin. Antimicrob. Agetits Chemother. 41, 2059-2060.
222
Bibliography
Rogers, H.J. and Forsberg, C.W. (1971) Role of autolysins in the killing of bacteria by
some bactericidal antibiotics. J. Bacteriol. 108, 1235-1243.
Rolinson, G.N. (1980) Effect of (3-lactam antibiotics on bacterial cell growth rate. J.
Gen. Microbiol. 120, 317-323.
Rosenberg, S.M., Harris, R.S. Longerich, S. and Galloway, A.M. (1996)
Recombination-dependent mutation in non-dividing cells. Mutat. Res. 350, 69-76.
Ruiz, J., Cassellas, S., DeAnta, .T.J. and Vila, J. (1997) The region of the parE gene,
homologous to the quinolone resistant determining region of the gyrB gene, is not
linked with the acquisition of quinolone resistance in Escherichia coli clinical isolates.
./. Antimicrob. Chemother. 39, 839-840.
Ruiz, J., Marco, F., Goni, P., Gallardo, F., Mensa, J., Trilla, A., De Anta, T.J. and
Vila, J. (1995) High frequency of mutations at codon-83 of the gyrA gene of
quinolone-resistant clinical isolates of Escherichia coli. J. Antimicrob. Chemother.
36, 737-738.
Ruusala, T. and Kurland, G.C. (1984) Streptomycin preferentially perturbs ribosomal
proofreading. Mol Gen. Genet. 198, 100-104.
Schmitz, F.J., Fluit A C., Luckefahr, M., Engler, B., Hofmann, B., Verhoef, J., Heinz,
H P., Hadding, U. and Jones, M.E. (1998) The effect of reserpine, an inhibitor of
multi-drug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and
moxifloxacin against clinical isolates of Staphylococcus aureus. J. Antimicrob.
Chemother. 42, 807-810.
Shaw, K.J., Rather, P.N., Hare, R.S. and Miller, G.H. (1993) Molecular genetics of
aminoglycoside resistant genes and familial relationships of the aminoglycoside
modifying enzymes. Microbiol Rev. 57, 138-163.
223
Bibliography
Shapiro, J.A. (1984) Observations on the formation of clones containing araB-lacZ
cistron fusions. Mol. Gen. Genet. 194, 79-90.
Shapiro, J.A. (1997) Genome organisation, natural genetic engineering and adaptive
mutation. Trends in Genetics 13, 98-104.
Shen, L.L., Mitscher, L.A., Sharma, P.N., O'Donnell, T.J., Chu, D.W.T., Cooper,
C.S., Rosen, T. and Pernet, A.G.(1989) Mechanism of inhibition of DNA gyrase by
quinolone antibacterials: A co-operative drug-DNA binding model. Biochemistry 28,
3886-3894.
Smith, J.T. (1986) The mode of action of 4-quinolones and mechanisms of resistance.
J. Antimicrob. Chemother. 18 (Suppl D), 21-29.
Smith, J.T. and Lewin, C.S. (1988) Chemistry and mechanism of action of the
quinolone anti-bacterials. In: Andriole, V. T. (Editor) The quinolones; London,
Academic Press 23-82.
Snyder, M. and Drlica, K. (1979) DNA gyrase on the bacterial chromosome: DNA
cleavage induced by oxolinic acid. J. Mol. Biol. 131, 287-302.
Sokawa, Y., Nakao, E. and Kaziro, Y. (1968) On the nature of the control by RC
gene in Escherichia coli :amino-acid dependent control of lipid synthesis. Biochem.
Biophys. Res. Commun. 33, 108-112.
Soussy, C.J., Wolfson, J.S., Ng, E.Y., Hooper, D.C. (1993) Limitations of the
plasmid complementation test for determination of quinolone resistance due to
changes in the gyrase A protein and identification of conditional quinolone resistance
locus. Antimicrob. Agents Chemother. 37, 2588-2592.
224
Bibliography
Starka, J. and Moravova, J. (1967) Cellular division of penicillin induced filaments of
Escherichia coli. FoliMicrobiologica 12, 240-247.
Stern, S., Powers, T., Changchien, L.M., and Noller, H.F. (1988) Interaction of
ribosomal proteins S5, S6, Sll, S12, S18 and S21 with 16S rRNA. J. Mol. Biol. 201,
683-695.
Swanberg, S.L. and Wang, J.C. (1987) Cloning and sequencing of the Escherichia
coli gyrA gene coding for the A subunit ofDNA gyrase. J. Mol. Biol. 197, 729-736.
Taddei, F., Radman, M., MaynardSmith, J., Tuopance, B., Gouyon, PH. and
Godelle, B. (1997) Role of mutator alleles in adaptive evolution. Nature 387, 700-
702.
Tavio, M.D., Vila, J., Ruiz, J., Martin-Sanchez, A.M. and de Anta, T.J. (1999)
Mechanisms involved in the development of resistance to fluoroquinolones in
Escherichia coli isolates. JAntimicrob. Chemother. 44, 735-742.
Tenover, F.C., Arbeit, R.D., Goering, R.V., Mickelsen, P.A., Murray, B E., Persing,
D.H. and Swaminathan, B. (1995) Interpreting chromosomal DNA restriction
patterns produced by pulsed-field gel electrophoresis: Criteria for bacterial strain
typing. J. Clin. Microbiol. 33, 2233-2239.
Thomson, C.J. (1999) The global epidemiology of resistance to ciprofloxacin and the
changing nature of antibiotic resistance: a 10 year perspective. J. Antimicrob.
Chemother. 43 (Suppl. A), 31-40.
Threlfall, E.J., Cheasty, T., Graham, A. and Rowe, B. (1997) High-level resistance to
ciprofloxacin in Escherichia coli. Lancet 349, 403.
225
Bibliography
Timms, A.R., Steingrimsdottir, H., Lehmann, A.R. and Bridges, B.A. (1992) Mutant
sequences in the rpsL gene of Escherichia coli B/r: mechanistic implications for
spontaneous and ultraviolet light mutagenesis. Mol. Gen. Genet. 232, 89-96.
Tipper, D.J. and Strominger, J.L. (1965) Mechanism of action of penicillins: a
proposal based on their structural similarity to acyl-D-alanyl-D-alanine. Proc. Natl.
Acad. Sci. U.S.A. 54, 1133-1141.
Toivonen, J.M., Boocock, M.R. and Jacobs, H.T. (1999) Modelling in Escherichia
coli of mutations in mitoribosomal protein SI2: novel mutant phenotypes of rpsL.
Mol. Microbiol. 31, 1735-1746.
Truong, Q.C., Ouabdesselam, S., Hooper, DC., Moreau, N.J. and Soussy, C.J.
(1995) Sequential mutations of gyrA in Escherichia coli associated with quinolone
therapy../. Antimicrob. Chemother. 36, 1055-1059.
Tuomanen, E. (1986) Phenotypic tolerance: the search for P-lactam antibiotics that
kill non-growing bacteria. Rev. Infect. Dis. 8, (SuppI 3), S279-S291.
Versalovic, J., Koeuth, T. and Lupski, J.R. (1991) Distribution of repetitive DNA
sequences in eubacteria and application to fingerprinting of bacterial genomes.
Nucleic Acids Res. 16, 6823-6831.
Vila, J., Riuz, J. Marco, F., Barcelo, A., Goni, P., Giralt, E. and de Anta, T.J. (1994)
Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical
isolates of Escherichia coli and MICs. Antimicrob. Agents Chemother. 38, 2477-
2479.
Vila, J., Ruiz, J., Goni, P. and DeAnta, T.J. (1996) Detection of mutations in parC in
quinolone-resistant clinical isolates of Escherichia coli. Antimicrob. Agents
Chemother. 40, 491 -493.
226
Bibliography
Vos, P., Hogers, R., Bleeker, M., Reijans, M., van de Lee, T., Homes, M., Frijters,
A., Pot, J., Peleman, J., Kuiper, M. and Zabeau, M. (1995) AFLP: a new technique
for DNA fingerprinting. Nucl. Acids Res. 23, 4407-4414.
Walker, G.C. (1984) Mutagenesis and inducible response to deoxyribonucleic acid
damage in Escherichia coli. Microbiol. Rev. 48, 60-93
Waters, B. and Davies, J. (1997) Amino-acid variation of bacteria potentially
associated with natural resistance to fluoroquinolone antibiotics. Antimicrob. Agents
Chemother. 41, 2766-2769.
Wickens, H.J., Pinney, R.J., Mason, D.J. and Gant, V.A. (2000) Flow cytometric
investigation of filamentation, membrane potency, and membrane potential in
Escherichia coli following ciprofloxacin exposure. Antimicrob. Agents Chemother.
44, 682-687.
Yamagishi, J.I., Kojima, T., Oyamada, Y et al. (1996) Alterations in the DNA
topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus
aureus. Antimicrob. Agents Chemother. 40, 1157-1163.
Yamagishi, J., Yoshida, H., Yamyoshi, M., Nakamura, S. (1986) Nalidixic acid-
resistant mutation of the gyrB gene ofEscherichia coli. Mol. Gen. Genet. 204, 367-
373.
Yoshida, H., Bogaki, M., Nakamura, M. and Nakamura, S. (1990) Quinolone
resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.
Antimicrob. Agents Chemother. 34,1271-1272.
227
Bibliography
Yoshida, H., Bogaki, M., Najkamura, M., Yamanaka, L.M. and Nakamura, S. (1991)
Quinolone resistance determining region in the DNA gyrase gyrB gene ofEscherichia
coli. Antimicrob. Agents Chemother. 35,1647-1650.
Yoshida, H., Kojima, T., Yamagishi, J. and Nakamura, S. (1988) Quinolone-resistant
mutations of the gyrA gene ofEscherichia coli. Mol. Gen. Genet. 211, 1-7.
Yoshida, H., Nakamura, M., Bogaki, M., Ito, H., Kojima, T., Hattori, H. and
Nakamura, S. (1993) Mechanism of action of quinolones against Escherichia coli
DNA gyrase. Antimicrob. Agents Chemother. 37, 839-845.
Zhao, S., Mitchell, S.E., Meng, J., Kresovich, S., Doyle, M.P., Dean, R.E., Casa,
A.M. and Weller, J.W. (2000) Genomic typing ofEscherichia coli 0157:H7 by semi-
automated fluorescent AFLP analysis. Microbes and Infection 2, 107-113.
Zhao, B.Y., Pine, R., Domagala, J. and Drlica, K. (1999) Fluoroquinolone action
against clinical isolates of Mycobacterium tuberculosis. Effects of a C-8 methoxyl
group on survival in liquid media and in human macrophages. Antimicrob. Agents
Chemother. 43, 661-666.
Zhao, X.L., Xu, C., Domagala. J. and Drlica, K. (1997) DNA topoisomerase targets
of the fluoroquinolones: A strategy for avoiding bacterial resistance. Proc. Natl.
Acad. Sci. USA 94, 13991-13996.
228
